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To Mum and Dad
“Now consider the tortoise and the eagle.
The tortoise is a ground-living creature. It is impossible to live nearer 
the ground without being under it. Its horizons are a few inches away. It has 
about as good a turn of speed as you need to hunt down a lettuce. It has 
survived while the rest of evolution flowed past it by being, on the whole, no 
threat to anyone and too much trouble to eat.
And then there is the eagle. A creature of the air and high places, 
whose horizons go all the way to the edge of the world. Eyesight keen 
enough to spot the rustle of some small and squeaky creature half a mile 
away. All power, all control. Lightning death on wings. Talons and claws 
enough to make a meal of anything smaller than it is and at least take a 
hurried snack of anything bigger.
And yet the eagle will sit for hours on the crag and survey the 
kingdoms of the world until it spots a distant movement and then it will focus, 
focus, focus on the small shell wobbling among the bushes down there on the 
desert. And it will leap ...
And a minute later the tortoise finds the world dropping away from it. 
And it sees the world for the first time, no longer one inch from the ground 
but five hundred feet above it, and it thinks: what a great friend I have in the 
eagle.
And then the eagle lets go.
And almost always the tortoise plunges to its death. Everyone knows 
why the tortoise does this. Gravity is a habit that is hard to break off. No 
one knows why the eagle does this. There’s good eating on a tortoise but, 
considering the effort involved, there’s much better eating on practically 
anything else. It’s simply the delight of eagles to torment tortoises.
But of course, what the eagle does not realise is that it is participating 
in a very crude form of natural selection.
One day the tortoise will learn how to fly.”
Small Gods by Terry Pratchett
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Abstract
A robust six-step synthesis of substituted flavone-8 -acetic acid sodium salts 
has been developed and optimised to allow preparation of a wide variety of 
products for testing as anti-tumour agents. The condensation and cyclisation 
steps have been combined in an efficient one-pot procedure and efficient 
procedures for subsequent oxidative cleavage of an allyl group and salt 
formation have been developed.
Using this method a total of 18 derivatives bearing substituents on the 
2-phenyl ring have been prepared. Based on encouraging activity from 
methoxy substituted compounds, attention has been concentrated on these and 
various mono-, di-, tri- and tetramethoxy compounds have been prepared, 
most for the first time. Activity of these against MAC 15A, both in vitro and 
in vivo has been determined by collaborators at Bradford and several 
compounds have comparable or greater activity than the unsubstituted 
prototype. The presence of a 2’-methoxy 1 substituent appears to be 
particularly favourable to activity.
Five different heterocyclic analogues with furyl, thienyl and 
benzothienyl groups at the 2 -position have been obtained and these also show 
good activity with the 3-methyl-2 -thienyl compound showing the highest in 
vivo activity of any compound examined. Attempts to prepare pyridyl and 
quinolyl derivatives were unsuccessful.
The 2-benzyl and 2-diphenylmethyl compounds have also been 
prepared and while the former shows good activity in vitro, it is inactive in 
vivo  probably due to metabolic breakdown. The latter compound is 
completely inactive probably due to a requirement for planarity in the 2 - 
substituent.
An extended derivative has been obtained by an unexpected mode of 
reaction encountered in an attempt to prepare the 2 -phenylethynyl compound.
Both this and a dimeric ether analogue show significant activity, thereby 
adding to our understanding of the structural requirements for activity.
Variation in the 8 -acetic acid substituted has been examined by synthesis 
of three compounds with CH2C(0 )CH2 0 H at this position and, by a separate 
multi-stage synthesis, the compound with tetrazolylmethyl. The former 
compounds are too insoluble for activity to be measured, while the latter is 
inactive.
A comparison of electron density, as reflected by iH and NMR 
shifts, against activity in vitro has been made for all the compounds prepared, 
and while some trends may be discerned, the correlation is generally poor.
A suitable single crystal of flavone acetic acid was prepared and its X- 
ray structure was obtained by the SERC Crystallography Unit, Cardiff. The 
structure, which proved to be of the monohydrate showed the preferred 
orientation of the 2 - and 8 -substituents and provided accurate dimensions for 
future theoretical work.
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INTRODUCTION
1A. C ancer
1. Classification
A chemically or genetically mutated cell will become cancerous if its own 
D A causes it to replicate without control.^ The mitotic replication rate 
of the tumour depends solely on the type of tissue affected with fast 
growing tumours normally less likely to be fatal for the patient as they can 
be inhibited to a certain extent by D A intercalating drugs, which mimic 
nucleoside bases, leading to cessation of transcription. Slow growing solid 
tumours are harder to treat as they modify the surrounding body tissues to 
supply the tumour’s needs. The diverting of host blood through the 
building of tumour vasculature, the change in plasma clotting times and 
changes in platelet and white blood cell counts are some ways that the 
cancer ensures its survival.
2. Therapeutics
a. General
Cancer chemotherapeutics can be split into several categories.^ 
Antineoplastic agents that are steroidal in nature, resemble the female 
hormones, and are used in the treatment of prostate cancer. An example is 
diethylstilbestrol 1 and their mode of action is believed to be inhibition of 
protein synthesis. Cis-platin 2, the square planar platinum complex drug, 
is converted to 3 in the body by replacing labile chlorines with hydroxyls 
and it is this activated form which interferes with the cell's D A. 
Unfortunately it also attacks normal D A replication associated with such 
functions as follicle hair production and so a new complex carboplatin 4 
with fewer side effects was synthesised. Various toxic alkylating agents 
such as mustard gas 5 and nitrosoureas such as CC U (lomustine 6 ) 
modify cellular D A by mismatching strands therefore interfering with 
cell division. Cell disrupting anti-metabolites interfere with cell processes, 
by imitating vital cytoplasmic compounds, binding irreversibly or
2competitively with host structures - various anti-metabolites are 
antagonists for nucleoside bases e.g. 5-fluorouracil 7 and 6 - 
mercaptopurine 8 , hence interfering with DA replication.
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Antibiotics, such as adriamycin 9, daunorubicin 10 and bleomycin A2 11 
also have the capacity to kill cancer cells by blocking the synthesis of vital 
proteins.
Fragment 12 (daunosamine) falls off the active molecules in acid 
media. The anthracycline antibiotics 9 and 10 are based on anthraquinone 
structures which certainly intercalate with DA. Bleomycins also cause 
DA strand scission and have been shown to possess a type of oxygen 
transferase activity. Certain other drugs currently in use fall into a 
separate and fast growing area of research, that of phytochemistry.
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b. Phytochemistry
Phytochemistry, the chemistry of plants and the substances produced 
therefrom, has become the focus of a lot of academic attention within the 
last twenty years.^'^ Tribal medicines, ancient rituals and folklore all use 
plants to a greater or lesser extent. The properties of these plants have 
been recognised by the pharmacist and by collaboration with other 
sciences especially chemistry, large scale syntheses of the plant drugs can 
be carried out. TaxoP 13, the latest in a long line of anti-cancer plant 
extracts, originates from the bark of the Pacific Yew tree Tax us 
brevifolia. Although this tree is in danger of extinction, taxol's activity is 
so great that whole areas of forest are disappearing to accommodate the 
new-found interest.^ Several groups are working on the total synthesis^-^ %
4
and a semi-synthetic route to taxol has already been achieved by several 
g r o u p s f r o m  10-deacetyl baccatin III 14.
H O "
n Aco
14
NH O
P ^ ô  H 5^  n A cO ^OO
13
The mechanism of taxol’s cytotoxicity stems from its ability to increase 
both rate and yield of microtubule assembly and it inhibits the tubulin 
disassembly process. This activity is opposite to the normal effect of 
mitotic inhibitors, with ovarian and breast cancers surprisingly susceptible 
to this treatment. As a result of phase II trials it is currently under 
investigation^"^ by the U.S. Food and Drug Administration.
Wall and Wani, also discovered another drug camptothecin^^ 15, a 
novel alkaloid with a quinoloindolizine structure, which similarly has 
cytotoxic properties. Discovered in 1966 and isolated from the stem wood 
of Camptotheca acuminata it inhibits topoisomerase I. Its toxicity, 
however, has led to congeners such as topotecan, a dimethylaminomethyl 
derivative, which has recently entered phase II clinical trials.
^OH
Camptothecin = H = H 
Topotecan R^  = OH R  ^= (CHg)2NHCH2
V incristine 16 and vinblastine 17 , currently used in cancer 
chemotherapy,2 have interesting structures.
Catharanthine h OH
MeOOC>
Vindoline - MeO OCOMeR ^(^COOMe
1 6  Vinblastine R = Me
1 7  Vincristine R = CHO
Both molecules were obtained from Vinca rosea extracts. The molecules 
act on cells by binding to tubulin and inhibiting microtubule activity which 
makes them more selective to proliferating tumour cells.
B. Flavone-8-acetic acid
1. Cancer Screening
Early cancer screens from the ational Cancer Institute (CI) were based 
on leukaemia m o d e l s . S u c h  fast growing tumours are susceptible to 
DA intercalating drugs which not only interfere with the tumour cell 
cytology but also the host organism’s cytology. In recent times, with 
increases in the knowledge of carcinogenesis, the CI changed their in 
vitro  screens of human cell lines to incorporate slow growing solid 
tumours. These highly vascularised tumours, like murine colon 
adenocarcinoma 38 (MAC38), were previously untreatable and hence 
usually fatal. With the inclusion of cancerous cell lines like MAC38 it was 
possible to test the whole spectrum of drugs against solid tumours.
2. Discovery of flavone-8 -acetic acid
A French company, Lyonnaise Industrielle Pharmaceutique (Lipha), was 
synthesising a lot of flavonoids when the above pre-clinical screen 
highlighted a flavone as active. It was originally developed as an anti­
inflammatory agent showing no anti-metabolite activity and having little 
or no DA binding affinities.
From these studies flavone-8 -acetic acid 18 (FAA, LM975, 
SC347512) and its diethyl aminoethyl derivative 19 (LM985) came to 
the fore as agents which were less suitable at combating fast growing 
malignant cells but were almost universally effective, causing 
haemorrhagic necrosis, in slow growing cachectic tumours.
OH
o
o
18
Et2
19
As hypoxic cancer cells may well constitute a significant subpopulation of 
a tumour and as they obtain their energy solely from a higher than normal 
glycolytic rate, it is reasonable to assume that any compound that 
interferes with glycolysis would be regarded as partially selective towards 
tumour cytotoxicity. Bioflavonoids are known^i to inhibit enzymes in the 
glycolytic pathway, specifically a+-K+-ATPase of the plasma membrane, 
by interfering with generation of adenosine diphosphate and inorganic 
phosphate.
FAA is an analogue of the natural plant pigments, hydroxylated 
flavones, which are found throughout the plant kingdom^ where their pH 
dependence gives rise to a wide variety of colours. They are, however.
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not found in animals in which they exhibit effects^ ranging from toxic to 
b e n e f i c i a l . T h e  related family of coumarins and chromones have 
found wide ranging applications e.g. as herbicides, anti-fungal and anti­
viral agents. Warfarin is a good example of the toxicity found in animals 
in that it interrupts the cascade effect of blood clotting in rats.
Due to the high activity the company rapidly synthesised a number 
of analogues and produced a patent.^^ In the light of disappointing clinical 
trial results, which will be explained later, they dropped the project and 
lost interest in the drug. The company did not publish most of the activity 
results and the two papers that did contain activity results^^'^^ were only 
for simple derivatives and were not comprehensive.
3. In vivo activitv and mechanism of action
a. In vivo activitv
FAA treatment was effective in transplantable solid tumours, namely colon 
51, 07, 10, 26, pancreatic adenocarcinomas 02 and 03, mammary 
adenocarcinoma 16/C/Adr, M5076 reticulum cell sarcoma and Glasgow's 
osteosarcoma. It was found^^ that high concentrations and long exposure 
times were necessary in vitro to achieve the same result as a single low 
dose in vivo. Kerr et al. showed^^ that LM985, the ethyl diaminoethyl 
derivative of FAA 19 was more efficacious but also more toxic to the 
mice due to the catabolism of the ester functionality.
Smith et al.^^ showed that the murine tumours were necrotic after 
only 4 hours of treatment with FAA and that after 24 hours the few 
tumours cells that were still viable could hardly be recognised. The 
authors claimed that this effect was remarkably similar to that of tumour 
necrosis factor-a (TF-a).
b. Indirect mechanism of action
Studies of Bibby et showed that the concentrations in vivo were too 
low to have a direct effect on the tumour and hypothesised that FAA must 
be acting by some indirect mechanism or as a response modifier.^ 
Highly vascularised solid tumours, which either scavenged the host's own 
vascular system or, through tumour angiogenesis, created small knotted or 
meandering blood tubules, were more susceptible to FAA treatment than 
leukaemia models. An example of such a susceptible solid tumour is 
MAC 16 which causes weight loss in animals without a reduction in food 
intake and is also highly vascularised. This normally drug-resistant 
tumour becomes necrotic quickly on FAA treatment which showed that 
some novel factor was responsible whose effectiveness was not only 
governed by vasculature but also tumour site.^®’^  ^ This fact was further 
exemplified by MAC26TC tumour cells that were shown to be resistant to 
FAA when transplanted interperitoneally or intravenously but responded 
with 1 0 0 % inhibition of growth when transplanted subcutaneously.
c. Vasculature Targeting
From evidence so far it seems that direct cytotoxicity is not the reason for 
activity in vivo but it is possibly due to some other factor unique to the 
host. Various groups^ '^^o showed that FAA caused tumour regression via 
a vasculature shutdown process. Tumour blood flow was monitored^^ 
over a 24 hour period as a single peritoneal injection of FAA was 
administered. This caused a 90% inhibition of tumour volume and a 60% 
tumour blood flow reduction with necrotic changes as early as 2  hours 
after drug treatment related to the reduced vascular blood flow to the 
tumour. With certain anti-cancer agents (e.g. hydralazine) this reduction 
in tumour blood flow can happen in several ways.'^ -^'^  ^ The most 
important of these ways being the 'steal effect' where the rest of the body’s 
blood vessels undergo vasodilation, hence lowering the volume of blood
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available to the tumour. However it was found that at therapeutic doses 
FAA had no effect on systemic blood pressure.
d. Coagulation and interstitial pressure
The question raised by researchers was 'if FAA is not acting by the steal 
effect then what exactly is the mode of action?' Electron microscopy 
showed that FAA caused epithelial cell separation and stromal damage but 
with no obvious damage to endothelial c e l l s . I n te r e s t i n g  studies^ 
using EMT- 6  spheroids showed that when they were allowed to vascularise 
and then treated with FAA the cells close to the blood supply died rapidly 
while the avascular portion of cells survived. However, FAA does not 
stop the formation of new tumour v e s s e l s . W h e n  various other tissues 
were analysed by Honess and Bleehen"^^ i.e. skin, muscle, lung, liver, 
spleen and kidney it was found that only blood flow in the spleen was 
affected. FAA was also found to break single stranded DA in Glasgow's 
osteosarcoma by Bissery et but this was found to be an effect rather 
than the cause of cell death. Reduction in tumour blood flow over a 
certain period correlated well with tumour regression.
Studies into blood clotting times showed that at 15-30 minutes after 
FAA administration of 300 mg/kg both tumour and non-tumour bearing 
animals showed a distinct reduction in clotting t i m e s . T h i s  initial 
decrease was followed 4-6 hours later by an increase in clotting times, 
thrombin time, fibrin degradation level and platelet count. Conclusions 
from this study were that it was indeed the reduction in blood flow that 
caused extensive necrosis due to increased endothelial barrier permeability 
and increased pro-coagulant activity by tumour necrosis factor-a.
e. Involvement of nitric oxide and endotoxin
itrate/nitrite level was monitored in treated mice and the results showed 
that levels of both increased, reinforcing the presence of TF-a. TF-a
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has been associated with the in vivo and in vitro killing of cancer cells. 
Direct cytotoxicity was first discovered from the inoculation of mice with 
Mycobacterium bovis strain Calmette-Guerin (BCG). A clear relationship 
was demonstrated between nitrate/nitrite levels in the plasma and the 
ensuing tumour regression and growth delay caused by FAA. ow that 
their precursor nitric oxide (O) was inferred as the cytotoxic agent 
various studies^^’^  ^were targeted at this radical.
Endotoxin is a heat-stable lipopolysaccharide protein. It is a 
biological modifier which causes haemorrhagic necrosis in transplanted 
murine tumours via stimulated production of nitric oxide by way of the 
arachidonic acid pathway. It induces both interferons in plasma and TNF- 
a  and has therefore very similar action to FAA. A study^^ was carried 
out on endotoxin resistant mice (CsH/HeJ) and normal mice (CsH/HeN) to 
investigate the effect of FAA’s and XAA’s (see later) when one facet of the 
immune system is removed. Both strains of mice were injected with 
cancer cells at six weeks old and the cancers allowed to develop a blood 
vasculature before drug treatment. In vitro tests were conducted by 
examining nitrite produced and although a greater concentration of FAA 
(890pM) was required than 5,6-dimethyl XAA (80jiM) for optimum 
activity the method of action is the same. It was found that endotoxin 
stimulates NO production only in the C3H/HeN (normal) mice and not in 
the resistant mutant whereas FAA and XAA analogues have similar dose- 
response curves for NO production in both variants. Peak nitrate 
l e v e l s ^ f r o m  the plasma of each of the mouse strains were taken 1 2  
hours after drug infusion. It was found that FAA (1180|iM) and 5,6- 
dimethyl XAA (100|iM) gave similar values for haemorrhagic necrosis 
(within experimental error). A summary of the results obtained is found 
in the table below.
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Haemorrhagic ecrosis
Treatment CsH/He mice CsH/HeJ mice
o treatment 12±4 18±2
FAA (llSOumol/kg) 81+11 78+9
5,6-diMeXAA( 1 OOpmol/kg) 50+14 58+18
Endotoxin (10|ig/mouse) 63+24 8+4
Endotoxin (100|lg/mouse) 95+3 27+22
Endotoxin (600|ig/mouse) Death 50+3
As can be seen there is a marked contrast between the effect of endotoxin 
and FAA or XAA analogues in the CsH/HeJ mice. Moreover endotoxin 
caused haemorrhagic necrosis in the CgH/HeJ mice at a concentration that 
would have killed the normal mice. The conclusion from this study was 
that FAA or its relative XAA did not. stimulate the endotoxin pathway in 
mice.
f. Immune Effects
NO was indeed proved to be the killing agent but unfortunately the 
mode of action was still unclear. Various studies^^’'^ ’^^ ’^^ '^  pinpointed the 
macrophages in the host as playing the role of NO producers. FAA 
stimulates not only these natural killer (NK) cells in the spleen in mice but 
also lymphokine activated killer cells (LAK) which are potent interferon 
(IFN) inducers of polyinosinic-polycytidylic acid. The highest 
macrophage activity occurs 24 hours after treatment, returning to normal 
levels after 6  days.
A preliminary study by Urba et showed that FAA caused a 
significant increase in NK cell activity in three out of six patients with no 
induction of IFN-y. The evidence that anti-IFNa/|3 antibodies inhibited 
FAA action at 4 hours suggests that FAA mediated its tumour response
1 2
indirectly by immunomodulation as well as directly by anti-proliferative 
or cytotoxic activity. Further evidence that it is macrophage and 
lymphocyte activity that causes tumour necrosis by 	O came from Bibby 
and Double^^ using normal NMRI, thymectomised mice and nude mice 
strains. Normal mice have a fully functioning immune system, 
thymectomised mice have all of their immune system removed surgically 
and chemically and nude mice are genetically altered to be born 
immunodeficient. They found that the tumours were highly responsive to 
FAA only in the normal mice but the nude mice and thymectomised strain 
showed no tumour regression. This research, more than any other proves 
that FAA acts on some part of the immune system, perhaps through a 
cascade effect. Recently Futami et al^’^ showed that when murine splenic 
leukocytes were cultured with 100 |ilg/ml of FAA there was an increase in 
the cytokine mRNA expression which led to expression of TNF-a after 1 
hour and maximal expression of TNF-a, IFN-a, IFN-y mRNA after 3 
hours. Unfortunately human peripheral blood leukocytes did not respond 
by cytokine expression.
Inhibition of platelet aggregation and adhesion by NO may be two 
of the reasons that affected vessels become leaky and divert host blood 
from the tumour site.^^ Direct cytotoxicity could be explained by the 
production of high concentrations of NO which would occur during cell­
cell contact with the macrophage.
4. Clinical Trials
The concept of a pharmaceutical window for flavone acetic acid was 
presented by Zaharko et al. The maximum tolerated dose was found to 
be 600p.g/ml in the plasma for short periods with delayed lethality 
resulting from long exposure (24hrs) at a range of doses.
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From these results three conditions must be fulfilled for maximum 
anti-cancer effect:
• The concentration of the drug in the plasma must lie within the 
therapeutic window of activity.
• There must exist an adequate blood vasculature to the cancer.
• The immune system must be fully functioning.
Preclinical results^^ selected LM985 (ethyl diaminoethyl derivative 
of FAA) 19 as a good agent for cancer treatment due to the fact that it had 
few side effect and little or no myelosuppression or major organ toxicity. 
The drug was found, however, to break down into the parent acid 18 via a 
de-esterification enzyme and it was the parent FAA therefore that was 
finally chosen for full clinical trials.^
a. Metabohsm
Cummings et attempted to characterise the two major metabolites
of FAA found in the plasma because the phase II clinical trials showed that 
drug concentrations were much lower in man than that found in mice. 
Urine was taken from patients and the metabolites purified by HPLC. 
Metabolite 1 (Ml) was a glucuronide conjugated to the acetic acid group 
which was shown to be chemically labile and tended to rearrange under 
alkaline pH conditions. Metabolite 2 (M2) was also a glucuronide and was 
shown to be an isomer of M l with both M l and M2 being non-cytotoxic. 
As much as 80% of low doses were excreted in the urine as M l and M2 
but at high drug doses peak concentrations were reached which showed 
saturation of the glucuronidation pathway explaining low clearance rates. 
Studies in the UK and Italy have shown that tumour FAA levels in patients 
are similar to those obtained in mice reinforcing the fact that the lack of 
efficacy of FAA in humans is not due to a lack of penetration of the drug.
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b. Plasma Concentration
Whereas plasma clearance of any drug is proportional to the body surface 
area and hence faster in small animals the converse is true of FAA, it 
being removed more readily from man and dog than in mouse models. 
Analysis of the plasma by Damia et found that FAA clearance from 
mice was monoexponential and dose dependent. Highest drug 
concentrations were found in the liver and small intestine in humans with 
the lowest concentration found in the brain. Later studies confirmed that 
FAA was found in high concentrations in the gastrointestinal tract, mainly 
in the duodenum, which would suggest biliary excretion as the main 
excretory path for the drug.
c. Toxicitv in vivo
The phase I and II trials^^'^+^^'^^"^^ showed six main areas of 
contraindication. These areas included temperature regulation, blood 
pressure changes, central nervous systems effects, gastrointestinal system 
effects, allergic effects at point of entry and myalgias. Severity of these 
effects encountered during the trials range from slight warming effects to 
dose limiting extreme hypotension with one fatal cardiac arrest.
5. Developments since the discoverv of FAA
a. Xanthenone-4-acetic acids
Several years after the first FAA patent appeared in the literature a group 
from 
ew Zealand headed by Denny reported a homologue of FAA 
known as xanthenone-4-acetic acid (XAA)^'^’'^ '^^  ^ 20. They claimed not 
only that this compound was as non-toxic as FAA and that it was an 
effective anti-cancer drug but also that it was tenfold more active than 
FAA. More recently the 5,6-dimethyl XAA derivative 21 has been shown 
to be ten times more active than 2 0  and clinical trials using this are now in 
p r og res s .T he i r  synthetic plan is shown in section C.
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b. Flavone-8 -carboxylic acid
The paper by Blanton et alJ^ outlining the synthesis of flavone-8 - 
carboxylic acids 2 2  and their biological activity produced startling results. 
They discovered that the Diels-Alder cycloaddition reaction of substituted 
3-cyanofurans with vinylketones yielded the corresponding 3-cyano-2- 
hydroxyacetophenones which they realised were useful starting materials 
for flavone synthesis. The biological activity for the series of 
functionalised flavone-8 -carboxylic acids were disappointing showing no 
activity in vitro but comparable activity in vivo with flavone-8 -acetic acid. 
The most active compound was 22. Their synthetic plan is shown in 
section C.
C. Synthetic Methods for Flavonoids
I. General
A large number of synthetic routes to flavonoids have been developed. A 
representative selection of these is shown here.
a. The Baker-Venkataraman Rearrangement
In 1933 Baker reported a method for the formation of flavones"^  ^ (later 
known as the Baker-Venkataraman rearrangement) starting from 
resacetophenone 23. This serendipitous discovery (actually starting out to 
make resacetophenone dibenzoate 24) involved firstly the reaction with 
one equivalent of benzoyl chloride to form 25 followed by the
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introduction and migration of a second benzoyl group to form 26. The 
reaction does form 24, however the conditions are such that the 
rearrangement occurs spontaneously with 24 never being isolated. The 
flavone itself is formed by dehydration. This reaction promoted great 
interest and further synthetic work began on functionalising the starting 
acetophenone.
Me BzCI Me
NaOHHO PhCOOOH PhCOOOH OCOPh
23
PhCOO
25 24
BzClK2CO3 K2CO3
PhCOOOH
26
For the general reaction of 27 to 28 it was found that R3 may be alkyl or 
aryl, hence flavones, and that Ri could only be alkyl or hydrogen because 
of the reactivity of the ketone towards nucleophiles.
3 base 2il
OH
27
R'
However it is possible to alkylate the (3-diketone once formed, usually 
though, with low yields. This leads to a 3-substituted benzopyranones.
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It was found that if Ri in 27 was an ester group, reacting compounds such 
as 29 with ethyl formate 30 in the presence of sodium gave a 71% yield 
of the 4-hydroxycoumarin 31. The intermediate 32 is never isolated.
OH
Na^^^HCOOEt 71 %
OH 30
29
o
OEt
OHOEt
32
b. The Kostanecki Robinson reaction
An important synthetic route to 3-substituted flavones was exploited by 
Kostanecki and Robinson.^'^ '^  ^ It was shown that the substituent affected 
the products obtained from the reaction. When an a - subs t i tu ted  
hydroxyacetophenone 33 was reacted with any aliphatic or aromatic 
anhydride in the presence of the corresponding base of the anhydride, then 
several pathways existed for the initially formed acyloxyacetophenone 34 
It could undergo a Baker-Venkataraman rearrangement to yield the two 
products 35 and 36 (37 can also be obtained) shown or if R  ^ was a 
substituent other than hydrogen then the chromone 35 was formed. It was 
possible, however, that a further reaction could occur involving the 
intramolecular aldol condensation with elimination of water to form the 
coumarins 38 and 39.
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A study was undertaken by owlan et aV^ to discover the reason for 
facile synthesis of chromones discovered by Baker. In their paper, which 
compared the reactivity of 2 -(nitrobenzoyloxy)acetonaphthones, it was 
found that the rearrangement intermediate 40 was influenced by the 
position of the double bond between the two reacting groups. Isomeric 
napthones were prepared and their ease of transformation monitored. In 
general it seems that the high electron density of the 7C-electrons between 
the acetyl group and the ester group in 41 and 42 decreases the rate of 
rearrangement. Molecule 43, however, rearranges under the same 
conditions in around one minute due to the lessened electron density 
between the reacting groups on the ring.
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Electron density 
between reacting 
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the reaction rate
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c. Via Coumaranones
In papers by Auwers^^ and later Minton , f lavones  were prepared from 
benzofuranones. Minton's synthesis started from 2-chlorophenol 44 
reacting with chloroacetic acid in base followed by the further formation 
of the acid chloride 45. Cyclisation of this molecule using aluminium 
chloride as catalyst yielding 46 followed by condensation with 
benzaldehyde resulted in the format ion of 7-chloro-2-  
benzylidenecoumaran-3-one 47 in good yield. Bromination across the 
double bond led to 48 which was then reacted with sodium hydroxide and 
dehydrated to form the 8-chloro-3-hydroxyflavone (8 -chloroflavonol) 49.
1) CICH2CO2H 
/ base ^
2 ) SOCI2
AiCh
Benzaldehyde
Base
OH NaOH
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d. Condensation of protected salicylates
Much work has been done on naturally occurring flavones for example the 
synthesis of polyhydroxylated analogues by Cushman et Their
work stems from an interest in the inhibition of retroviral reverse 
transcriptases, protein-tyrosine kinases and serine/threonine kinases related 
especially to ring A hydroxylated flavones. In their synthesis they protect 
the hydroxyl group of methyl salicylate with Bu^MezSiCl to avoid side 
reactions in the presence of base. When this compound is coupled with 
any aryl ketone 51 in the presence of base it forms a protected (3-diketone 
52 which can be deprotected using fluoride. The hydroxy p-diketone is 
then set for cyclisation under acid conditions to isolate the flavone 53 in 
good yield.
OH DMF/Pr'zNEt
OMe
50
LiHMDS/THF
OH
— Si 52AcOHH2SO4
95-100 “C
53
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e. Using intramolecular Wittig reaction
High yields (83-94%) for the coupling reactions have been reported. Le 
Floc'h et a l  based their synthesis^^ on the overall y lid formation followed 
by subsequent removal to form the flavone. Following the bromination of 
54 and the addition of triphenylphosphine, the bromophosphonium salt 55 
is formed. This phosphonium salt can either be pushed on directly to the 
flavone 56 or can be made into the y lid 57 which will then undergo an 
intramolecular Wittig reaction with the 0-acyl group to form 56.
o
54
1 )B r,/C C L  _
2) P(Ph)3 /  Toluene
1) CH2CI2, N^COg aq.^  
2) NaOH O.IM / dioxan
^1) RCOCl /  pyridine 
2) NaOH O.IM 50 T
56
© 0  P(Ph)3 Br
1)HBr47% , 100 “C
2) NaOH O.IM 50 “C
P(Ph)3
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f. Acvlation under acidic conditions
Chromones may also be formed under acidic conditions. The reaction 
pathway exploited by Dorofeenko and Tkachenko^^ in 1971 involves 
treating substituted phenols 58 with acetic anhydride and perchloric acid. 
The phenol undergoes successive 0-acylation 59, Fries rearrangement 60, 
C-acetylation 61 and finally cyclisation to the benzopyrilium salt 62 which 
can be hydrolysed to the chromone 63.
2 2
R'
Ac^ Q
HCIORQ- ^  'OH
58
4
R' R' O
RO
irV R’ OMe
OAc RO RO
59
Aqueous workup
O Me
60
OH
cio.-
RO Me
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g. From flavanols
Flavanone involvement in the reactions has been exploited in the synthesis 
by Dauzonne et 3-Nitroflavone 64 and its derivatives have been
postulated by them as having novel biological properties.
NO
NO
66
6765
/E tgN /T H F  
r.t, 16 h 
42-80%OH
68
,Ç| + enantiomer
69
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In their synthesis they take the aldehyde 65 and treat it with 
chloronitromethane 6 6  to form 67. Reaction of this compound with the 
other aldehyde 6 8  forms an enantiomeric mixture of the diastereomers 
with the relative configuration 2R*, 3R*, 4R*. Their procedure towards 
the 3-nitroflavone target encompasses two relatively simple steps. Firstly 
sonication of the flavanol 69 in the presence of PCC oxidises the hydroxyl 
to the ketone 70. Oh treatment of 70 with DBU in THF the target 
nitroflavone 64 is formed in reasonably good yield via HCl elimination.
H OH
racemates
.xNOs 
Cl P C C /C H ,C lg  
"H ))))
racemates
.NO 2 , DBU/THFr.t
H
2. Svntheses used bv Lipha
The company produced many derivatives by following the routes shown
b e l o w . 23.89-91
COON
MeOH
OHOH OH
71 7372 OMe
HBrKCN
OH
77 76 75ON OMe
Ar
2NaH
O
XMeO Ar
74
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In the first route, starting from a substituted hydroxyacetophenone 71, 
they chloromethylated the 3 -position to give 72 and then replaced the 
chlorine with a methoxy group 73. Standard condensation with any aryl 
ester 74 under basic conditions resulted in the p-diketone 75 which could 
be cyclised and brominated in one step. Treatment of 76 with potassium 
cyanide gave 77 and further acid hydrolysis gave the substituted flavone- 
8 -acetic acid 18. This route has problems in that the chlorométhylation 
step occurs not only on the 3-position but also on the 5-position (see 
section 4).
The other route was in essence a reversal of the more conventional 
first route. This time the company started from a methyl salicylic acid 
78, firstly producing the ester 79, then brominating the 3-methyl 
substituted to give 80. Conversion of this brominated compound to the 
methoxy compound 81 then allowed coupling to the complementary 
acetophenone 82 to form the p-diketone 83. The rest of the synthesis of 
flavone-8 -acetic acids 18 was the same as the above route.
Me Me
OMe OMe
OMe NaOMe
78 79 80
KCN HBr
OMe
OMe R =  HCOOH ON
18 77 76 83
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3. Synthesis of related compound types
a. Flavone-8 -carboxylic acids
Blanton et a lP  used classical Baker-Venkataraman methodology finally 
cyclising the flavone and hydrolysing the cyano group to the carboxylic 
acid 8 6 . Starting from substituted 3-cyanofurans 87 and reacting with 
vinylketones, in a Diels Alder fashion, yielded the corresponding 3-cyano- 
2 -hydroxyacetophenones 8 8 . They realised that these compounds were 
useful starting materials for flavone synthesis and reacted these 
acetophenones with substituted acid chlorides. This gave a molecule which 
could undergo classical Baker-Venkataraman rearrangement into a (3- 
diketone which could be cyclised using acid conditions.
O NHMe CN NC
Me
Me NH MeMe'
87
CNCN
OHMeMe
MeMeMe Me
CN
,0HMe Me
Me Me
86
= CN, COOH, CONB
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b. Xanthenone-4-acetic acids
The synthetic routes shown below have been developed by Denny and co­
workers.
© Ph + " ' i
R OHn -f- R
H
89
BzO
COOH
93
Scheme la COOH
Scheme lb
CH gZ
Z = OH 
Z = Halogen 
Z = CN
Scheme 2
COOH
O
HO
89
4 r^
Z = CH3 
Z = CHzBr 
Z = CH2CN
0
- 0 ^
20 C^OOH
t
0
94 \ COOH Scheme 3
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The first involved the initial Ullmann coupling of either halobenzoic acids 
(X= Br or Cl) 89 or diphenyliodonium-2-carboxylates 90 with substituted 
phenols forming substituted 2-phenoxybenzoic acids 91 followed by 
cyclodehydration using a range of acids (including concentrated sulphuric 
acid, methanesulphonic acid and polyphosphoric acid). This reaction, 
which gave moderate yields, was carried out by heating to 140 °C in 
excess phenol or DMF for 5 to 10 hours.
The halobenzoic acids 89, however, required a higher temperature, 
typically 180 °C, in more dipolar aprotic solvents with catalytic amounts 
of CuCl and TDA-1 (tris-[2-(2-methoxyethoxy)ethyl]amine). The 
methylxanthenones were then brominated by BS with a radical initiator 
and thence converted to their cyano derivatives with inorganic cyanides. 
Subsequent acid hydrolysis gave the corresponding xanthenone-4-acetic 
acids in good yields.
Scheme 2 shows a variation of the above reactions by having the 
acetic acid moiety already in place. The 2-hydroxyphenylacetic acids 92 
were prepared as shown by the reaction of benzylated salicylic acids 93 
under phase-transfer catalysis. Firstly the acid chloride is produced and 
after reduction, with sodium borohydride, the corresponding protected 
acid is obtained. On conversion to the halogen derivative and subsequent 
cyanation and alkaline deprotection the required product 92 is available to 
enter the coupling reaction.
Allylphenols 94 and halobenzoic acids 89 also form the xanthenone 
target when coupled together and cyclised, as shown in scheme 3, followed 
by careful permanganate oxidation in low to moderate yields.
4. Previous work in this laboratory
Work started in this group to use the first synthesis reported®^ by Lipha 
and described in section 2  above to prepare a range of substituted 
derivatives for anti-tumour evaluation. The synthesis began with the
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reaction of methyl salicylate 95 and paraformaldehyde under acidic 
conditions. This step, however, produced two isomers which proved 
difficult to isolate. The correct isomer 96 was then pushed on in the 
scheme substituting the pendant chlorine with a methoxy group. This 
compound 97 could then be reacted in the standard fashion with any aryl 
ketone 30 to form the 2 -hydroxy-3 -methoxymethyl p-diketone 98. 
Cyclisation of 98 with hydrobromic acid not only forms the flavone 99 
but also replaces the methoxy group with bromine. Cyanation of this 
compound and subsequent acid hydrolysis gives 18 in reasonable yield.
0 0 0
^  ;
Separate isomers
OH HCl
COOH
, 1) KCN 
2) H2SO4
96
OMe
97
HBr
OH
OMe
Ar
99 98
It did not prove possible however to separate the isomeric chloromethyl 
compounds^^ and so an attempt was made to delay the separation until the 
next stage with the methoxy group replacing the chlorine. This proved
29
not to be any more of an advantage and thus it was decided to prevent 
formation of the unwanted isomer by blocking the site para to the hydroxy 
group. The rest of the synthesis was still viable with only the starting 
material needing to be changed.
MeMeMeMe MeMe
OHGAcOH
101 100
M eOH/Fe
MeMeMe HBr MeAr  ^ NaH
OHOH
OMeOMe
103
KCN
O o
Me
Ar
COOHON
104
Ar
102
To overcome separation problems 2-hydroxy-5-methylacetophenone 100 
was chosen as the starting material. Acétylation and Fries rearrangement 
of p-cresol 101 yielded the product 100 that was protected at the para  
position. This could then be chloromethylated and reacted with methanol 
to give the main reactant for all of the further syntheses. This compound, 
2-hydroxy-3-m ethoxym ethyl-5-m ethylacetophenone 102, could be 
coupled to any alkyl or aryl ester 74 under the influence of sodium 
hydride in THF as a solvent. The coupled molecule could then be cyclised 
using acetic acid and hydrobromic acid simultaneously replacing the
30
methoxy group with bromine. The bromine on 103 could then be 
displaced with cyanide and ultimately hydrolysed off under aqueous acid 
conditions to produce the 6 -methyl flavone acetic acid 104. Using this 
method a number of 6 -methyl analogues were prepared and evaluated for 
anti-tumour activity in vitro and in vivo.^^ However these proved to be 
less effective as anti-cancer agents than the unsubstituted FAA itself. The 
reason for the 6 -methyl FAA’s lack of efficacy can be in part inferred 
from the fate of benzene versus toluene in vivo. The extra methyl group 
provided a useful handle for the enzymes of the body to dispose of toluene 
easier than benzene. It seems therefore that 6 -methyl FAA’s would be as 
cytotoxic to cancer cells if only they survived the transport to the cells.
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D. Programme of Research
As described in section B, FAA initially seemed a promising candidate for 
the treatment of solid tumours. The disappointing results with human 
patients contrasted with the encouraging preliminary results in the mouse 
models. Although a great deal of biological work has now been done into 
the mode of a action of this compound, we do not yet have a full 
understanding of its mechanism of action.^"^
The biological work as well as the clinical trials have concentrated 
almost exclusively on FAA itself. There was clearly a need to broaden the 
study by evaluation of a range of analogues with more diverse structures. 
A large number of these have indeed been prepared, but these are mostly 
described in p a t e n t s , a n d  activity results have only been reported in 
two papers.
We therefore set out to prepare a range of FAA analogues with 
differing substitution on the 2 -phenyl group and the 8 -acetic acid group 
for in vitro and in vivo anti tumour evaluation in collaboration with Prof. 
J. A. Double and Dr. M. C. Bibby at the Clinical Oncology Unit, 
University of Bradford. The compounds were required in gram quantities 
and so a robust straightforward synthesis had to be developed which 
allowed ready incorporation of the desired substitutents. When a range of 
compounds were in hand their electronic structure could be examined by 
MR and any correlation between this and the structure-activity 
relationships discovered might lead to some understanding of their 
mechanism of action and allow design of new, more active analogues.
EXPERIMENTAL
32
A. Symbols and Abbreviations
mmol millimoles
M mol dm-3
h, min hours, minutes
GC-MS gas chromatography-mass spectrometry 
tic thin layer chromatography
MR nuclear magnetic resonance
5  chemical shift in ppm
ppm parts per million
Hz hertz
J  spin-spin coupling constant in Hz
s, d, t, q, m singlet, doublet, triplet, quartet, multiplet
Vmax infrared absorption frequency in cm-i
m/z mass to charge ratio
M+ mass of molecular ion
FAB fast atom bombardment
A nitrobenzylalcohol matrix
m.p. melting point
b.p. boiling point
eq. equivalent
1 mmHg 133.32 Pa
33
B. Instrumentation and General Techniques
1, .M.R. Spectroscopy
a) iHMR
Ail routine spectra were recorded at 200 MHz on a Varian Gemini 
2 0 0  instrument by the author while those of new compounds were 
recorded by Mrs M. Smith on a 300MHz Bruker AM-300 spectrometer.
b) 13ÇMR
All routine spectra were recorded by the author on a Varian Gemini 
200 instrument operating at 50 MHz while spectra of new compounds 
were recorded by Mrs M. Smith on a Bruker AM-300 running at 75.5 
MHz.
All iH and MR spectra were obtained from solutions in 
deuteriochloroform, except where the compound was a carboxylic acid or 
its sodium salt in which case deuteriodimethyl sulphoxide or deuterium 
oxide were used. Chemical shifts for both ^H and are expressed in 
parts per million to high frequency of internal tetramethylsilane or, in the 
case of D2O solutions internal 3-(trimethylsilyl)-1 -propanesulphonic acid 
sodium salt.
2. Infrared Spectroscopy
Spectra were recorded using a Perkin-Elmer 1420 ratio recording 
spectrophotom eter or Perkin-Elm er 1710 Fourier transform  
spectrophotometer. The spectra were run on sodium chloride plates as a 
nujol mull for solids or as a thin film for liquids. The spectra were 
calibrated with the polystyrene peak at 1603 cm-h
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3. Mass Spectrometry
Mass spectra were obtained on a Finnigan Incos 50 mass 
spectrometer or a Fisons VG Autospec by Mr C. Millar.
4. Elemental Analysis
Microanalysis for carbon, hydrogen and nitrogen were carried out 
by Mrs S. Smith using a Carlo-Erba 1106 elemental analyser.
5. Melting points
Routine melting points were determined on an Electrothermal 
melting point machine while accurate melting points of new compounds 
were determined on a Reichert hot-stage microscope.
6 . Thin Layer Chromatography
Aluminium sheets coated with 0.2 mm of silica (Merck, Kieselgel 
6 OF254) were used and the components observed under ultraviolet light.
7. Column Chromatography
This was carried out using Fisons silica gel (60-120 mesh).
8 . Drying and Evaporation of Organic Solutions
All organic solutions were dried by adding appropriate amounts of 
anhydrous magnesium sulphate. This was filtered off and the filtrate 
evaporated under reduced pressure on a Biichi rotary evaporator.
9. Drying and Purification of Organic Solvents 
Methanol
Following a procedure by Lund and Bjerrum^^ warmed clean dry 
magnesium turnings (5 g) and iodine (0.5 g) was added to 50-75 ml of
35analar methanol until the iodine disappeared and all the magnesium was 
converted to methoxide. More methanol (11) was added and the mixture 
heated under reflux for 2 h. The methanol was then distilled and stored 
over molecular sieve (4Â)
Tetrahydrofuran
Dry THF was prepared by distillation from potassium benzophenone 
ketyl under 2 .
Dimethylformamide
DMF was stored over molecular sieve (4Â).
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C. P rep ara tio n  of Flavone-8 -acetic Acid and  M onosubstitu ted  
D erivatives
1. F lavone-8 -acetic Acid
a. Preparation of 2-allyloxyacetophenone 108
Anhydrous potassium carbonate (41.5 g, 0.3 mol) was added to a solution 
of 2 -hydroxyacetophenone 95 (40.9 g, 0.3 mol) and allyl bromide 
(36.3 g, 0.3 mol) in A.R. acetone (250 ml). The mixture was then 
heated under reflux with stirring for 4 h after which it was filtered and 
the filtrate poured into water (300 ml). The mixture was extracted with 
ether (3 x 25 ml) and the combined extracts washed with 2M sodium 
hydroxide (100 ml), dried over potassium carbonate and evaporated. The 
resulting yellow oil was d istilled  in vacuo  to afford 2 - 
allyloxyacetophenone (44.0 g, 83%) as a colourless liquid which solidified 
on storage, m.p. 19-21 °C; b.p. 263-265 “C (lit.,^^ 263 °C); (melt) 
1667 (C=0), 1595, 1292, 1235, 1162, 1123 and 758 cm~i; 6 ^ 7.70
(1 H, d, J  8 ), 7.38 (1 H, m), 6.90 (2 H, m), 6.02 (1 H, m), 5.45 (1 H, d, 
J  16), 5.26 (1 H, d, J  8 ), 4.59 (2 H, d, J  5) and 2.61 (3 H, s); 8 ^ 199.5
(4:-y), 157.9 (4:1^ ), 133.6 (CH), 132.6 (CH), 130.3 (CH), 128.5 (4^y), 120.7 
(CH), 118.1 (CH2), 112.8 (CH), 69.3 (CH2) and 32.0 (CH3); m/z 176 (M+, 
20%), 161 (29), 147 (11), 133 (31), 121 (100), 105 (37), 91 (15) and 78 
(25).
b. Preparation of 3-allvl-2-hvdroxvacetophenone 109 
2 -allyloxyacetophenone ( 2 0  g, 0 .1 1  mol) was heated under reflux in a 
nitrogen atmosphere for 5 h. The flask was cooled and the mixture 
d istilled between 140-160 “C at 16 mmHg to afford 3-allyl-2- 
hydroxyacetophenone (13.2 g, 6 6 %) as a light yellow liquid, b.p. 110 “C 
at 0.3 mmHg (lit.,^^ 258 T ); v^^^3380, 2979, 1637, 1317, 1246, 1126,
37983, 917, 768 and 751 cm~^; 6 y 12.61 (1 H, s), 7.58 (1 H, d, 7 7), 7.32
(1 H, d, J  7), 6.80 (1 H, t, J  7), 6.08-5.89 (1 H, m), 5.11-5.02 (2 H, 
m), 3.37 (2H , d, 7 7) and 2.57 (3 H, s); 6 ^ ^04.7 (4::y), 160.4 (4«:y),
136.4 (CH), 136.1 (CH), 129.3 (4^y), 128.8 (CH), 119.2 (4^), 118.4 (CH),
116.0 (CHz), 33.4 (CH2) and 26.7 (CH3); m/z 176 (M+, 8 6 %), 161 (100), 
143 (11), 133 (28), 115 (13), 105 (17), 84 (25) and 77 (26).
c. Preparation of l-G-allvl-2-hvdroxvphenvl)-3-phenvlpropane-1.3-dione 
112
Sodium hydride (60% dispersion in oil, 0.88 g, 22 mmol) was washed 
with petroleum (b.p. 40-60 °C) and the petroleum decanted. A solution 
of methyl benzoate (1.50 g, 11 mmol) in dry THF (50 ml) was added and 
the mixture was heated under reflux while 3-allyl-2-hydroxyacetophenone 
1 0 9  (1.94 g, 11 mmol) in dry THF (50 ml) was added dropwise. After 
heating under reflux for 5 h the mixture was allowed to cool and dry 
methanol ( 2 0 0  ml) was added cautiously followed by dropwise addition of 
concentrated sulphuric acid until pH4 was reached. The mixture was 
evaporated and water (50 ml) was added to the residue which was 
extracted with methylene chloride (2 x 50 ml). The extracts were dried 
and evaporated to give a yellow solid which was recrystallised from 
ethanol to give l-(3-allvl-2-hydroxvphenvl)-3-phenylpropane-1.3-dione 
(2.68 g, 87%) as yellow plates, m.p. 84-86 °C (Found: M+, 280.1099. 
C 18H 16O3 requires M, 280.1099); V^^  ^ 1695, 1606, 1296, 1235, 1186, 
1067, 913, 762 and 684 cm-i; 6 ^ 15.50 (1 H, s), 12.43 (1 H, s), 7.95 
(2 H, m), 7.67 (1 H, dd, 7 8 , 2), 7.61-7.42 (3 H, m), 7.38 (1 H, dd, 7 8 ,
2), 6.85 (2 H, m), 6.10-5.90 (1 H, m), 5.11-5.00 (2 H, m) and 3.42 
(2H , m); 6 ^ 196.0 (4ry), 177.2 (4ry), 160.5 (4ry), 136.2 (CH), 135.9
(CH), 133.7 (4ry), 132.3 (CH), 129.7 (4^y), 128.8 (2 x CH), 126.8 (2 x 
CH), 126.7 (CH), 118.6 (CH), 118.5 (4ry), 116.0 (CH2), 92.5 (CH) and
3833.6 (CHi); m/z 280 (M+, 63%), 263 (5), 161 (29), 132 (17), 105 (100),
91 (5) and 77 (62).
d. Preparation of 8 -allvlflavone 123
A solution of l-(3-allyl-2-hydroxyphenyl)-3-phenylpropane-l,3-dione 
(2.50 g, 8.92 mmol) in methanol was heated under reflux for 1 0  min then 
5  drops of concentrated sulphuric acid were added and the mixture heated 
under reflux for a further 4 h. The solvent was removed and the resulting 
cream solid recrystallised from ethanol to give 8 -allylflavone (1.87 g, 
80%) as colourless needles, m.p. 138 °C (Found: C, 82.6; H, 5.4. 
C 18H 14O2 requires C, 82.4; H, 5.4%); 1637, 1596, 1585, 1498, 1213,
1140 and 1044 cm~i; 8^8.10 (1 H, dd, 7 8 , 2, H-5), 7.91 (2 H, m, H- 
2',6'), 7.53 (4H , m, H-7,3',4',5'), 7.32 (1 H, t, 7 8 , H-6 ), 6.83 (1 H, s, 
H-3), 6.17-6.00 (1 H, m), 5.17 (2 H, m) and 3.75 (2 H, d, 7 8 ); 
8 c 178.7 (4:^ )^, 163.0 (4":y), 154.2 (4^y), 135.3 (CH), 134.1 (CH), 132.1
(4cy), 131.6 (CH), 129.5 (4:y),' 129.1 (2 x CH), 126.3 (2 x CH), 125.0 
(CH), 124.0 (41 )^, 123.9 (CH), 117.0 (CH2), 107.4 (CH) and 34.0 (CH2); 
m/z 262 (M+, 100%), 234 (6 ), 160 (19), 145 (11), 131 (53), 115 (11), 89 
(7) and 77 (33).
e. One-pot preparation of 8 -allylflavone 123
Sodium hydride (60% dispersion in oil, 0.88 g, 22 mmol) was washed 
with petroleum (b.p. 40-60 °C) and the petroleum decanted. A solution 
of methyl benzoate (1.50 g, 11 mmol) in dry THF (50 ml) was added and 
the mixture was heated under reflux while 3-allyl-2-hydroxyacetophenone 
109 (1.94 g, 11 mmol) in dry THF (50 ml) was added dropwise. After 
heating under reflux for 5 h the mixture was allowed to cool and dry 
methanol ( 2 0 0  ml) was added cautiously followed by dropwise addition of 
concentrated sulphuric acid until pH 4 was reached. The mixture was once 
again heated under reflux for 3 h. Water (20 ml) was added and the
39solution partly evaporated. Water (100 ml) was added and the mixture 
extracted with dichloromethane (3 x 50 ml). The extracts were washed 
with 2M sodium hydroxide to remove starting materials, dried and 
evaporated. The resulting solid was recrystallised from ethanol to afford 
8 -allylflavone (2.14 g, 74%) as colourless needles, m.p. 138 “C, identical 
to that obtained in d. above.
f. Preparation of flavone-8 -acetic acid 129
A solution of 8 -allylflavone 123 (5.2 g, 20 mmol), acetone (200 ml), 
glacial acetic acid ( 2 0 0  ml) and water ( 1 0 0  ml) was stirred with cooling 
to below 5 °C during the addition of potassium permanganate (16.6 g, 
110 mmol) over a period of 6  h. Saturated aqueous sodium 
metabisulphate was added dropwise until the solution turned a cream 
colour. The solution was evaporated and added to water (200 ml). The 
precipitate was then filtered off, washed with water and dissolved in a 
saturated solution of sodium bicarbonate (20 ml). The resulting 
suspension was filtered and the filtrate carefully acidified to pH 4. The 
precipitate that formed was filtered off, washed with water and 
recrystallised from glacial acetic acid and water (2 :1) to afford flavone-8 - 
acetic acid (2.86 g, 51%) as colourless needles, m.p. 238-240 °C (lit.,^^ 
234 T )  (Found: C, 73.1; H, 4.4. Calc, for C 17H 12O4 C, 72.9; H, 4.3%);
1716, 1628, 1601, 1583, 1273, 1186 and 1171, 988 cm -i;
Sy (CD 3SOCD 3) 13.0-12.0 ( 1  H, br s, OH), 8.10 ( 2  H, dd, 7  8 , 2 , H- 
2',6'), 8.00 (1 H, dd, 7 8 , 2, H-5) 7.78 (1 H, dd, 7 8 , 2, H-7), 7.61 (3 H, 
m, H-3',4',5'), 7.45 (1 H, t, 7 8 , H-6 ), 7.03 (1 H, s, H-3) and 4.03 (2 H, 
s); 8 c (CD 3SOCD 3 ) 177.1 (4^y), 171.6 (4^y), 162.3 (4":y), 154.0 (4^y),
135.6 (CH), 131.7 (CH), 131.3 (4:"y), 129.1 (2 x CH), 126.3 (2 x CH),
125.6 (4»:y), 124.9 (CH), 123.6 (CH), 123.3 (4^y), 106.9 (CH) and 35.5 
(CH2); 280 (M+, 100%), 235 (42), 208 (7), 133 (65), 107 (30) and 7 7
(35).
402. 2 ’-M ethoxyflavone-8-acetic Acid
a. Preparation of methvl 2-methoxvbenzoate 118
A solution of 2 -methoxybenzoic acid (5.0 g, 33 mmol) in methanol 
(100 ml) was heated under reflux for 10 min. Five drops of concentrated 
sulphuric acid were added and heating was continued for a further 8  h. 
The solution was evaporated and the residue taken up in dichloromethane 
(200 ml). This was washed twice with 2M sodium hydroxide (50 ml), 
dried and evaporated to afford methyl 2 -methoxybenzoate (2.13 g, 39%) 
as a colourless liquid which was used without further purification, b.p. 
(oven temp.) 230 “C (lit.,9? 228 T ) ;  8 ^ 7.60 (1 H, dd, J  9, 2, H-6 ),
7.30 (1 H, dd, J  9, 2, H-3), 7.02 (1 H, t, J  9, H-4), 3.91 (3 H, s) and
3.85 (3 H, s).
b. Alternative preparation of methvl 2-methoxvbenzoate 118
A mixture of 2-methoxybenzoic acid (5.0 g, 33 mmol) and thionyl 
chloride (50 ml) was heated under reflux for 15 min and then evaporated. 
A.R. methanol (100 ml) was then added to the residue dropwise with 
caution and the mixture was heated under reflux for 1 h. The solvent was 
evaporated leaving a yellow oil which was Kugelrohr distilled to afford 
methyl 2 -methoxybenzoate (4.76 g, 87%) as a colourless liquid, b.p. 
(oven temp.) 230 T  (lit.,^^ 228 T ) ;  8 ^ 7.62 (1 H, dd, 7 9, 2, H-6 ),
7.34 (1 H, dd, 7 9, 2, H-3), 7.05 (1 H, t, 7 9, H-4), 3.91 (3 H, s) and 
3.83 (3 H, s).
c. Preparation of 8-allvl-2'-methoxvflavone 124
The method of C le was followed using methyl 2-methoxybenzoate 
(1.83 g, 1.58 ml, 11 mmol) to afford 8-allvl-2’-methoxyflavone (1.84 g, 
52%) as colourless crystals, m.p. 88-89 °C (Found: C, 77.9; H, 5.4. 
C 19H 16O3 requires C, 78.1; H, 5.5%); 1732, 1637, 1601, 1584, 1249,
1183, 1165, 1130, 1086, 1051, 917, 832 and 706cm -i; 8 ^ 8.10 (1 H,
41dd, J  8 , 2, H-5), 7.88 (1 H, dd, /  8 , 2, H-7), 7.52 (1 H, d, J  6 , H-3'), 
7.44 (1 H, t, J  6 , H-5'), 7.33 (1 H, t, J  8 , H-6 ), 7.16 (1 H, s, H-3), 7.09 
(1 H, t, 7 6 , H-4'), 7.03 (1 H, d, 7 6 , H-6 ’), 6.13-6.00 (1 H, m), 5.16- 
5.10 (2 H, m), 3.93 (3 H, s) and 3.70 (2 H, d, 7 6 ); 6 ^ 179.2 (4^y),
160.6 (4n )^, 158.0 (4:y), 154.4 (4n )^, 135.5 (CH), 133.8 (CH), 132.4 (CH),
129.4 (4^y), 129.2 (CH), 124.6 (CH), 123.70 (CH), 123.69 (4^y), 120.9 
(4^y\ 120.8 (CH), 116.8 (CH2), 112.4 (CH), 111.8 (CH), 55.6 (OCH3) and
34.0 (CH2); 292 (M+, 35%), 161 (1 0 0 ), 145 (1 0 ), 131 (95), 103 (30),
89 (27) and 77 (40).
d. Preparation of 2'-methoxyflavone-8 -acetic acid 130
The method of C lf  was followed using 8-allyl-2'-methoxyflavone (5.84 g,
20 mmol) to afford 2 '-methoxyflavone-8 -acetic acid (3.23 g, 52%) as 
colourless crystals, m.p. 203-205 °C (lit.,^^ 203-205 °C); 1694,
1622, 1566, 1253, 1189, 1073, 982, 8 8 6  and 683 cm-i; 8 ^ (CD3SOCD3) 
12.50 (1 H, br s, OH), 7.98 (1 H, dd, 7 8 , 2, H-5), 7.89 (1 H, d, 7 6 , H- 
6 '), 7.73 (1 H, dd, 7 8 , 2, H-7), 7.57 (1 H, t, 7 6 , H-4'), 7.43 (1 H, t,
, 7 8 , H-6 ), 7.23 (1 H, d, 7 6 , H-3'), 7.14 (1 H, t, 7 6 , H-5'), 6.94 (1 H, s, 
H-3), 3.95 ( 2  H, s) and 3.95 (3 H, s); 8 ^ (CD3SOCD3) 177.1 (4^^), 171.6
(4=1^ ), 160.2 (4n )^, 157.7 (4^), 154.3 (4^ :y), 135.5 (CH), 132.8 (CH), 129.0 
(CH), 125.4 (4n )^, 124.7 (CH), 123.5 (CH), 123.1 (4^7), 120.7 (CH), 120.0 
(4n )^, 112.6 (CH), 111.4 (CH), 55.9 (OCH3) and 35.2 (CH2); 7M/z 310 (M+, 
96%), 282 (18), 266 (27), 179 (27), 161 (38), 147 (38), 135 (78), 133 
(100), 106 (37), 89 (38) and 77 (55).
e. Preparation of sodium 2'-methoxyflavone-8-acetate 136
The acid (0.93 g, 3.0 mmol) and sodium hydroxide (0.12 g, 3.0 mmol) 
were added to 5 ml of water. The mixture was then heated with stirring 
to 70 “C, filtered and the filtrate evaporated to dryness. The brown 
residue was not further purified. This method did not give the required
42purity for the biological testing and therefore it was abandoned in favour 
of the method below.
f. Improved preparation of sodium 2'-methoxvflavone-8 -acetate 136 
A mixture of 2'-methoxyflavone-8-acetic acid (1.0 g, 3.2 mmol) and 
water (10 ml) was heated to 70 °C. Sodium bicarbonate (0.25 g,
3.0 mmol) was added very slowly. After the effervescence had subsided 
the mixture was heated to 70 °C again with stirring and then allowed to 
cool to 30 °C and filtered. The filtrate was then added dropwise to 
acetone (400 ml) and the white precipitate which formed was filtered off 
and washed with acetone to yield the sodium 2  '-methoxvflavone- 8  - acetate 
(1.06 g, -100%) as a white powder, m.p. >350 °C; 1625, 1578,
1249, 1162, 1124, 1014, 864, 756 and 744cm -i; 6 ^ (CD3SOCD3) 8.09 
(1 H, dd, J  8 , 2, H-5), 7.84 (1 H, dd, J  8 , 2, H-7), 7.62 (1 H, d, J  8 , H- 
6'),'7.54 (1 H, t, J  8 , H-5'), 7.33 (1 H, t, J  8 , H-6 ), 7.23 (1 H, d, J  8 , H- 
3'), 7.14 (1 H, t, J  8 , H-4'), 6.95 (1 H, s, H-3), 3.94 (3 H, s) and 3.60 
(2 H, s); Spi (D 2 O) 7.57 (2 H, d, 7 8 ), 7.46 (1 H, d, 7 8 ), 7 .26-7.10
(2 H, m), 6.89-6.82 (2 H, m), 6.63 (1 H, d, 7 8 ), 3.63 (3 H, s) and 3.61 
(2H , s); 8 c (D2O) 183.8 (4n )^, 181.3 (4 ^^ ), 164.0 (4^y), 160.7 (4^y), 156.8
(4 ry), 138.8 (CH), 136.1 (CH), 131.2 (CH), 129.9 (4 y^), 127.9 (CH), 125.4 
(CH), 124.3 (4 ^^ ), 123.4 (CH), 120.6 (4^y), 114.4 (CH), 112.6 (CH), 57.8
(OCH3) and 41.3 (CH2); m/z (FAB, glycerol) 687 ([2M+a]+, 31%), 355 
([M+ 100), 333 ([M+H]+, 26), 311 ([M+H-a]+, 31), 288 ([M-COaJ^, 
14), 267 (46), 199 (14), 176 (64) and 154 (12).
3. 3 ’-M ethoxyflavone-8-acetic  Acid
a. Preparation of methvl 3 -methoxvbenzoate 119
The method of C2a was followed using 3-methoxybenzoic acid (20.0 g, 
132 mmol) to yield methyl 3-methoxybenzoate (15.3 g, 70%) as a 
colourless liquid, b.p. 88-89 °C at 1.0 mmHg (lit.,^^ 236-238 °C).
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h. Preparation of 3'-methoxv-8-allvlflavone 125
The method of C le was followed using methyl 3-methoxybenzoate 
(1.83 g, 11 mmol) to afford 8-a1]vl-3'-methoxvflavone (2.99 g, 93%) as 
colourless crystals, m.p. 109-110 °C (Found; C, 78.0; H, 5.6. C 19H 16O3 
requires C, 78.1; H, 5.5%); v,^ax 1735, 1655, 1602, 1297, 1273, 1075 and 
879 cm -i; 5^ 8.07 (1 H, dd, /  8 , 2, H-5), 7.52 (1 H, dd, J  8 , 2 , H-7),
7.47-7.34 (3 H, m, H-2',5',6'), 7.32 (1 H, t, J  8 , H-6 ), 7.05 (1 H, d, J  8 , 
H-4'), 6.77 (1 H, s, H-3), 6.14-6.00 (1 H, m), 5.18-5.11 (2 H, m), 3.85 
(3 H, s) and 3.71 (2 H, d, 7 6 ); Sc 178.6 (4^y), 162.7 (4^y), 160.0 (4^y),
154.1 (40'), 135.2 (CH), 134.1 (CH), 133.2 (4?), 130.1 (CH), 129.5 (4o),
124.9 (CH), 123.9 (4'y), 123.8 (CH), 118.5 (CH), 117.1 (CH), 117.0 
(CH2), 111.6 (CH), 107.4 (CH), 55.4 (CH3) and 33.9 (CH2); m/z 292 (M+, 
100%), 264 (6), 160 (17), 145 (11), 132 (51), 115 (9), 103 (16), 89 (13) 
and 77 (20).
c. Preparation of 3'-methoxvflavone-8-acetic acid 131 
The method of C lf  was followed using 8-aIlyl-3'-methoxyflavone (5.85 g, 
20 mmol) to afford 3'-methoxyflavone-8-acetic acid (4.84 g, 78%) as 
colourless crystals, m.p. 253-257 °C (lit.,^^ 238-241 °C) (Found: C, 
69.7; H, 4.4. Calc, for C 18H 14O 5 C, 69.7; H, 4.5%); 1713, 1627,
1583, 1283, 1171, 1080, 973 and 872 cm-i; S^ (CD3SOCD3) 13.5-12.0 
(1 H, br s, OH), 7.98 (1 H, dd, J  8 , 2, H-5), 7.75 (1 H, dd, J 8 , 2, H-7), 
7.64 (1 H, d, J  8 , H-6 '), 7.58 (1 H, d, J  2, H-2'), 7.46 (2 H, m, H-6,5'), 
7.15 (1 H, dd, J  8 , 2, H-4'), 7.03 (1 H, s, H-3), 4.01 (2 H, s) and 3.88 
(3 H, s); Sc (CD 3SOCD 3 ) 177.2 (4:y), 171.7 (4^y), 162.1 (4>-y), 159.8
(4>-y), 154.1 (4-'y), 135.7 (CH), 132.6 (4>'y), 130.3 (CH), 125.5 (4<'y), 125.0 
(CH), 123.7 (CH), 123.3 (4fy), 118.6 (CH), 118.0 (CH), 111.0 (CH), 107.1 
(CH), 55.4 (OCH3) and 35.6 (CH^); m/z 310 (M+, 100%), 265 (25), 133 
(65), 106 (20) and 77 (20).
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d. Preparation of sodium 3'-methoxyflavone-8-acetate 137 
The method of C2f was followed using 3'-methoxyflavone-8-acetic acid 
( 1 .0  g, 3 . 2  mmol) to produce sodium 3'-m ethoxvflavone-8 -acetate 
(1.04 g, 98%) as a white powder, m.p. >350 ‘’C; 1648, 1632, 1272,
1136, 1056, 790 and 701 cm~i; 6 ^ (D2O) 7.71 (1 H, d, J  8 ), 7.55 (1 H,
d, 7 8 ), 7.32 (2 H, t, 7 8 ), 7.23 (1 H, t, 7 8 ), 7.11 (1 H, s), 6 . 8 6  (1 H, d, 
7 8 ), 6.58 (1 H, s), 3.72 (3 H, s) and 3.67 (2H , s); 0^ (D 2O) 183.5
(4»7), 181.1 (4n )^, 166.0 (4 :^/), 161.5 (4n )^, 156.8 (4^^), 139.1 (CH), 134.0 
(4n^), 133.0 (CH), 130.1 (4»7), 128.3 (CH), 125.6 (CH), 124.8 (4 n^ ), 121.7 
(CH), 120.9 (CH), 113.0 (CH), 108.1 (CH), 58.0 (OCH3) and 41.5 (CH2); 
m/z (FAB, glycerol) 623 ([(2 x M )-C0 2 +a]+, 26%), 355 ([M+a]+, 56), 
289 (50), 267 (64), 137 (62), 115 (100), 91 (9) and 77 (5).
4. 4 ’-M ethoxyflayone-8-acetic Acid
a. Preparation of methyl 4-methoxybenzoate 120
The method of C2a was followed using 4-methoxybenzoic acid (20.0 g, 
132 mmol) to afford methyl 4-methoxybenzoate (16.5 g, 75%) as a white 
powder, m.p. 48-49 °C (lit.,^^ 49-51 °C); 8^7.99 and 6.91 (4H , AB
pattern, 7 6 ), 3.91 (3 H, s) and 3.87 (3 H, s).
b. Preparation of 8-allvl-4'-methoxyflavone 126
The method of C le was followed using methyl 4-methoxybenzoate 
(1.83 g, 11 mmol) to afford 8-allyl-4'-methoxyflavone (2.83 g, 8 8 %) as 
colourless crystals, m.p. 113-115 °C (Found: C, 77.7; H, 5.2. CigH^^Og 
requires C, 78.1; H, 5.5%); 1718, 1637, 1513, 1282, 1169, 917, 833,
772 and 697 cm-i; 6 ^ 8.12 (1 H, dd, 7 8 , 2, H-5), 7.93 and 7.04 (4 H, 
AB pattern, H-2',3',5',6'), 7.53 (1 H, dd, 7 8 , 2, H-7), 7.35 (1 H, t, 7 8 , 
H-6 ), 6.83 (1 H, s, H-3), 6.13 (1 H, m), 5.16 (2 H, m), 3.89 (3 H, s) and 
3.76 (2H , d, 7 8 ); 6 ^ 178.6 (4 y^), 163.4 (4^y), 162.5 (4^ y^), 154.2 (4 ^y),
45135.3 (CH), 134.1 (CH), 129.4 (4^y), 128.1 (2 x CH), 124.9 (CH), 124.1 
(4n^), 123.9 (CH), 123.7 (4^^), 117.0 (CH2), 114.6 (2 x CH), 105.8 (CH),
55.5 (OCH3) and 34.0 (CH2); m/z 292 (M+, 100%), 161 (42), 152 (20),
132 (6 6 ), 115 (13), 103 (15), 89 (17) and 77 (35).
c. Preparation of 4'-methoxyflavone-8-acetic acid 132
The method of C lf was followed using 8-allyl-4’-methoxyflavone (5.85 g,
20 mmol) to afford 4'-methoxyflavone-8 -acetic acid (3.10 g, 50%) as 
colourless crystals, m.p. 252-254 X  (lit.,^^ 228-232 X ) (Found; C, 
69.9; H, 4.5. Calc, for CigH^Og C, 69.7; H, 4.5%); 1718, 1634,
1604, 1586, 1182, 1078, 879 and 760cm -i; 6 H (C D 3S 0 C D 3) 12.51 
(1 H, br s, OH), 8.03 (2 H, d, J  9, H-2',6'), 7.96 (1 H, dd, J  8 , 2, H-5),
7.72 (1 H, dd, J  8 , 2, H-7), 7.42 (1 H, t, J  8 , H-6 ), 7.12 (2 H, d, J  9, H- 
3 ',5 '), 6.90 (1 H, s, H-3), 3.99 (2 H, s) and 3.86 (3 H, s);
6 c (CD3SOCD3) 176.9 (4^y), 171.7 (4:y), 162.3 (4n^), 162.2 (4^y), 153.9
(4n^), 135.4 (CH), 128.1 (2 x CH), 125.4 (4^y), 124.7 (CH), 123.6 (CH),
123.4 (4:y), 123.3 (4^y), 114.6 (2 x CH), 105.4 (CH), 55.5 (OCH3) and
35.5 (CH2); m/z 310 (M+, 39%), 266 (100), 132 (83), 106 (23), 89 (13) 
and 77 (30).
d. Preparation of sodium 4'-methoxyflavone-8 -acetate 138
The method of C2f was followed using 4'-methoxyflavone-8 -acetic acid 
(1.0 g, 3.2 mmol) to yield sodium 4'-methoxyflavone-8-acetate (1.0 g, 
94%) as a white powder, m.p. 334-336 X ; 1635, 1580, 1245, 1144, 
1026, 885, 851 and 763 cm~L 6 ^ (D2O) 7.55 (1 H, d, J  8 , H-5), 7.49
(1 H, d, 7 8 , H-7), 7.40 and 6.45 (4 H, AB pattern, d, 7 9), 7.21 (1 H, t,
7 8 , H-6 ), 6.24 (1 H, s, H-3), 3.61 (2 H, s) and 3.47 (3 H, s); 6 ^ (D2O)
183.0 (4ry), 181.3 (4ry), 166.3 (4ry), 164.2 (4ry), 156.5 (4ry), 138.8 (CH),
130.4 (2 X CH), 129.9 (4ry), 128.0 (CH), 125.4 (CH), 124.9 (4^y), 124.6 
(4ry), 116.6 (2 X CH), 106.3 (CH), 57.8 (OCH3) and 41.5 (CHi); m /z
(FAB, glycerol) 687 ([2M+a]+, 26%), 355 ([M+a]+, 74), 333 ([M+H] 
49), 288 (14), 267 (14), 199 (14), 176 (100) and 154 (31).
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5. 4 '-M ethylfIavone-8-acetic  Acid
a. Preparation of methvl 4-methylbenzoate 121
The method of C2a was followed using 4-methylbenzoic acid (5.0 g, 
37 mmol) to afford methyl 4-methylbenzoate (4.05 g, 73.5%) as a low 
melting solid, m.p. 35-36 X  (lit.,^oo 3 2  X ); 6^ 7.91 and 7.22 (4 H, AB
pattern, 7 7), 3.87 (3 H, s) and 2.37 (3 H, s).
b. Preparation of 8-allvl-4'-methvlflavone 127
The method of C le was followed using methyl 4-methylbenzoate (1.65 g, 
11 mmol) to afford 8-allyl-4'-methylflavone (1.91 g, 63%) as colourless 
needles, m.p. 108-110 X  (Found: C, 82.6; H, 5.6. C19H 16O2 requires C, 
82.6; H, 5.8%); 1637, 1212, 1142, 1039, 923, 824, 754 and 613 cm-
1; Ôh 8.06 (1 H, dd, 7 8 , 2, H-5), 7.74 (2 H, half AB pattern, 7 8 , H- 
2',6'), 7.50 (1 H, dd, 7 8 , 2, H-7), 7.33-7.24 (3 H, m, H-6,3',5'), 6.74 
(1 H, s, H-3), 6.12-5.99 (1 H, m), 5.19-5.09 (2 H, m), 3.70 (2 H, d, 
7 6 ) and 2.37 (3H , s); 6 ^ 178.6 (4^ y^), 163.0 (4^ :y), 154.1 (4^y), 142.2
(4:y), 135.3 (CH), 133.9 (CH), 129.8 (2 x CH), 129.6 (4^7), 129.4 (4^y),
126.1 (2 X CH), 124.8 (CH), 123.9 (4^7), 123.8 (CH), 117.0 (CH2), 106.6 
(CH), 34.0 (CH2) and 21.5 (CH3); m/z 276 (M+, 41%), 261 (5), 248 (6 ), 
160 (13), 145 (8 ), 131 (43), 115 (100), 103 (32), 89 (22) and 77 (38).
c. Preparation of 4'-methvlfiavone-8-acetic acid 133
The method of C lf  was followed using 8-allyl-4'-methylflavone (5.52 g, 
20 mmol) to afford 4’-methylflavone-8-acetic acid (2.18 g, 37%) as a 
white powder, m.p. 250-252 X  (lit.,^^ 250-252 X ); 1724, 1635,
1600, 1510, 1220, 1075, 1040, 836 and 758 cm-i; 6 ^ (CD3SOCD3) 12.3 
(1 H ,br, OH), 7.95 (3 H, m, H-5,2’,6’), 7.74 (1 H, dd, 7 8 , 2, H-7),
477.47-7.33 (3 H, m, H-6,3',5'), 6.99 (1 H, s, H-3), 4.01 (2 H, s) and 2.38 
(3 H, s); 6 c (CD 3SOCD 3) 177.0 (4:y), 172.0 (4^y), 162.3 (4n^), 153.9
(4n )^, 142.0 (4^), 135.6 (CH), 129.6 (2 x CH), 128.4 (4n )^, 126.2 (2 x CH),
125.5 (4^y), 124.8 (CH), 123.6 (CH), 123.2 (4^7), 106.1 (CH), 35.5 (CH2) 
and 21.0 (CH3); 294 (M+, 100%), 279 (10), 266 (10), 249 (20), 221
(3), 133 (19), 115 (10), 106 (7) and 77 (8 ).
d. Preparation of sodium 4'-methylflavone-8-acetate 139 
The method of C2f was followed using 4'-methylflavone-8-acetic acid 
(1.0 g, 3.4 mmol) to afford sodium 4'-methvlflavone-8-acetate (0.99 g, 
92%) as a white powder, m.p. >350 “C; 1631, 1590, 1250, 1120,
870 and 751 cm-i; 6 ^ (D^O) 7.56 (1 H, dd, J  8 , 2, H-5), 7.50 and 7.32 
(4 H, AB pattern, d, 7 8 , H-2',3',5',6'), 7.48 (1 H, dd, 7 8 , 2, H-7), 7.21 
(1 H, t, 7 8 , H-6 ), 6.27 (1 H, s, H-3), 3.60 (2 H, s) and 2.14 (3 H, s);
6 c (D2 O) 183.1 (4ry), 181.2 (4ry), 166.0 (4^7), 156.6 (4ry), 139.0 (CH),
130.0 (2 X CH), 129.8 (4ry), 128.0 (CH), 127.6 (4^y), 126.2 (2 x CH), 
125.74 (CH), 125.71 (4^y), 124.6 (4 ry), 108.3 (CH), 41.6 (CH2) and 21.6 
(CH3).
6. 4 ’-Chloroflavone-8-acetic Acid
a. Preparation of methvl 4-chlorobenzoate 122
The method of C2a was followed using 4-chlorobenzoic acid (20.0 g, 
128 mmol) to afford methyl 4-chlorobenzoate (21.4 g, 98%) as 
colourless plates, m.p. 40-43 °C (lit.,^^^ 42-43 °C); 6 y 8.03 and 7.44
(4 H, AB pattern, 7 8 ) and 3.94 (3 H, s).
b. Preparation of 4*-chloro-8 -allvlflavone 128
The method of C le was followed using methyl 4-chlorobenzoate (1.88 g,
11 mmol) to afford 4'-chloro-8-allylflavone (2.71 g, 83%) as colourless 
crystals, m.p. 133-135 ^C (Found: C, 72.9; H, 4.1. C 18H 13CIO2 requires
48C, 72.9; H, 4.4%) 1726, 1637, 1597, 1277, 1194, 1092, 1016, 917,
851 and 761 cm-i; 6 ^ 8.07 (1 H, dd, J  8 , 2, H-5), 7.82 (2 H, half AB 
pattern, J  8 , H-2’,6’), 7.54-7.47 (3 H, m, H-7,3',5'), 7.33 (1  H, t, J  8 , H-
6 ), 6.77 (1 H, s, H-3), 6.13-5.99 (1 H, m), 5.19-5.09 (2 H, m) and 3.72 
(2 H, d, 7 6 ); 5c 178.5 (4^), 161.8 (4''^), 154.1 (4'y), 137.8 (4^^), 135.1
(CH), 134.3 (CH), 130.3 (4^y), 129.4 (2 x CH), 129.4 (4:y), 127.4 (2 x 
CH), 125.1 (CH), 123.9 (CH), 123.8 (4:y), 117.1 (CH^), 107.4 (CH) and
34.0 (CHz); m/z 296 (35C1-M+, 29%), 176 (100), 161 (100), 133 (64), 105 
(34) and 77 (51).
c. Preparation of 4'-chloroflavone-8-acetic acid 134
The method of C lf  was followed using 8-allyl-4'-chlorofIavone (5.93 g,
20 mmol) to afford 4'-chloroflavone-8-acetic acid (3.15 g, 50%) as 
colourless crystals, m.p. 234-237 °C (lit.,^’ 238-242 °C); 1726,
1688, 1624, 1586, 1269, 1114, 1093, 1075, 996, 813 and 721 cm-i;
5h (CD3SOCD3) 12.12 (1 H, hr s, OH), 8.09 and 7.63 (4 H, AB pattern,
7 8 , H-2’,3',5',6'), 7.96 (1 H, dd, 7 8 , 2, H-5), 7.75 (1 H, dd, 7 8 , 2, H-
7), 7.45 (1 H, t, 7 8 , H-6 ), 7.04 (1 H, s, H-3) and 4.00 (2 H, s);
5c (CD3SOCD 3) 177.0 (4^y), 171.7 (4:y), 1 6 1 .0  (4^y), 153.9 (4'y), 136.6
(4?), 135.6 (CH), 130.1 (4 ry), 129.1 (2 x CH), 128.0 (2 x CH), 125.5 (4>-y),
125.0 (CH), 123.7 (CH), 123.3 (4 '?), 107.2 (CH) and 35.5 (CHj); m/z 314 
(35C1-M+, 100%), 300 (24), 296 (32), 134 (96), 106 (40), 83 (40) and 77 
(32).
d. Preparation of sodium 4'-chloroflavone-8-acetate 140
The method of C2f was followed using 4'-chloroflavone-8-acetic acid 
(1.0 g, 3.2 mmol) to give sodium 4'-chloroflavone-8-acetate (1.03 g, 
96%) as a white powder, m.p. >350 °C; 1550, 1250, 1129, 1042,
1005, 911, 832 and 750 cm -'; 5„ (D2O) 7.58 (1 H, dd, 7 8 , 2, H-5),
7.72 and 7.34 (4 H, AB pattern, d, 7 9), 7.46 (1 H, dd, 7 8 , 2, H-7), 7.20
49(1 H, t, 7 8 , H-6 ), 6.30 (1 H, s, H-3) and 3.58 (2 H, s); 6 ^ (D2O) 183.2 
(4ry), 181.1 (4ry), 165.3 (4ry), 156.6 (4J7), 140.7 (4ry), 139.4 (CH), 133.2 
(2 CH), 132.0 (CH), 131.1 (2 CH), 129.9 (CH), 128.5 (4 ry), 125.8 (4ry),
124.7 (4ry), 108.0 (CH) and 41.7 (CH2); m/z (FAB, glycerol) 695 ([(2 x 
M)+a]+ 15%), 359 ([M+a]+, 44), 337 (M+, 40), 315 (10), 176 (100), 
154 (36), 133 (45) and 95 (99).
7. 4 ’-N itroflavone-8-acetic Acid
a. Preparation of methyl 4-nitrobenzoate 141
The method of C2a was followed using 4-nitrobenzoic acid (20.0 g, 
120 mmol) to yield methyl 4-nitrobenzoate (13.2 g, 61%) as cream 
plates, m.p. 93-96 °C (lit.,102 9 4 . 9 6  T ) ;  8^8.31 and 8.20 (4H , AB
pattern, J  10, H-2,3,5,6) and 3.96 (3 H, s).
b. Attempted preparation of 8-allyl-4'-nitroflavone 142
The method of C le was followed using methyl 4-nitrobenzoate (1.99 g,
11 mmol) to afford a brown oil which, on analysis by and MR, 
showed unreacted 3-allyl-2-hydroxyacetophenone and methyl 4- 
nitrobenzoate.
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P . Preparation of Polvm ethoxv Substituted Flavone-8-acetic 
Acids
1. 2',3'-D im ethoxyflavone-8-acetic Acid
a. Preparation of methvl 2.3-dimethoxybenzoate 143
The method of C2a was followed using 2,3-dimethoxybenzoic acid 
(20.0 g, 110 mmol) to yield methyl 2,3-dimethoxybenzoate (16.4 g, 
76%) as colourless cubes, m.p. 56-57 °C (lit.,^°^ 57.5 °C); 0^ 7.29
(1 H, m, H-5), 7.05 (2 H, m, H-4,6), 3.90 (3 H, s), 3.89 (3 H, s) and
3.86 (3 H, s).
b. Preparation of 8-allvl-2*.3'-dimethoxyflavone 147
The method of C le was followed using methyl 2,3-dimethoxybenzoate 
(2.16 g, 11 mmol) to yield 8-allyl-2*.3'-dimethoxvflavone (2.80 g, 79%) 
as yellow plates, m.p. 87-88 °C (Found: C, 74.7; H, 5.4. C20H 18O 4 
requires C, 74.5; H, 5.6%); 1636, 1583, 1265, 1101, 1031, 997, and
749 cm -i; 6 ^ 8.10 (1 H, dd, J  8 , 2, H-5), 7.50 (1 H, dd, J  8 , 2, H-7), 
7.40-7.27 (2 H, m, H-6 ,6 '), 7.17 (1 H, t, 7 8 , H-5'), 7.04 (2 H, m, H- 
3,4'), 6.10-6.00 (1 H, m), 5.14-5.06 (2 H, m), 3.90 (3 H, s), 3.85 (3 H, 
s) and 3.69 (2 H, d, 7 6 ); 8 ^ 179.0 (4:"y), 160.9 (4^ :y), 154.4 (4:y), 153.4
(4n^), 148.1 (4^y), 135.4 (CH), 133.9 (CH), 129.5 (4=7), 126.4 (4^y), 124.8 
(CH), 124.3 (CH), 123.81 (4^y), 123.80 (CH), 120.6 (CH), 117.0 (CH2),
114.9 (CH), 112.2 (CH), 60.9 (OCH3), 56.0 (OCH3) and 33.8 (CH2);
332 (M+, 56%) 239 (22), 199 (18), 185 (15), 161 (100), 149 (23), 131 
(32), 115 (26), 97 (48), 81 (90) and 77 (33).
c. Preparation of 2'.3'-dimethoxvflavone-8-acetic acid 151
The method of C lf  was followed using 2',3'-dimethoxy-8-(3-hydroxy-2- 
oxopropyl)flavone (see section G ib) (7.08 g, 20 mmol) and potassium 
permanganate (9.48 g, 60 mmol) to afford 2'.3'-dimethoxvflavone-8-
51acetic acid (3.06 g, 45%) as a white powder, m.p. 188-190 °C (Found: C, 
67.4; H, 4.5. CipHigOg requires C, 67.1; H, 4.7%); 1729, 1633,
1575, 1285, 1105, 1034, 995, 863 and 797 cm-i; 6 ^ (CD3SOCD3) 13.0-
11.0 (1 H, hr s, OH), 8.00 (1 H, dd, J  8 , 2, H-5), 7.76 (1 H, dd, J  8 , 2, 
H-7), 7.48-7.42 (2 H, m, H-6,5'), 7.31-7.26 (2 H, m, H-4',6'), 6.87 
(1 H, s, H-3), 3.96 (2 H, s), 3.90 (3 H, s) and 3.83 (3 H, s);
6 c (CD3SOCD3) 177.2 (4^y), 171.7 (4'"y), 160.6 (4^y), 154.4 (4^y), 153.1
(4n^), 147.5 (4n )^, 135.7 (CH), 125.5 (2 C, 4^), 124.9 (CH), 124.5 (CH),
123.6 (CH), 123.2 (4^y), 120.4 (CH), 116.1 (CH), 111.4 (CH), 60.5 
(OCH3), 56.1 (OCH3) and 35.2 (CH2); m/z 340 (M+, 100%), 326 (41), 
311 (6 ), 294 (14), 280 (23), 265 (20), 253 (14), 237 (17), 209 (13), 179 
(30), 161 (69), 147 (6 6 ), 133 (82), 120 (16), 106 (34), 91 (34) and 77 
(42).
d. Preparation of sodium 2 '.3-dimethoxvfIavone-8 -acetate 154 
The method of C2f was followed using 2',3'-dimethoxyflavone-8-acetic 
acid (1 .0  g, 2 .9  mmol) to afford sodium 2 '.3'-dimethoxvflavone-8 -acetate 
(0.88 g, 87%) as a white powder, m.p. >350 “C; 1562, 1247, 1086,
1000, 855 and 752cm -i; 6 ^ (D2O) 7.69 (1 H, dd, 7 8 , 2, H-5), 7.57 
(1 H, dd, J  8 , 2, H-7), 7.32 (1 H, t, J 8 , H-6 ), 7.22 (1 H, dd, J  9, 2, H- 
6 '), 6.96 (1 H, t, 7 9, H-5'), 6 . 8 6  (2H , m, H-3,4'), 3.71 (3H , s), 3.68 
(3 H, s) and 3.62 (2 H, s); 6 c (D2O) 183.9 (4ry), 181.3 (4ry), 164.0 (4ry),
157.0 (4ry), 155.1 (4ry), 150.0 (4ry), 139.2 (CH), 130.1 (4^y), 128.3 (CH),
127.8 (CH), 126.5 (4 y^), 125.6 (CH), 124.6 (4 ry), 123.0 (CH), 118.6 (CH),
1 1 2 .6  (CH), 63.1 (OCH3), 58.3 (OCH3) and 41.3 (CH2).
2. 2 ’,4 ’-D im ethoxyflavone-8-acetic Acid
a. Preparation of methyl 2.4-dimethoxybenzoate 144
The method of C2b was followed using 2,4-dimethoxybenzoic acid
(20.0 g, 110 mmol) to afford methyl 2,4-dimethoxybenzoate (16.3 g,
76%) as a yellow liquid, b.p. (oven temp.) 154 “C at 1.5 mmHg (lit./^ "^^  
294-296 °C); 0^ 7.83 (1 H, d, /  10, H-6 ), 6.43 (2 H, m, H-3,5), 3.87
(3 H, s), 3.82 (3 H, s) and 3.81 (3 H, s).
b. Preparation of 8-allvl-2'.4'-dimethoxvflavone 148
The method of C le was followed using methyl 2,4-dimethoxybenzoate 
(2.16 g, 11 mmol) to yield 8-allvl-2'.4'-dimethoxvflavone (1.91 g, 54%) 
as a yellow solid, m.p. 113-114 °C (Found: C, 74.4; H, 6.0. C20H 18O 4 
requires C, 74.5; H, 5.6%); 1628, 1564, 1256, 1215, 1023, 843 and
817 cm-i; 6 ^ 8.10 (1 H, dd, J  8 , 2, H-5), 7.88 (1 H, d, J  6 , H-6 '), 7.50 
(1 H, dd, J  8 , 2, H-7), 7.30 (1 H, t, J  8 , H-6 ), 7.15 (1 H, s, H-3), 6.63 
(1 H, dd, 7 6 , 2, H-5'), 6.53 (1 H, d, 7 2, H-3'), 6.15-6.01 (1 H, m), 
5.18-5.09 (2 H, m), 3.93 (3 H, s), 3.88 (3 H, s) and 3.70 (2 H, d, 7 6 ); 
6 c 179.2 (4::y), 163.2 (4^y), 160.5 (4^y), 159.7 (4^y), 154.3 (4:"y), 135.5
(CH), 133.6 (CH), 130.3 (CH), 129.2 (4^), 124.4 (CH), 123.7 (CH), 116.8 
(CH2), 113.7 (4^y), 112.3 (4:y), 111.1 (CH), 105.3 (CH), 98.9 (CH), 55.6 
(OCH3), 55.5 (OCH3) and 34.0 (CH2); m/z 322 (M+, 100%), 282 (15), 
199 (3), 161 (67), 132 (12), 119 (7), 103 (9), 91 (7) and 77 (12).
c. Preparation of 2'.4'-dimethoxyflavone-8-acetic acid 152
The method of C lf  was followed using 8-allyl-2',4'-dimethoxyflavone 
(6.45 g, 20 mmol) to afford 2',4'-dimethoxyflavone-8-acetic acid 
(4.83 g, 71%) as colourless crystals, m.p. 225-228 °C (lit.,^^ 225- 
227 "C) (Found: C, 65.7; H, 4.8. Calc, for CigHigO^ + 0.5 H2O C, 65.3; 
H, 4.9%); 1709, 1620, 1555, 1260, 1216, 1172, 1155, 1025, 839 and
759 cm -i; 6 ^ ( C D 3 S O C D 3 )  13.0-12.6 (1 H, br s, OH), 7.97 (1 H, dd, 
7 8 , 2, H-5), 7.91 (1 H, d, 7 8 , H-6 '), 7.72 (1 H, dd, 7 8 , 2, H-7), 7.42 
(1 H, t, 7 6 , H-6 ), 6.98 (1 H, s, H-3), 6.79-6.71 (2H , m, H-3',5'), 3.98 
( 2  H, s), 3.96 (3 H, s) and 3.90 (3 H, s); 6 c (CD3SOCD 3) 177.2 (4^y),
172.0 (4^y), 163.3 (4^y), 160.2 (4''y), 159.6 (4^y), 154.2 (4^y), 135.4 (CH),
52
53130.2 (CH), 125.4 (4^ )^, 124.6 (CH), 123.6 (CH), 123.1 (4^0, 112.4 (4n )^,
110.0 (CH), 106.2 (CH), 99.1 (CH), 56.1 (OCH3), 55.7 (OCH3) and 35.5 
(CHz); m/z 340 (M+, 90%), 300 (7), 277 (15), 251 (14), 162 (100), 152 
(30), 135 (80), 119 (50), 97 (61) and 77 (19).
d. Preparation of sodium 2'.4'-dimethoxvflavone-8-acetate 155 
The method of C2f was followed using 2',4’-dimethoxyflavone-8-acetic 
acid (1 .0  g, 2 .9  mmol) to afford sodium 2 '.4'-dimethoxyflavone-8 -acetate 
(0.83 g, 82%) as a cream powder, m.p. >350 °C; 1600, 1561, 1262,
1199, 1081, 1032, 920, 898 and 804cm-i; 8 ^ (D^O) 7.52 (1 H, dd, 7 8 ,
2, H-5), 7.44 (2 H, m, H-7,5'), 7.20 (1 H, t, 7 8 , H-6), 6.67 (1 H, s, H-3),
6.13 (1 H, d, 7 8 , H-6'), 5.76 (1 H, s, H-3'), 3.57 ( 6  H, s) and 3.42 (2 H, 
s); ôc (D2 O) 183.4 (4ry), 181.2 (4ry), 165.2 (4ry), 163.8 (4ry), 162.4 (4^y),
156.4 (4ry), 138.3 (CH), 132.4 (4ry), 129.8 (CH), 127.6 (CH), 125.1 (CH),
124.2 (4ry), 113.4 (4ry), 110.9 (CH), 108.6 (CH), 100.0 (CH), 57.7 (2 x 
OCH3) and 41.3 (CH2 ).
3. 2 ’,5 ’-D im ethoxyfIavone-8-acetic Acid
a. Preparation of 2.5-dimethoxybenzoate 145
The method of C2b was followed using 2,5-dimethoxybenzoic acid 
(20.0 g, 110 mmol) to yield methyl 2,5-dimethoxybenzoate (17.2 g, 
80%) as a colourless liquid, b.p. (oven temp.) 150 °C at 0.1 mmHg 
(lit.,105 95-98 °C at 1 mmHg); 6 ^ 7.31 (1 H, d, 7 3, H-6 ), 7.02 (1 H,
dd, 7 10, H-4), 6.79 (1 H, d, 7 10, H-3), 3.89 (3 H, s), 3.85 (3 H, s) and
3.75 (3 H, s).
b. Preparation of 8-allvl-2'.5'-dimethoxyflavone 149
The method of C le was followed using methyl 2,5-dimethoxybenzoate 
(2.16 g, 11 mmol) to yield 8-allyl-2'.5'-dimethoxvflavone as colourless 
needles (2.73 g, 77%), m.p. 96-98 “C (Found: C, 74.6; H, 5.4. C20H 18O4
54requires C, 74.5; H, 5.6%); 1580, 1550, 1274, 1 2 2 2 , 1033, 931, 843,
801 and 742 cm-i; 8.11 (1 H, dd, J  8 , 2, H-5), 7.53 (1 H, dd, J  8 , 2, 
H-7), 7.46 (1 H, d, 7 2, H-6 '), 7.34 (1 H, t, 7 8 , H-6 ), 7.20 (1 H, s, H-3), 
7.10-6.95 (2 H, m, H-3',4’), 6.16-6.02 (1 H, m), 5.18-5.06 (2 H, m), 
3.90 (3 H, s), 3.84 (3 H, s) and 3.72 (2 H, d, 7 6 ); 6 ^ 179.2 (4 ^^ ), 160.1
(4n^), 154.4 (4^), 153.4 (4:y), 152.4 (4^ )^, 135.4 (CH), 134.0 (CH), 129.3 
(4n^), 124.7 (CH), 123.81 (CH), 123.79 (4'x), 121.3 (4' '^), 117.7 (CH),
116.8 (CH2), 114.1 (CH), 113.0 (CH), 112.6 (CH), 56.1 (OCH3), 55.8 
(OCH3) and 34.0 (CH2); m/z 322 (M+, 64%), 307 (9), 196 (34), 181 (71), 
161 (100), 147 (40), 131 (19), 119 (16), 107 (20) and 92 (10).
c. Preparation of 2'.5'-dimethoxyflavone-8-acetic acid 153
The method of C lf  was followed using 2',5'-dimethoxy-8-(3-hydroxy-2- 
oxopropyl)flavone (see section G lc) (7.08 g, 20 mmol) and potassium 
permanganate (9.48 g, 60 mmol) to afford 2'.5'-dimethoxvflavone-8- 
acetic acid (4.28 g, 63%) as a white powder, m.p. 182-184 °C (Found: C, 
65.3; H, 4.5. CigHi^Og + 0.5 H2O requires C, 65.3; H, 4.8%); 1707,
1620, 1569, 1271, 1239, 1044, 821 and 748 cm-i; 6 H (C D 3S 0 CD 3 )
12.5-12.0 (1 H, br s, OH), 7.96 (1 H, dd, 7 8 , 2, H-5), 7.74 (1 H, d, 7 8 ,
2, H-7), 7.46 (1 H, d, 7 8 , H-6 '), 7.43 (1 H, t, 7 8 , H-6 ), 7.22-7.11 (2 H, 
m, H-3',4'), 7.01 ( IH , s, H-3), 3.91 (2H ,s), 3.89 (3H , s) and 3.82 
(3H , s); ô c  ( C D 3 S O C D 3 )  177.2 (4^ :y), 171.6 (4»:y), 159.6 (4^y), 154.2
(4^y), 153.2 (4:y), 152.0 (4^), 135.6 (CH), 125.5 (4n )^, 124.7 (CH), 123.8 
(CH), 123.1 (4:y), 120.2 (4«^ y), 118.9 (CH), 114.1 (CH), 113.1 (CH), 111.5 
(CH), 56.3 (OCH3), 55.6 (OCH3) and 35.5 (CH2); m/k 340 (M+, 17%), 
296 (54), 253 (55), 162 (100), 133 (41), 105 (21), 91 (21) and 77 (67).
d. Preparation of sodium 2'.5'-dimethoxvflavone-8-acetate 156
The method of C2f was followed using 2',5'-dimethoxyflavone-8-acetic 
acid (1.0 g, 2.9 mmol) to yield sodium 2'.5'-dimethoxvflavone-8-acetate
55(0.83 g, 82%) as a white powder, m.p. 304-306 °C; 1571, 1229,
1173, 1115, 1031, 853, 801 and 738 cm~i; 8 ^ (D2O) 7.63 (1 H, d, 7 8 , 
H-5), 7.49 (1 H, d, 7 8 , H-7), 7.27 (1 H, t, 7 8 , H-6 ), 6.93 (2 H, m, H-3, 
6 '), 6.58 (2 H, m, H-3',4'), 3.64 (3 H, s), 3.61 (2 H, s) and 3.57 (3 H, s);
8 c (D2 O) 183.7 (4ry), 180.6 (4ry), 163.0 (4ry), 156.6 (4ry), 155.6 (4ry),
154.5 (4ry), 138.9 (CH), 129.8 (CH), 128.0 (4ry), 125.4 (4^y), 124.3 (CH),
122.0 (4ry), 120.5 (CH), 115.8 (CH), 114.1 (CH), 112.8 (CH), 58.1 
(OCH3), 58.0 (OCH3) and 41.1 (CH2).
4. 2',6'-Dimethoxyflavone-8-acetic Acid
a. Preparation of methvl 2.6-dimethoxybenzoate 146
The method of C2a was followed using 2,6-dimethoxybenzoic acid 
(15.0 g, 82 mmol) to yield methyl 2 ,6 -dimethoxybenzoate (7.61 g, 47%) 
as colourless crystals, m.p. 87 °C (lit.,^°^ 8 8  “C); 8 ^ 7.29 (1 H, t, 7 9,
H-4), 7.53 (2 H, d, 7 9, H-3,5), 3.91 (3 H, s) and 3.79 ( 6  H, s).
b. Attempted preparation of 8-allyl-2'.6-dimethoxvflavone 150
The general method of C le  was followed using methyl 2,6- 
dimethoxybenzoate (2.16 g, 11  mmol) to produce a brown tar which was 
shown spectroscopically to be the unreacted ester and the 3-allyl-2- 
hydroxyacetophenone.
5. 3 ',4 ’-DimethoxyfIavone"8-acetic Acid
a. Preparation of methvl 3.4-dimethoxybenzoate 157 
The method of C2a was followed using 3,4-dimethoxybenzoic acid 
(20.0 g, 110 mmol) to afford methyl 3,4-dimethoxybenzoate (14.3 g, 
6 6 %) as colourless needles, m.p. 60-61 ”C (lit.,^ ®'^  62 °C); 8 y 7.71 (1 H,
dd, 7 6 , 2, H-6 ), 7.54 (1 H, d, 7 2, H-2), 6.89 (1 H, d, 7 6 , H-5), 3.93 
(3 H, s), 3.92 (3 H, s) and 3.86 (3 H, s).
56h. Preparation of 8-al1vl-3'.4'-dimethoxvflavone 160 
The method of C le was followed using methyl 3,4-dimethoxybenzoate 
(2.16 g, 11 mmol) to afford 8-allvl-3 '.4 '-dim ethoxvflavone (2.76 g, 
78%) as colourless crystals, m.p. 141-142 °C (Found: C, 74.8; H, 5.6. 
C20H 18O4 requires C, 74.5; H, 5.6%); 1645, 1598, 1518, 1148, 1025,
880 and 724cm -i; Sg 8.10 (1 H, dd, 7 8 , 2, H-5), 7.55 (2 H, m, H- 
7,6’), 7.39 (1 H, d, J 2, H-2’), 7.32 (1 H, t, J  8 , H-6 ), 6.99 (1 H, d, J  8 , 
H-5’), 6.77 (1 H, 8 , H-3), 6.19-6.00 (1 H, m), 5.17-5.09 (2 H, m), 3.97 
(3 H, s), 3.96 (3 H, s) and 3.75 (2 H, d, J  8 ); 178.7 (4^ -y), 163.0 (4'y),
154.2 (40'), 152.1 (40'), 149.3 (4^y), 135.3 (CH), 134.1 (CH), 129.2 (4'-y),
124.9 (CH), 124.5 (4''y), 123.95 (CH), 123.94 (4^y), 119.9 (CH), 116.9 
(CHj), 111.3 (CH), 108.8 (CH), 106.2 (CH), 56.1 (OCH3), 56.0 (OCH3) 
and 34.1 (C%); m/z 322 (M+, 1 0 0 %), 307 (1 0 ), 279 (70), 162 (32), 147 
(16), 131 (16), 103 (13), 91 (17) and 77 (16).
c. Preparation of 3’.4’-dimethoxvflavone-8-acetic acid 163 
The method of C lf was followed using 8-allyI-3’,4’-dimethoxyflavone 
(6.45 g, 20 mmol) to afford 3’,4’-dimethoxyflavone-8-acetic acid 
(2.14 g, 31%) as colourless crystals, m.p. 254-256 °C (lit.,^^ 250- 
254 ”0 ;  1710, 1624, 1582, 1279, 1051, 872 and 762 cm -i;
§ H  ( C D 3 S O C D 3 )  12.49 (1 H, b r  s, OH), 8.01 (1 H, d d ,  7 8, 2, H-5), 
7.74-7 .70  (2 H, m ,  H-7,6’), 7.61 (1 H, d ,  7 2, H-2’), 7.42 (1 H, t ,  7 8 ,  H- 
6), 7.11 (1 H, d ,  7 8, H-5’), 7.06 (1 H, s, H-3), 4.02 (2 H, s), 3.93 (3 H, 
s) a n d  3.90 (3 H, s); ( C D 3 S O C D 3 )  176.9 (4^y), 171.9 (4'y), 162.3 (4''y),
153.9 (4^y), 151.8 (4^y), 148.9 (4-'y), 135.4 (CH), 125.4 (4^y), 124.7 (CH),
123.6 (CH), 123.4 (4^y), 123.2 (4?), 119.9 (CH), 111.9 (CH), 108.9 (CH),
105.6 (CH), 55.8 (OCH3), 55.7 (OCH3) and 35.6 (CH2); m/z 340 (M+, 
13%), 296 (71), 253 (23), 162 (100), 133 (42), 105 (15), 91 (20) and 77
(15).
57d. Preparation of sodium 3'.4'-dimethoxvflavone-8-acetate 166 
The method of C2f was followed using 3',4'-dimethoxyflavone-8-acetic 
acid (1.0 g, 2.9 mmol) to yield sodium 3'.4'-dimethoxvflavone-8-acetate 
(0.96 g, 90%) as a white powder, m.p. 160-161 °C; 1550, 1250,
1129, 1006, 831 and 751 cm-i; 6 g (D2O) 7.45 (2 H, m, H-5,7), 7.18 
(1 H, t, J  8 , H-6 ), 7.03 (1 H, d, J  9, H- 6  ), 6.65 (1 H, d, J  2, H-2'), 6.36 
(1 H, d, 7 9, H-5'), 6.18 (1 H, s, H-3), 3.57 (2 H, s), 3.53 (3 H, s) and 
3.44 (3 H, s); 5c (D2O) 182.6 (4^y), 180.8 (4 o'), 165.8 (4ry), 156.2 (4>-y),
153.6 (4ry), 150.1 (4:y), 138.6 (CH), 129.7 (CH), 127.9 (4^y), 125.2 (CH),
124.6 (4ry), 124.3 (CH), 122.8 (4ry), 113.5 (CH), 109.7 (CH), 106.0 (CH),
57.9 (OCH3), 57.1 (OCH3) and 41.5 (CH2); m/z (FAB, glycerol) 749 
([2M+ﬀa]+, 5%), 683 (2 [M-C0 2 ]+, 11), 385 ([M+ﬀﬁﬂﬃ 34), 363 (M+, 7), 
319 (15), 296 (11), 223 (11), 165 (10), 137 (76) and 115 (100).
6 . 3 ',5 '-D im ethoxyflavone-8 -acetic  Acid
a. Preparation of methvl 3.5-dimethoxvbenzoate 158 
The method of C2a was followed using 3,5-dimethoxybenzoic acid 
(20.0 g, 110 mmol) to afford methyl 3 ,5 -dimethoxybenzoate (19.3 g, 
90%) as a low melting solid, m.p. 40-42 °C (lit.,"»» 42-44 °C); 5^ 7.18
(2 H, m, H-2,6), 6.62 (1 H, t, 7 2, H-4), 3.90 (3 H, s) and 3.81 ( 6  H, s).
h. Preparation of 8-allvl-3'.5'-dimethoxvflavone 161 
The method of C le was followed using methyl 3,5-dimethoxybenzoate 
(2.16 g, 11 mmol) to afford 8-allvl-3'.5'-dimethoxvflavone as colourless 
crystals (2.27 g, 64%), m.p. 137-138 ”C (Found: C, 74.3; H, 5.7. 
C20H 18O4 requires C, 74.5; H, 5.6%); 1732, 1644, 1602, 1588, 1573,
1300 and 1288 cm-i; 5^ 8.05 (1 H, dd, 7 8 , 2, H-5), 7.50 (1 H, dd, 7 8 ,
2, H-7), 7.38 (1 H, t, 7 8 , H-6 ), 7.07 (2 H, d, 7 2, H-2',6'), 6.83 (1 H, s, 
H-3), 6.65 (1 H, t, 7 2, H-4 ), 6.20-6.00 (1 H, m), 5.20-5.10 (2 H, m),
3.89 ( 6  H, s) and 3.71 (2 H, d, 7 8); 5c  178.5 (4^y), 162.6 (4^y), 161.1
(2C , 4n )^, 154.1 (4n )^, 135.2 (CH), 134.1 (CH), 133.7 (4n )^, 129.4 (4:y),
124.9 (CH), 123.9 (4^y), 123.8 (CH), 117.0 (CH2), 107.5 (CH), 104.3 (2 x 
CH), 103.4 (CH), 55.5 ( 2  x OCH3) and 34.0 (CH2); m/z 322 (M+, 100%), 
162 (15), 132 (24), 115 (7), 103 (11), 89 (6 ) and 77 (14).
c. Preparation of 3'.5'-dimethoxy£Iavone-8-acetic acid 164
The method of C lf  was followed using 8 -ally 1-3',5'-dimethoxyflavone 
(6.45 g, 20 mmol) to afford 3',5'-dimethoxyflavone-8-acetic acid 
(3.03 g, 44%) as colourless crystals, m.p. 267-269 °C (lit.,^^ 261- 
263 °C); v^a^l713, 1627, 1597, 1582, 1251, 1172 and 1065 cm -i; 
5h (CD3SOCD3) 12.50 (1 H, br s, OH), 7.97 (1 H, dd, J  8 , 2 , H-5), 7.74 
(1 H, dd, 7 8 , 2, H-7), 7.45 (1 H, t, 7 8 , H-6 ), 7.22 (2 H, d, 7 2, H-2',6'),
7.09 (1 H, s, H-3), 6.70 (1 H, t, 7 2, H-4'), 3.99 (2 H, s) and 3.85 ( 6  H, 
s); 8 c (CD3SOCD3) 177.1 (4n )^, 171.6 (4^ )^, 161.8 (4ry), 160.9 ( 2  C, 4^ :y),
154.0 (4 7^ ), 135.7 (CH), 133.2 (4n )^, 125.5 (4 y^), 124.9 (CH), 123.6 (CH), 
123.3 (4n )^, 107.2 (CH), 104.2 (CH), 104.1 (2 x CH), 55.5 (2 x OCH3) and
35.6 (CH2); m/z 340 (M+, 7%), 296 (100), 268 (2 ), 152 (34), 134 (14), 
106 (10), 89 (4) and 77 (8 ).
d. Preparation of sodium 3'.5'-dimethoxyflavone-8-acetate 167
The method of C2f was followed using 3’,5'-dimethoxyflavone-8-acetic 
acid (1.0 g, 2.9 mmol) to yield sodium 3'.5'-dimethoxvflavone-8 -acetate 
(0.96 g, 92%) as a white powder, m.p. >350 °C; 1632, 1206, 1157,
1063, 926, 838 and 723 cm-i; 8 ^ (D^O) 7.75 (1 H, d, 7 8 ), 7.60 (1 H,
d, 7 8 ), 7.37 (1 H, t, 7 8 ), 6.87 (2 H, s), 6.71 (1 H, s), 6.42 (1 H, s),
3.76 ( 6  H, s) and 3.70 (2 H, s); 8 c (D2O) 183.0 (4^y), 180.8 (4ry), 165.0
(4ry), 162.4 (2 x C, 4ry), 156.4 (4ry), 139.0 (CH), 134.2 (4ry), 129.9 (CH),
128.2 (CH), 125.5 (CH), 124.6 (4ry), 107.9 (4^y), 106.1 (2 x CH), 58.0 (2 x 
OCH3) and 41.3 (CH2); m/z (FAB, glycerol) 747 ( [ ( 2  x M)+ a]+, 2 2 %),
58
59385 ([M+!a]+, 100), 363 ([M]+, 25), 319 (40), 297 (46), 199 (17), 176 
(93) and 154 (22).
7. 3*,4’-Methylenedioxyflavone-8-acetic Acid
a. Preparation of methyl 3.4-methvlenedioxybenzoate 159
The method of C2a was followed using 3,4-methylenedioxybenzoic acid 
(20.0 g, 120 mmol) to afford methyl 3,4-methylenedioxybenzoate 
(10.3 g, 47%) as a white powder, m.p. 53 °C (lit.,^^^ 53 ^C); 7.67
(1 H, dd, 7 9, 2, H-6 ), 7.52 (1 H, d, 7 2, H-2), 6 .8 8  (1 H, d, 7 9, H-5), 
3.94 ( 6  H, s) and 3.89 (3 H, s).
b. Preparation of 8 -ally 1-3'.4'-methvlenedioxyflavone 162
The m ethod of C le  was follow ed using m ethyl 3,4- 
methylenedioxybenzoate (1.98 g, 11 mmol) to afford 8-allvl-3 '.4 '- 
methvlenedioxvflavone (1.96 g, 58%) as colourless needles, m.p. 178- 
179 “C (Found: C, 74.1; H, 4.5. C 19H 14O4 requires C, 74.5; H, 4.6%);
1732, 1645, 1595, 1506, 1252, 1165, 945, 864 and 725 cm-i; 
8 ^ 8.10 (1 H, dd, 7 8 , 2, H-5), 7.55-7.49 (2H , m, H-7,6'), 7.36-7.33
(2H , m, H-6,2'), 6.92 (1 H, d, 7 8 , H-5'), 6.69 (1 H, s, H-3), 6.18-6.00 
(3 H, m), 5.20-5.15 (2 H, m) and 3.73 (2 H, d, 7 8 ); 8 ^ 178.5 (4^y),
162.6 (4^ :y), 154.1 (4n )^, 150.6 (4^ :y), 148.5 (4^y), 135.3 (CH), 134.0 (CH),
129.3 (4^y), 125.9 (4:"y), 124.9 (CH), 123.91 (4'"y), 123.89 (CH), 121.3 
(CH), 117.0 (CH2), 112.3 (CH), 108.8 (CH), 106.4 (CH), 101.9 (CH2) and
34.0 (CH2); m/z 306 (M+, 100%), 278 (6 ), 160 (11), 146 (75), 131 (32), 
103 (13), 8 8  (11) and 77 (19).
c. Preparation of 3'.4'-methylenedioxyflavone-8-acetic acid 165
The m ethod of C l f  was fo llow ed using  8 -a lly l-3 ',4 '-  
m ethylenedioxyflavone (6.13 g, 20 mmol) to yield 3 '.4 '-  
methylenedioxyflavone-8 -acetic acid (2.79 g, 43%) as a white powder.
60m.p. 2 3 5 -2 3 7 ‘’C (Found: C, 63.9; H, 4.15. C igH i2 0 6  + 0.75 H2 O 
requires C, 64.0; H, 4.0%); 1718, 1642, 1595, 1256, 1029, 913, 858
and 761 cm-i; 6 ^ (CD 3SOCD 3) 12.7 (1  H, br s, OH), 7.95 (1 H, dd,
7 8 , 2, H-5), 7.76-7.68 (2 H, m, H-7,6’), 7.61 (1 H, s, H-2'), 7.42 (1 H, 
t, 7 8 , H-6 ), 7.11 (1 H, d, 7 8 , H-5'), 6.98 (1 H, s, H-3), 6.17 (2 H, s) 
and 4.00 ( 2  H, s); 6 ^ (CD3SOCD3) 176.9 (4^), 171.9 (4^ 1^ ), 162.0 (4n^),
154.0 (4 :7 ), 150.3 (4^y), 149.1 (4n )^, 135.5 (CH), 125.4 (4 ^^ ), 125.0 (4ry),
124.8 (CH), 123.5 (CH), 123.1 (4^ )^, 121.5 (CH), 109.6 (CH), 106.1 (CH),
105.8 (CH), 102.0 (CH2) and 35.5 (CH2); m/z 324 (M+, 100%), 310 (11), 
279 (10), 146 (52), 133 (22), 105 (10), 8 8  (6 ) and 77 (12).
d. Preparation of sodium 3'.4'-methvlenedioxyflavone-8-acetate 168 
The method of C2f was followed using 3',4'-methylenedioxyflavone-8- 
acetic  acid (1.0 g, 3.1 mmol) to y ield  sod ium  3 '.4 '-  
methylenedioxyflavone-8 -acetate fO.79 g, 73%) as a cream powder, m.p. 
>350 'C; V^^  ^ 1645, 1586, 1301, 1251, 1212, 1111, 1028, 864 and 
754 cm-i; 6 ^ (D2O) 7.56 (2 H, m, H-5,7), 7.27 (1 H, t, 7 8 , H-6 ), 7.10
(1 H, dd, 7 9, 2, H-5'), 6.89 (1 H, s, H-3), 6.44 (1 H, d, 7 9, H-6 '), 6.26 
(1 H, d, 7 2, H-2'), 5.77 (2H , s) and 3.64 (2H , s); 8 ^ (D 2 O) 183.0
( 4 r y ) ,  181.2 (4 ry ) , 165.9 (4 ry ) ,  156.5 (4 ^ y ), 152.9 (4 ^ y ) , 150.2 (4 ry ) ,  138.9
(CH), 137.6 (4 ry ) , 131.6 (4 ry ) , 130.0 (CH), 128.1 (CH), 126.3 (4 ^y ), 125.4
(CH), 124.6 (CH), 111.2 (CH), 108.1 (CH), 104.8 (CH2) and 41.5 (CH2); 
m/z (FAB, glycerol) 713 ([2M+"a]+, 6 %), 405 (40), 313 (93), 207 (20) 
and 115 (100).
8 . 4 '-C h lo ro -2 '-m ethoxyflavone-8 -ace tic  A cid
a. Preparation of methyl 4-chloro-2-methoxybenzoate 169 
The method of C2b was followed using 4-chloro-2-methoxybenzoic acid 
(20.0 g, 117 mmol) to afford an brown oil which was distilled at 143 °C 
at 0.2 mmHg to give methyl 4-chloro-2-methoxybenzoate (19.9 g, 93%)
61as cream needles, m.p. 36 °C (lit.,^^° 36 °C); 6 y 7.71 (1 H, d, J  10, H-
6 ), 6.91 (2 H, m, H-3,5), 3.82 (3 H, s) and 3.81 (3 H, s).
b. Preparation of 8-allyl-4'-chloro-2'-methoxvflavone 171
The method of C le  was followed using methyl 4-chloro-2-
methoxybenzoate (2.21 g, 11 mmol) to afford 8-allv l-4 '-chloro-2 '-
methoxvflavone as yellow plates (2.08 g, 58%), m.p. 140-142 °C (Found: 
C, 70.1; H, 4.8. C 19H 15CIO3 requires C, 69.8; H, 4.6%); 1635, 1590,
1108, 8 6 8  and 733 cm-i; 6 ^ 8.09 (1 H, dd, J  8 , 2, H-5), 7.82 (1 H, d, 
J  8 , H-6 '), 7.52 (1 H, dd, J  8 , 2, H-7), 7.33 (1 H, t, J  8 , H-6 ), 7.13 (1 H, 
s, H-3), 7.10 (1 H, dd, J  8 , 2, H-5'), 7.02 (1 H, d, J  2, H-3'), 6.12-5.98 
(1 H, m), 5.17-5.10 (2 H, m), 3.94 (3 H, s) and 3.68 (2 H, d, 7 8 ); 
8 c 179.0 (4^ y^), 159.5 (4:"y), 158.5 (4'"y), 154.3 (4^y), 138.2 (4^y), 135.4
(CH), 134.0 (CH), 130.0 (CH), 129.3 (4^y), 124.7 (CH), 123.8 (CH), 123.7 
(4n^), 121.1 (CH), 119.5 (4n )^, 116.9 (CH2), 112.5 (CH), 112.4 (CH), 56.0 
(OCH3) and 34.0 (CH2); m/z 326 (35C1-M+, 56%), 161 (100), 131 (71), 
103 (37) and 77 (35).
c. Preparation of 4’-chloro-2'-methoxyfIavone-8-acetic acid 173
The method of C lf  was followed using 8-allyl-4 '-chloro-2 '-
m ethoxyflavone (6.53 g, 20 mmol) to afford 4 '- c h lo r o -2 '-
methoxyflavone-8 -acetic acid (4.00 g, 58%) as colourless crystals, m.p. 
260-262 °C (Found: C, 62.7; H, 4.0. C 18H 13CIO5 requires C, 62.7; H, 
3.8%); V^^ 1729, 1621, 1579, 1556, 1161, 1144, 1109, 1017, 885 and 
758 cm -i; 8 ^ (CD 3SOCD 3) 13.0-12.0 (1  H, br s, OH), 7.92 (1  H, dd, 
7 8 , 2, H-5), 7.87 (1 H, dd, 7 7, 2, H-5'), 7.73 (1 H, dd, 7 8 , 2, H-7),
7.43 (1 H, t, 7 8 , H-6 ), 7.33 (1 H, d, 7 2, H-3'), 7.18 (1 H, d, 7 7, H-6 '),
6.93 (1  H, s, H-3), 3.96 (3 H, s) and 3.95 (2H , s); 8 c (CD 3SO C D 3)
177.0 (4'-y), 171.8 (4^y), 159.1 (4^y), 158.3 (4:"y), 154.1 (4:"y), 137.3 (4ry),
135.6 (CH), 130.2 (CH), 125.4 (4' '^), 124.8 (CH), 123.5 (CH), 122.9 (4«^ y),
120.7 (CH), 118.8 (4:y), 113.0 (CH), 111.4 (CH), 56.5 (OCH3) and 35.2 
(CH2); m/z 344 (35C1-M+, 1 0 0 %), 300 (57), 179 (16), 165 (81), 147 (64), 
133 (85), 106 (32) and 77 (48).
d. Preparation of sodium 4'-chloro-2'-methoxvflavone-8-acetate 175 
The method of C2f was followed using 4'-chloro-2'-methoxyflavone-8- 
acetic acid (1.0 g, 2.9 mmol) to afford sodium  4 '-ch lo ro -2 '-  
m ethoxvflavone-8 -acetate  (0.96 g, 90%) as a white powder, m.p. 
>350 'C; 1712, 1623, 1588, 1248, 1145, 1022, 891, 837, 808 and
753 cm -i; 0^ (D2O) 7.27 (3 H, m, H-5,7,6'), 6.97 (1 H, t, J  8 , H-6 ),
6.46 (2 H, m, H-3,5'), 6.20 (1 H, d, /  1, H-3') and 3.30 (5 H, s); 
8 c (D2O) 183.3 (4ry), 181.0 (4^y), 162.6 (4ry), 160.8 (4ry), 156.4 (4ry),
141.3 (CH), 138.9 (4ry), 131.8 (CH), 129.6 (CH), 128.0 (4ry), 125.4 (4ry),
124.0 (CH), 123.6 (CH), 118.9 (CH), 114.8 (4ry), 112.4 (CH), 58.3 
(OCH3) and 41.3 (CH2); m/z (FAB, glycerol) 366 (M+, 15%), 345 (35), 
302 (10), 176 (23), 154 (23), 131 (28), 119 (51), 109 (63), 95 (100) and 
91 (21).
9. 5 '-C h lo ro -2 '-m ethoxyflavone-8 -ace tic  Acid
a. Preparation of methyl 5-chloro-2-methoxybenzoate 170
The method of C2b was followed using 5-chloro-2-methoxybenzoic acid 
(20.0 g, 117 mmol) to afford methyl 5-chloro-2-methoxybenzoate 
(18.3 g, 85%) as a colourless liquid, b.p. (oven temp.) 240 °C (lit.,‘ i^ 
235-240 'O ;  8 y 7.71 (1 H, d, 7 3, H-6 ), 7.40 (1 H, dd, 7 10, 3, H-4),
6.90 (1 H, d, 7 10, H-3) and 3.90 ( 6  H, s).
b. Preparation of 8-allyl-5'-chloro-2'-methoxvflavone 172
The method of C le  was followed using methyl 5-chloro-2- 
methoxybenzoate (2.21 g, 11 mmol) to afford 8 -allvI-5 '-chloro-2 '- 
methoxvflavone as yellow plates (1.40 g, 39%), m.p. 108-110 °C (Found:
62
63C, 70.0; H, 4.7. C 19H 15CIO3 requires C, 69.8; H, 4.6%); 1637, 1594,
1395, 1283, 1146, 1029, 919 and 858 cm-i; 8 ^ 8.08 (1 H, dd, J  8 , 2, H-
5), 7.87 (1 H, d, J  2, H-6 ’), 7.53 (1 H, dd, J  8 , 2, H-7), 7.38 (1 H, dd,
J  8 , 2, H-4'), 7.33 (1 H, t, J  8 , H-6 ), 7.12 (1 H, s), 6.95 (1 H, d, J  8 , H- 
3'), 6.11-5.98 (1 H, m), 5.20 (2 H, m), 3.93 (3 H, s) and 3.70 (2 H, d,
7 8 ); 8 c 179.0 (4:y), 158.8 (4^y), 156.6 (4n^), 154.4 (4^y), 135.4 (CH)
134.2 (CH), 131.8 (CH), 129.4 (4''y), 128.3 (CH), 126.0 (4n )^, 124.8 (CH),
123.80 (CH), 123.79 (4^y), 122.1 (4^y), 117.0 (CH2), 113.1 (CH), 112.8 
(CH), 56.0 (CH3) and 34.2 (CH2); m/z 326 (35C1-M+, 57%), 161 (100), 
131 (52), 103 (30) and 77 (31).
c. Preparation of 5’-chloro-2'-methoxyflavone-8-acetic acid 174
The method of C lf  was followed using 8-allyl-5’-chloro-2'- 
m ethoxyflavone (6.53 g, 20 mmol) to afford 5 '- c h lo r o -2 '-  
methoxyflavone-8 -acetic acid (3.17 g, 46%) as colourless needles, m.p. 
247-249 “C (Found: C, 62.7; H, 3.4. C 18H 13CIO5 requires C, 62.7; H, 
3.8%); V^^ 1725, 1622, 1585, 1257, 1184, 1033, 1015 and 816cm -i;
8 h (CD3SOCD3) 12.50 (1 H, br s, OH), 7.97-7.88 (2 H, m, H-5,6'), 7.74 
(1 H, d, 7 8 , H-7), 7.60 (1 H, dd, 7 9, 2, H-4'), 7.44 (1 H, t, 7 8 , H-6 ), 
7.29 (1 H, d, 7 9, H-3'), 6.98 (1 H, s, H-3), 3.98 (2 H, s) and 3.95 (3 H,
8); 8 c (CD 3SOCD 3 ) 177.1 (4ry), 171.6 (4^y), 158.6 (4ry), 156.5 (4^y),
154.2 (4 H:), 135.6 (CH), 132.2 (CH), 128.3 (CH), 125.5 (4^y), 124.91 (4ry),
124.90 (CH), 123.5 (CH), 123.0 (4^y), 121.4 (4^y), 114.5 (CH), 111.9 
(CH), 56.4 (OCH3) and 35.3 (CH2); m/z 344 (35C1-M+, 0.9%), 300 (8 ), 
240 (5), 166 (7), 135 (17), 120 (8 ) and 91 (100).
d. Preparation of sodium 5’-chloro-2'-methoxyflavone-8 -acetate 176 
The method of C2f was followed using 5'-chloro-2'-methoxyflavone-8- 
acetic acid (1.0 g, 2.9 mmol) to afford sodium  5 ’-ch lo ro -2 '-  
methoxvflavone-8 -acetate (0 . 8 6  g, 81%) as a white powder, m.p. 2 0 0 -
202 “C; 1733, 1582, 1255, 1181, 1145, 1017, 975, 911, 807 and
723 cm-i; §h (D2O) 7.54 (1 H, dd, J  8 , 2, H-5), 7.46 (2 H, m, H-7, 4'),
7.26 (1 H, t, J  8 , H-6 ), 6.97 (1 H, s, H-3), 6.81 (1 H, d, J  8 , H-3'), 6.61 
(1 H, s, H-6 '), 3.63 (3 H, s) and 3.61 (2 H, s); 6 ^ (D2O) 183.8 (4ry),
181.1 (4ry), 162.5 (4ry), 159.5 (4 t), 156.8 (4ry), 139.1 (CH), 135.5 (CH),
130.4 (CH), 130.1 (4ry), 128.2 (CH), 128.1 (4n-), 125.6 (CH), 124.4 (4^y),
121.9 (4ry), 116.3 (CH), 113.2 (CH), 58.4 (OCH3) and 41.6 (CH2); m/z 
(FAB, NOBA) 389 ([M+Na]+, 11%), 367 (35), 345 (76), 329 (16), 301 
(30), 289 (11), 176 (76), 154 (100), 136 (82), 123 (17) and 107 (35).
10. 2',3',4'-Trimethoxyflavone-8-acetic Acid
a. Preparation of methvl 2.3.4-trimethoxybenzoate 180
The method of C2a was followed using 2,3,4-trimethoxybenzoic acid 
(20.0 g, 94 mmol) to yield methyl 2,3,4-trimethoxybenzoate (19.1 g, 
90%) as a colourless oil, b.p. (oven temp.) 100-102 °C at 1.0 mmHg 
(lit.," 2  281 °C); 5h 7.51 (1 H, d, J  8 ), 7.62 (1 H, d, J  8 ) 3.88 (3 H, s),
3.83 (3 H, s) and 3.82 ( 6  H, s).
b. Preparation of 8-allvl-2'.3'.4'-trimethoxvf!avone 177
The method of C le was followed using methyl 2,3,4-trimethoxybenzoate 
(2.49 g, 11 mmol) to afford 8-allvl-2'.3'.4'-trimethoxvflavone (2.44 g, 
63%) as cream needles, m.p. 115-117 °C (Found: C, 71.7; H, 5.7. 
C21H20O5 requires C, 71.6; H, 5.7%); 1634, 1287, 1167, 1005, 917,
796 and 761 cm -'; 6 ^ 8.12 (1 H, dd, J  8 , 2, H-5), 7.61 (1 H, d, J  8 , H- 
6 '), 7.53 (1 H, dd, J  8 , 2, H-7), 7.38 (1 H, t, J  8 , H-6 ), 7.12 (1 H, s, H- 
3), 6.83 (1 H, d, 7 8 , H-5'), 6.10-6.00 (1 H, m), 5.19-5.14 (2 H, m), 
3.97 (9 H, s) and 3.71 (2 H, d, 7 6 ); 0^ 179.1 (4‘'y), 160.6 (4>'y), 156.2
(4'-y), 154.1 (4'y), 153.2 (4'y), 142.6 (4^y), 135.5 (CH), 133.8 (CH), 129.3 
(4 y^), 124.6 (CH), 124.0 (CH), 123.82 (CH), 123.81 (4'y), 119.0 (4''y),
116.9 (CH2), 111.0 (CH), 107.4 (CH), 61.1 (OCH3), 61.0 (OCH3), 56.1
64
65(OCH 3) and 33.9 (CHj); m/z 352 (M+. 84%), 192 (6 6 ), 177 (2 1 ), 162 
(22), 161 (100), 131 (13), 103 (8 ) and 77 (7).
c. Preparation of 2'.3'.4'-trimethoxvflavone-8-acetic acid 188
The method of C lf  was followed using 8-allyI-2',3',4'-trimethoxyflavone 
(7.05 g, 20 mmol) to afford 2'.3'.4'-trimethoxvflavone-8-acetic acid 
(3.44 g, 49%) as colourless crystals, m.p. 185-186 °C (Found: C, 64.7; 
H, 5.0. C20H 18O 7 requires C, 64.9; H, 4.9%); 1718, 1618, 1577,
1418, 1293, 1114, 1012, 807, 766, 687 and 623 cm -'; 8 ^ (CD3SOCD3)
12.6 (1 H, br s, OH), 7.97 (1 H, dd, J  8 , 2, H-5), 7.73 (1 H, dd, J  8 , 2, 
H-7), 7.65 (1 H, d, J  9, H-6 '), 7.44 (1 H, t, J  8 , H-6 ), 7.01 (1 H, d, /  9, 
H-5'), 6.98 (1 H, s, H-3), 3.97 (2 H, s), 3.92 (3 H, s), 3.89 (3 H, s) and
3.83 (3 H, s); 5c (CD 3SO C D 3) 177.1 (4'y), 172.0 (4'y), 160.1 (4'y),
156.2 (4'y), 154.2 (4'y), 152.4 (4'y), 142.2 (4'y), 135.6 (CH), 125.4 (4'y),
124.8 (CH), 123.9 (CH), 123.6 (CH), 123.1 (4'y), 117.7 (4t ), 110.0 (CH),
109.2 ( C H ) ,  61.0 ( O C H 3 ) ,  60.5 ( O C H 3 ) ,  56.1 ( O C H 3 )  and 35.3 (CH;); m/z 
370 (M+, 100%), 356 (10), 325 (8 ), 309 (11), 295 (16), 281 (6 ), 267 (8 ), 
192 (31), 179 (23), 161 (29), 149 (13), 133 (42), 119 (6 ), 105 (16), 91 (6 ) 
and 77 (16).
d. Preparation of sodium 2'.3'.4'-trimethoxvflavone-8-acetate 185
The method of C2f was followed using 2',3',4'-trimethoxyfIavone-8-acetic 
acid (1.0 g, 2.7 mmol) to yield sodium 2'.3'.4'-trimethoxvflavone-8- 
acetate (0.83 g, 8 6 %) as a light pink powder, m.p. >350 °C; 1561,
1236, 1160, 1100, 990, 853 and 745 cm-'; 5^ (D ;0) 7.30 (2 H, m, H- 
5,7), 7.04 (1 H, t, J  8 , H-7), 6.95 (1 H, d, J  8 , H-6 '), 6.42 (1 H, s, H-3),
6.26 (1 H, d, J  8 , H-5'), 3.46 ( 6  H, s), 3.42 (2 H, s) and 3.38 (3 H, s); 
5c (D2O) 183.2 (4'y), 181.1 (4'y), 163.7 (4'y), 158.5 (4'y), 156.6 (4'y),
154.8 (4'y), 143.6 (4'y), 138.8 (CH), 129.9 (CH), 128.0 (CH), 127.1 (4'y),
66125.4 (4^y), 124.3 (CH), 118.8 (CH), 110.9 (CH), 110.7 (CH), 63.5 
(OCH3), 58.4 ( 2  X  OCH3) and 41.2 (CH2).
11. 2 ’,4 ',5 ’-Trimethoxyflavone-8-acetic Acid
a. Preparation of methvl 2.4.5-trimethoxvbenzoate 181
The method of C2b was followed using 2,4,5-trimethoxybenzoic acid 
(20.0 g, 94 mmol) to afford methyl 2,4,5-trimethoxybenzoate (16.8 g, 
79%) as colourless needles, m.p. 91-93 °C (lit.,^^^ 92.5 °C); 6 ^ 7.39
(1 H, s, H-6 ), 6.51 (1 H, s, H-3), 3.90 (3 H, s), 3.88 (3 H, s) and 3.84 
( 6  H, s).
b. Preparation of 8-allyl-2'.4'.5'-trimethoxyfIavone 178
The method of C le was followed using methyl 2,4,5-trimethoxybenzoate 
(2.49 g, 11 mmol) to yield 8-allyI-2'.4'.5'-trimethoxvflavone (2.13 g, 
55%) as colourless needles, m.p. 125-128 °C (Found: C, 71.6; H, 5.9. 
C21H20O5 requires C, 71.6; H, 5.7%); 1630, 1564, 1516, 1269, 1229,
1214, 1159, 1027, 908, 863, 817 and 763 cm-i; 6 ^ 8.08 (1 H, dd, 7 8 , 
2, H-5), 7.49 (1 H, dd, 7 8 , 2, H-7), 7.45 (1 H, s, H-6 '), 7.30 (1 H, t, 7 8 , 
H-6 ), 7.19 (1 H, s, H-3), 6.58 (1 H, s, H-3 ), 6,17-6.04 (1 H, m), 5.15-
5.05 (2H , m), 3.96 (6 H, s), 3.91 (3H , s) and 3.70 (2H , d, 7 6 ); 
6 c 179.0 (4^y), 160.2 (4^y), 154.2 (4^ y^), 154.0 (4^y), 152.4 (4^y), 143.2
(4n )^, 135.4 (CH), 134.0 (CH), 128.9 (4^7), 124.6 (CH), 123.8 (CH), 123.7 
(4:y), 116.7 (CH2), 111.8 (4 :7 ), 111.5 (CH), 111.2 (CH), 97.1 (CH), 56.5 
(OCH3), 56.2 (OCH3), 56.1 (OCH3) and 34.1 (CH2); m/z 352 (M+, 100%), 
337 (16), 322 (9), 309 (6 ), 295 (12), 192 (10), 177 (22), 161 (24), 149 
(14), 132 (24), 103 (16) and 77 (14).
c. Preparation of 2'.4'.5'-trimethoxyflavone-8-acetic acid 189
The method of C lf  was followed using 8-allyl-2',4'5'-trimethoxyfiavone 
(7.05 g, 20 mmol) to afford 2'.4'.5'-trimethoxvflavone-8-acetic acid
67(2.29 g, 31%) as yellow needles, m.p. 262-263 °C (Found: C, 64.6; H,
4.6. C20H 18O7 requires C, 64.9; H, 4.9%); 1715, 1616, 1558, 1271,
1 2 1 2 , 1159, 1044, 1017, 858 and 758 cm-i; (CD3SOCD3) 13.0-12.0 
(1 H, br s, OH), 7.94 (1 H, dd, J  8 , 2, H-5), 7.70 (1 H, dd, J  6 , 2, H-7), 
7.48 (1 H, s, H-6 '), 7.40 (1 H, t, J  8 , H-6 ), 7.00 (1 H, s, H-3), 6.84 (1 H, 
s, H-3'), 3.98 (3 H, s), 3.95 (2 H, s), 3.91 (3 H, s) and 3.84 (3 H, s);
6 c (CD3SOCD3) 177.1 (4::y), 171.6 (4:y), 159.8 (4^7), 154.1 (4n )^, 153.7
(4 :7 ), 152.7 (4n )^, 143.0 (4^^), 135.3 (CH), 125.2 (4^y), 124.5 (CH), 123.6 
(CH), 123.5 (4^y), 111.3 (CH), 110.4 (4^y), 110.0 (CH), 98.4 (CH), 56.5 
(OCH3), 56.0 (OCH3), 55.9 (OCH3) and 35.5 (CH2); 370 (M+, 35%),
341 (16), 309 (17), 295 (17), 213 (6 ), 192 (7), 161 (10), 149 (25), 129 
(24), 111 (26), 97 (51) and 77 (100).
d. Preparation of sodium 2'.4'.5'-trimethoxvflavone-8-acetate 186 
The method of C2f was followed using 2',4',5'-trimethoxyflavone-8-acetic 
acid (1.0 g, 2.7 mmol) to afford sodium 2'.4'.5'-trimethoxyflavone-8- 
acetate as a white powder, m.p. >350 °C; 1558, 1268, 1215, 1156,
1021, 852 and 755 cm-i; 6 ^ (D2O) 7.71 (1 H, d, 7 8 , H-5), 7.24 (1  H, 
d, 7 8 , H-7), 7.16 (1 H, s, H-3), 6.94 (1 H, t, 7 8 , H-6 ), 6.52 (1 H, s, H- 
3'), 6.46 (1 H, s, H-6 '), 3.47 ( 6  H, s), 3.34 (2 H, s) and 3.33 (3 H, s);
6 c (D2O) 183.4 (4ry), 180.7 (4ry), 163.4 (4^y), 157.7 (4ry), 156.6 (4ry),
154.8 (4ry), 144.0 (CH), 138.8 (4 7^), 129.8 (CH), 127.9 (4ry), 125.5 (4ry),
124.6 (CH), 111.4 (2 X CH), 111.3 (CH), 98.7 (4^y), 58.3 (OCH3), 58.1 (2 
XOCH3) and 41.4 (CH2).
12. 2 ',4 ',6 ’-T rim ethoxyflavone-8-acetic  Acid
a. Preparation of methyl 2.4.6-trimethoxybenzoate 184
The method of C2a was followed using 2,4,6-trimethoxybenzoic acid
(20.Og, 94 mmol) to afford methyl 2,4,6-trimethoxybenzoate (16.9 g,
6870%) as colourless needles, m.p. 65-68 °C (lit.,^ '^  ^ 67-70 °C); 8 ^ 6.12 
(2 H, s, H-3,5), 3.90 (3 H, s) and 3.82 (9 H, s).
b. Attempted preparation of 8-allyl-2'.4'.6’-trimethoxyflavone 183 
The method of C le was followed using methyl 2,4,6-trimethoxybenzoate 
(2.82 g, 11 mmol) to afford a brown oil which on analysis by ^H #MR 
was shown to be the unreacted ester and starting acetophenone.
13. 3*,4’,5 ’-Trimethoxyflavone-8-acetic Acid
a. Preparation of methvl 3.4.5-trimethoxvbenzoate 182
The method of C2a was followed using 3,4,5-trimethoxybenzoic acid 
(20.0 g, 94 mmol) to yield methyl 3,4,5-trimethoxybenzoate (13.2 g, 
62%) as colourless needles, m.p. 81-82 °C (lit.,^^  ^ g% 5 ^ 7.30 (2 H,
d, J  1, H-2,6) and 3.90 (12 H, s).
b. Preparation of 8-allyl-3’.4’.5'-trimethoxyfIavone 179
The method of C le was followed using methyl 3,4,5-trimethoxybenzoate 
(2.49 g, 11 mmol) to afford 8-allvl-3’.4’.5'-trimethoxvflavone (3.61 g, 
93%) as yellow needles, m.p. 179-181 °C (Found: C, 71.3; H, 5.5. 
C 2 1 H 2 0 O 5  requires C, 71.6; H, 5.7%); 1602, 1551, 1239, 1107, 982,
862 and 745 cm~i; 6 ^ 8.09 (1 H, dd, J  8 , 2, H-5), 7.53 (1 H, dd, J  8 , 2, 
H-7), 7.34 (1 H, t, J  8 , H-6 ), 7.13 (2 H, d, J  2, H-2',6'), 6.76 (1 H, s, H- 
3), 6.19-6.01 (1 H, m), 5.18-5.07 (2H , m), 3.94 (6 H, s), 3.92 (3 H, s) 
and 3.73 (2H, d, 7 6 ); 6 ^ 178.6 (4ry), 162.7 (4ry), 154.2 (4ry), 153.5 (2
C, 4ry), 141.0 (4ry), 135.3 ( C H ) ,  134.3 ( C H ) ,  129.1 (4ry), 127.1 (4ry), 125.0 
( C H ) ,  124.0 ( C H ) ,  123.9 (4 ry), 116.8 ( C H 2 ) ,  107.1 ( C H ) ,  103.5 (2 C H ) ,
61.1 ( O C H 3 ) ,  56.2 ( 2  X O C H 3 )  and 34.2 ( C H 2 ) ;  352 (M+, 1 0 0 %), 3 3 7
(41), 309 (19), 281 (10), 251 (9), 195 (9), 177 (14), 161 (23), 149 (13), 
133 (17), 103 (14), 89 (11) and 77 (26).
c. Preparation of 3'.4'.5’-trimethoxyflavone-8-acetic acid 190 
The method of C lf  was followed using 8-allyl-3',4',5'-trimethoxyflavone 
(7.05 g, 20 mmol) to afford 3'.4'.5'-trimethoxvflavone-8-acetic acid 
(5.47 g, 74%) as colourless needles, m.p. 233-235 °C (Found: C, 64.5; H,
4.6. C20H 18O7 requires C, 64.9; H, 4.9%); 1695, 1610, 1563, 1243,
1119, 983, 843 and 742cm -i; 8 ^ (CD3SOCD 3) 13.3-12.0 (1 H, br s, 
OH), 7.95 (1 H, dd, J  8 , 2, H-5), 7.73 (1 H, dd, J  8 , 2, H-7), 7.42 (1 H, 
t, J  8 , H-6 ), 7.35 (2 H, s), 7.12 (1 H, s), 4.01 (2 H, s), 3.92 ( 6  H, s) and 
3.79 (3 H, s); 8 ^ (CD3SOCD3) 177.1 (4ry), 171.8 (4ry), 161.8 (4ry), 154.0
(4ry), 153.3 (2 C, 4 y^), 140.7 (4^y), 135.6 (CH), 125.5 (4 y^), 124.9 (CH),
123.6 (CH), 123.2 (4^y), 106.5 (CH), 104.3 (4 ry), 103.9 (2 x CH), 60.2 
(OCH3), 56.2 (2 X OCH3) and 35.8 (CH2); 370 (M+, 1 %), 316 (87),
285 (14), 270 (11), 255 (10), 242 (10), 217 (8 ), 161 (14), 138 (100), 133 
(52), 123 (63), 105 (32) and 77 (52).
d. Preparation of sodium 3 '.4'.5'-trimethoxyflavone-8 -acetate 187
The method of C2f was followed using 3',4',5'-trimethoxyflavone-8-acetic 
acid (1.0 g, 2.6 mmol) to afford sodium 3'.4'.5’-trimethoxvflavone-8- 
acetate (0.86 g, 84%) as a white powder, m.p. 193-195 °C; 1563,
1240, 1161, 1109, 1046, 979, 842 and 739 cm-i; 8 ^ (D2O) 7.46 (2H ,
m, H-5,7), 7.15 (1 H, t, J 8 , H-6 ), 6.58 (1 H, s, H-3), 6.35 (2 H, s, H- 
2',6'), 3.66 (9 H, s) and 3.61 (2 H, s); 8 ^ (D2O) 182.7 (4ry), 180.5 (4ry),
164.8 (4ry), 162.3 (4^y), 156.3 (4^y), 154.6 (2 C, 4ry), 138.2 (CH), 134.5 
(4ry), 129.7 (CH), 127.9 (4ry), 125.2 (CH), 118.9 (4 y^), 106.2 (CH), 105.2 
( 2  X CH), 61.2 (OCH3), 58.4 ( 2  x OCH3) and 41.4 (CH2); m/z (FAB, 
glycerol) 415 ([M+$a]+, 6 %), 393 ([M+H]+, 14), 371 (8 ), 176 (36), 154 
(22), 133 (28), 119 (32), 109 (48), 95 (82) and 81 (100).
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7014. 2'-Brom o-3’,4 ’,5 ’-trimethoxyfIavone-8-acetic Acid
a. Preparation of 2-bromo-3.4.5-trimethoxvbenzoic acid 192 
Following the procedure of Mayer and Fikentscher^^^ a solution of 3,4,5- 
trimethoxybenzoic acid 191 (50.0 g, 236 mmol) in chloroform (500 ml) 
containing water (5 ml) was heated under reflux while a solution of 
bromine (12.2 ml, 238 mmol) in chloroform (100 ml) was added 
dropwise over a period of 2 h. After heating for a further 2 h evolution 
of HBr had ceased and the solution was evaporated to give a cream solid 
which was recrystallised from water/acetone (2 0 :1 ) to give 2 -bromo-
3 ,4 ,5 -trimethoxybenzoic acid (54.5 g, 79%) as colourless needles, m.p. 
146-148 “C (lit.,115 149-150 °C); 6 ^ 9.40 (1 H, br s, OH), 7.40 (1 H,
s, H-6 ), 3.97 (3 H, s) and 3.91 ( 6  H, s).
b. Preparation of methyl 2-bromo-3.4.5-trimethoxybenzoate 194
The method of C2b was followed using 2-bromo-3,4,5-trimethoxybenzoic 
acid (20.0 g, 6 8  mmol) to afford m ethyl 2-brom o-3,4 ,5- 
trimethoxybenzoate (14.1 g, 67%) as a colourless liquid, b.p. 200 “C at 
15 mmHg (lit.,n 6 202 “C at 16 mmHg); 0^ 7.15 (1 H, s, H-6 ), 3.93
(3 H, s), 3.92 (3 H, s), 3.89 (3 H, s) and 3.86 (3 H, s).
c. Preparation of 8-allyl-2-bromo-3*.4'.5’-trimethoxyflavone 196
The method of C le  was followed using methyl 2-bromo-3,4,5- 
trimethoxybenzoate (3.37 g, 11 mmol) to afford 8-allv l-2 '-brom o- 
3'.4’.5'-trimethoxvflavone (1.85 g, 39%) as colourless needles, m.p. 146- 
147 °C (Found: C, 58.1; H, 4.4. CiiHigBrOg requires C, 58.5; H, 4.4%); 
1632, 1566, 1196, 1099, 988, 919, 899, 834 and 737 cm-i; 6 ^ 8.10
(1 H, dd, J  8 , 2, H-5), 7.52 (1 H, dd, J  8 , 2, H-7), 7.35 (1 H, t, J  8 , H-
6 ), 6.91 (1 H, s), 6.55 (1 H, s), 6.12-5.92 (1 H, m), 5.13-5.02 (2 H, m),
4.00 (3 H, s), 3.99 (3 H, s), 3.91 (3 H, s) and 3.67 (2 H, d, 7 6 );
8 c 178.4 (4ry), 163.7 (4ry), 154.4 (4ry), 152.9 (4^y), 151.6 (4^y), 145.1
71(4ry), 135.5 (CH), 134.2 (CH), 129.7 (4 y^), 129.4 (4 y^), 125.0 (CH), 123.9 
(4ry), 123.8 (CH), 116.8 (CHi), 112.6 (CH), 109.9 (CH), 109.1 (4 y^), 61.2 
(OCH3), 61.1 (OCH3), 56.4 (OCH3) and 33.6 (CH2); m/z 430 (79Rr-M+, 
100%), 351 (24), 321 (6 ), 272 (14), 212 (6 ), 161 (13), 133 (19), 103 (11) 
and 77 (19).
d. Preparation of 2’-bromo-3'.4'.5'-trimethoxvflavone-8-acetic acid 198 
The method of C lf  was followed using 8-allyl-2'-bromo-3',4',5'- 
trimethoxyflavone (8.62 g, 20 mmol) to afford 2 ’-brom o-3 '.4 '.5 '- 
trimethoxvflavone-8 -acetic acid (4.06 g, 45%) as a white powder, m.p. 
233-236 °C (Found: C, 53.8; H, 3.8. C2oH nB r0 7  requires C, 53.5; H, 
3.8%); V^^1713, 1592, 1237, 1167, 1121, 1079, 1043, 862 and 754 cm- 
1; ôy (CD3SOCD3) 8.04 (1 H, dd, 7 8 , 2 , H-5), 7.79 (1 H, dd, 7 8 , 2 , H-
7), 7.51 (1 H, t, 7 8 , H-6 ), 7.25 (1 H, s), 6.69 (1 H, s), 3.91 (2 H, s), 
3.88 (3 H, s), 3.87 (3 H, s) and 3.85 (3 H, s) (acid proton not apparent);
6 c (CD 3SOCD 3 ) 177.1 (4ry), 171.9 (4ry), 163.1 (4ry), 154.6 (4ry), 153.1
(4ry), 151.1 (4ry), 144.7 (4ry), 136.3 (CH), 128.7 (4^y), 125.8 (CH), 125.5 
(CH), 124.0 (4ry), 123.4 (4ry), 112.4 (CH), 111.0 (CH), 108.1 (4^y), 61.2 
(OCH3), 61.1 (OCH3), 56.6 (OCH3) and 35.2 (CH2); m/z 450 (79Br-M+, 
10%), 400 (48), 375 (30), 281 (46), 231 (24), 181 (56), 149 (76), 119 
(6 8 ), 97 (43) and 77 (100).
e. Preparation of sodium 2'-bromo-3'.4'.5'-trimethoxyfiavone-8-acetate 
200
The method of C2f was follow ed using 2 '-brom o-3 ',4 ',5 '- 
trimethoxyflavone-8 -acetic acid ( 1 .0  g, 2 ,2  mmol) to afford sodium 2 '- 
brom o-3’.4 '.5 '-trim ethoxvflavone-8-acetate (0.95 g, 91%) as a grey 
powder, m.p. >350 "C; 1560, 1198, 1161, 1096, 989, 911, 854, 821
and 746 cm~i; 6 ^ (D2 O) 7.69 (1 H, dd, 7 8 , 2, H-5), 7.61 (1 H, dd,
7 8 , 2, H-7), 7.40 (1 H, t, 7 8 , H-6 ), 6.95 (1 H, s, H-3), 6.59 (1 H, s, H-
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6 '), 3.89 ( 6  H, s), 3.84 (2 H, s) and 3.78 (3 H, s); 6 ^ (D2O) 182.5 (4 ry),
180.9 (4ry), 166.3 (4ry), 157.0 (4ry), 154.6 (4ry), 152.9 (4ry), 146.9 (4ry),
139.2 (CH), 130.4 (4ry), 129.9 (4ry), 128.5 (CH), 125.8 (CH), 124.6 (CH),
113.9 (4ry), 113.0 (4ry), 1 1 1 .1  (CH), 63.9 ( 2  x OCH3), 58.9 (OCH3) and
40.9 (C%).
15. 2 ’,3 ’,4 ’,5 ’-Tetramethoxyflavone-8-acetic Acid
a. Preparation of 2.3.4.5-tetramethoxybenzoic acid 193
Following the procedure of Mayer and Fikentscher,^^^ 2-bromo-3,4,5- 
trimethoxybenzoic acid (20.4 g, 70 mmol) was dissolved in methanol 
(250 ml) containing freshly dissolved sodium metal (4.8 g, 210 mmol) 
and copper bronze powder (2.0 g). The mixture was stirred vigorously 
and heated under reflux for 17 h, filtered through celite which was washed 
with methanol and the combined filtrates evaporated. The residue was 
dissolved in water ( 2 0 0  ml) and the solution acidified carefully with 
concentrated hydrochloric acid until pH 4 was reached. The mixture was 
extracted with methylene chloride ( 2 0 0  ml) which was dried and 
evaporated to give a white solid. This was recrystallised from 
hexane/ethyl acetate (5:1) to yield 2,3,4,5-tetramethoxybenzoic acid 
(13.6 g, 80%) as colourless needles, m.p. 85-87 “C (lit.,^^  ^ 87-88 °C);
5h 10.0-8.0 (1 H, hr s, OH), 7.41 (1 H, s, H-6 ), 4.08 (3 H, s), 4.00
(3 H, s), 3.94 (3 H, s) and 3.90 (3 H, s).
b. Preparation of methvl 2.3.4.5-tetramethoxybenzoate 195
The method of C2b was followed using 2,3,4,5-tetramethoxybenzoic acid 
(12.9 g, 53 mmol) to afford methyl 2,3,4,5-tetramethoxybenzoate 
(12.7 g, 93%) as a colourless liquid, b.p. (oven temp.) 120 °C at 1 mmHg 
(lit.,I^7 125-126 “C at 1-2 mmHg); 8 ^ 7.11 (1 H, s, H-6 ), 3.97 (3 H, s),
3.92 (3 H, s), 3.91 (3 H, s), 3.87 (3 H, s) and 3.85 (3 H, s).
73c. Preparation of 8-allvl-2'.3'.4'.5'-tetramethoxvflavone 197
The method of C le  was follow ed using m ethyl 2,3,4,5- 
tetramethoxybenzoate (2.82 g, 11 mmol) to afford 8-allvl-2'.3 '.4 '.5 '- 
tetram ethoxvflavone (1.13 g, 27%) as cream needles, m.p. 95-97 °C 
(Found: C, 69.4; H, 6.1. C22H22O6 requires C, 69.1; H, 5.8%); 1581,
1551, 1222, 1092, 1037, 984, 900, 831 and 740 cm -'; 5^ 8.10 (1 H, dd,
7 7, 2, H-5), 7.53 (1 H, dd, 7 7, 2, H-7), 7.34 (1 H, t, 7 7, H-6), 6.91 
(1 H, s), 6.56 (1 H, s), 6.10-5.97 (1 H, m), 5.11-5.03 (2 H, m), 3.95 
(6 H, s), 3.94 (3 H, s), 3.88 (3 H, s) and 3.65 (2 H, d, 7 8); 5^ 178.4
(4ry), 163.7 (4ry), 154.5 (4'y), 153.0 (4^y), 151.7 (4:y), 145.2 (4fy), 135.5 
(CM), 134.2 (CH), 129.8 (4ry), 129.4 (4ry), 125.1 (CH), 123.9 (4ry), 123.9 
(CH), 116.8 (CH), 112.6 (CH), 109.9 (CH), 109.1 (4o'), 61.2 (OCH3), 61.2 
(OCH3), 56.4 (2 X OCH3) and 33.6 (CH2); m/z 382 (M+, 100%), 367 (24), 
336 (9), 309 (5), 281 (7), 253 (10), 222 (13), 183 (10), 161 (42), 133 
(24), 103 (18) and 77 (36).
d. Preparation of 2'.3'.4'.5'-tetramethoxvflavone-8-acetic acid 199
The method of C lf  was follow ed using 8 -ally l-2 ',3 ',4 ',5 ’- 
tetram ethoxyflavone (4.20 g, 11 mmol) to afford 2 '.3 '.4 '.5 '-  
tetramethoxvflavone-8 -acetic acid (2.07 g, 47%) as colourless needles, 
m.p. 248-250 °C (Found: C, 61.6; H, 4.7. C2 iH2oOg + 0.5 H2O requires 
C, 61.6; H, 5.1%); 1711, 1589, 1240, 1119, 1058, 867 and 760 cm-
1; Ôh (CD3SOCD3) 8.01 (1 H, dd, 7 8 , 2, H-5), 7.79 (1 H, dd, 7 8 , 2, H-
7), 7.50 (1 H, t, 7 8 , H-6 ), 7.23 (1 H, s, H-6 '), 6.63 (1 H, s, H-3), 3.97 
(2 H, s), 3.82 ( 6  H, s), 3.80 (3 H, s) and 3.79 (3 H, s) (acid proton not 
apparent); (CD3SOCD 3) 177.1 (4ry), 171.9 (4ry), 170.5 (4ry), 165.5
(4ry), 163.0 (4ry), 154.4 (4^y), 152.9 (4ry), 150.9 (4?), 136.1 (CH), 125.2 
(CH), 123.7 (CH), 123.2 (4^y), 112.4 (CH), 111.1 (4?), 107.5 (CH), 62.3 
(2 X OCH3), 56.6 (OCH3), 54.1 (OCH3) and 35.0 (CH;); m/z 400 (M+,
7438%), 356 (12), 296 (43), 253 (20), 162 (100), 133 (17), 119 (8 8 ), 97
(32) and 77 (84).
e. Preparation of sodium 2'.3*.4*.5*-tetramethoxyflavone-8-acetate 201 
The method of C2f was followed using 2',3',4',5’-tetramethoxyflavone-8- 
acetic acid (1.0 g, 2.5 mmol) to yield sodium  2 '.3 '.4 '.5 '-  
tetramethoxvflavone-8 -acetate (0.77 g, 73%) as a white powder, m.p. 
>350 T ;  1555, 1240, 1156, 1099, 989 and 756cm -i; 6 ^ (D2O)
7.37 (2H , m, H-5,7), 7.10 (1 H, t, /  8 , H-6 ), 6 . 6 6  (1 H, s, H-3), 6.31 
(1 H, s, H-6 '), 3.63 ( 6  H, s), 3.57 (2 H, s) and 3.52 ( 6  H, s); 8 ^ (D2O)
182.6 (4 ry ) ,  180.9 (4 ry ) , 166.4 ( 4 ry ) ,  157.1 (4 r y ) ,  154.7 (4 ry ) ,  152.9 (4 ^ y ) ,
146.9 (4 ry ) , 139.4 (4 ry ) , 130.4 (4 ry ) , 129.9 (CH), 128.5 (CH), 125.9 ( 4 ry ) ,
124.5 (CH), 114.0 (CH), 112.9 (CH), 111.2 (4 ry ) ,  64.0 (2 x OCH3), 63.9 
(OCH3), 58.9 (OCH3) and 41.0 (CH2).
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E. Preparation of 2-Heteroarvl Analogues of Flavone-8-acetic 
Acid
1. 2-(3-Thienyl)benzopyran-4-one-8-acetic Acid
a. Preparation of methyl thiophene-3-carboxvlate 204
The method of C2b was followed using thiophene-3-carboxylic acid 
(20.0 g, 156 mmol) to afford methyl thiophene-3-carboxylate (20.5 g, 
94%) as a colourless liquid, b.p. (oven temp.) 84 °C at 15 mmHg (lit.,^^  ^
90-91 °C at 17 mmHg).
b. Preparation of 8-allvl-2-f3-thienvDbenzopyran-4-one 202
The method of C le was followed using methyl thiophene-3-carboxylate 
(1.56 g, 11 mmol) to afford 8-allvl-2-(3-thienvH benzopvran-4-one 
(2.15 g, 73%) as colourless needles, m.p. 154-155.5 °C (Found: C, 71.5; 
H, 4.3. C 16H 12O2S requires C, 71.6; H, 4.5%); 1733, 1637, 1597,
1258, 1098, 948, 823, 759 and 699 cm-i; 6^ 8.09 (1 H, dd, 7 8, 2, H-
5), 8.00 (1 H, m, H-2'), 7.53 (1 H, dd, 7 8, 2, H-7), 7.46 (2 H, m, H- 
4',5'), 7.34 (1 H, t, 7 8, H-6), 6.71 (1 H, s, H-3), 6.15-6.01 (1 H, m),
5.20-5.13 (2H , m) and 3.73 (2H , d, 7 8); 8^ 178.7 (4^y), 159.3 (4^y),
154.0 (4»7), 135.8 (CH), 134.4 (4^y), 134.2 (CH), 129.3 (4n )^, 127.5 (CH),
126.7 (CH), 125.0 (CH), 124.9 (CH), 123.93 (CH), 123.91 (4ry), 117.0 
(CH2), 106.9 (CH) and 34.1 (CH2); m/z 268 (M+, 100%), 240 (5), 167 
(10), 160 (15), 132 (33), 103 (14) and 77 (19).
c. Preparation of 2-f3-thienvDbenzopyran-4-one-8-acetic acid 206
The method of C lf  was followed using 8-allyl-2-(3-thienyl)flavone 
(5.37 g, 20 mmol) to afford 2-(3-thienyl)benzopyran-4-one-8-acetic acid 
(2.36 g, 41%) as colourless crystals, m.p. 239-242 °C (Found: C, 62.0; 
H, 3.3. C 15H 10O4S + 0.25 H2O requires C, 62.0; H, 3.4%); 1710,
1628, 1611, 1588, 1269, 1225, 1093 and 974cm -i; 6 H (C D 3S 0 CD 3)
7612.6 (1 H, br s, OH), 8.39 (1 H, t, J  1, H-2'), 7.97 (1 H, dd, J  8 , 2, H-5),
7.74 (2 H, m, H-4',5’), 7.73 (1 H, dd, J  8 , 2, H-7), 7.42 (1 H, t, J  8 , H-
6 ), 6.93 (1 H, 8 , H-3) and 4.01 (2 H, s); (CD3SOCD 3) 177.1 (4:y),
171.9 (4n )^, 158.7 (4^), 153.8 (4^y), 135.5 (CH), 133.8 (4^^), 128.2 (CH),
127.8 (CH), 125.4 (CH), 125.3 (CH), 124.8 (CH), 123.6 (CH), 123.3 (4"v),
106.4 (CH) and 35.6 (CH2); 286 (M+, 100%), 241 (42), 134 (78), 105
(54) and 77 (60).
d. Preparation of sodium 2-r3-thienyDbenzopyran-4-one-8-acetate 208 
The method of C2f was followed using 2-(3-thienyl)benzopyran-4-one-8- 
acetic acid (1.0 g, 3.5 mmol) to give sodium 2-C3-thienvDbenzopyran-4- 
one-8 -acetate (0.95 g, 95%) as a white powder, m.p. >337 °C;
1700, 1561, 1240, 1090, 1020, 853 and 752 cm-i; 6 ^ (D2O) 7.88 (1 H,
d, 7 8 ), 7.58 (1 H, d, 7 8 ), 7.46 (1 H, d, 7 8 ), 7.32-7.18 (3 H, m), 6.22 
(1 H, s) and 3.56 (2 H, s); 6 ^ (D2O) 183.2 (4^ -y), 181.4 (4^y), 164.0 (4n^),
163.1 (4<3^ ), 139.0 (CH), 135.3 (4 ^^ ), 131.5 (CH), 130.6 (CH), 129.8 (4 '-y),
128.2 (CH), 127.3 (CH), 125.5 (CH), 124.6 (4^y), 107.4 (CH) and 41.5 
(CH2); m/z (FAB, glycerol) 639 (([2M+%a]+, 6 %), 331 ([M+%a]+, 34), 
309 (M+, 30), 176 (72), 155 (20), 109 (44) and 95 (100).
2. 2 -(3 -M ethyl-2-th ienyl)benzopyran-4-one-8-acetic  Acid
a. Preparation of methvl 3-methvlthiophene-2-carboxvlate 205 
The method of C2b was followed using 3-methylthiophene-2-carboxylic 
acid (20.0 g, 143 mmol) to yield methyl 3-methylthiophene-2-carboxylate 
(14.7 g, 67%) as a colourless liquid, b.p. 120 °C (lit.,^^  ^ 116-117.5 °C);
5N 7.40 (1 H, d, 7 7, H-4), 6.92 (1 H, d, 7 7, H-5), 3.86 (3 H, s) and
2.56 (3 H, s).
77b. Preparation of 8 -allvl-2-n-methvl-2-thienyDbenzopvran-4“One 203 
The method of C le was followed using methyl 3-methylthiophene-2- 
carboxylate (1.72 g, 11 mmol) to yield a brown liquid. This was distilled 
under reduced pressure (130 °C at 0.1 mmHg) and the resulting solid 
recrystallised from methanol to yield 8 -a llv l-2 - (3 -m e th v l-2 -  
thienyHbenzopvran-4-one (1.58 g, 51%) as colourless needles, m.p. 146- 
147 "C (Found: C, 72.5; H, 4.7. C 17H 14O2S requires C, 72.3; H, 5.0%);
1631, 1578, 1206, 1090, 925, 839, 796 and 753 cm-i; 0^ 8.10
(1 H, dd, J  8 , 2, H-5), 7.55 (1 H, dd, J  8 , 2, H-7), 7.48 (1 H, d, J  6 , H- 
4'), 7.35 (1 H, t, J  8 , H-6 ), 7.00 (1 H, d, J  6 , H-5'), 6.62 (1 H, s, H-3),
6.18-5.95 (1 H, m), 5.20-5.10 (2 H, m), 3.70 (2 H, d, 7 6 ) and 2.55 
(3 H, s); 6 c 178.1 (4»:y), 159.3 (4"7), 154.0 (4 ^^ ), 140.1 (4"7), 135.2 (CH),
134.0 (CH), 132.6 (CH), 129.3 (4^7), 129.2 (4n )^, 128.5 (CH), 124.9 (CH),
123.74 (4^7), 123.72 (CH), 117.0 (CH2), 108.1 (CH), 33.7 (CH2) and 16.8 
(CH 3); m/z 282 (M+, 100%), 267 (13), 251 (6 ), 224 (3), 200 (3), 161
(33), 132 (56), 121 (34), 115 (17), 103 (19), 91 (31) and 77 (42).
c. Preparation of 2-f3-methvl-2-thienyPbenzopyran-4-one-8-acetic acid 
207
The method of C lf  was followed using 8-allyl-2-(3-methyl-2- 
thienyl)benzopyran-4-one (5.65 g, 20 mmol) to afford 2-f3-methvl-2- 
thienyHbenzopyran-4-one-8-acetic acid (2.16 g, 36%) as colourless 
rhomboids, m.p. 225-227 “C (Found: C, 64.0; H, 4.0. C 16H 12O4S requires 
C, 64.0; H, 4.0%); 1713, 1619, 1575, 1210, 1139, 1031, 863, 759
and 729 cm-i; 6 ^ ( C D 3 S O C D 3 )  12.7-12.5 (1 H, br s, OH), 7.95 (1 H, 
dd, 7 8 , 2, H-5), 7.84 (1 H, d, 7 6 , H-4'), 7.75 (1 H, dd, 7 8 , 2, H-7),
7.43 (1 H, t, 7 8 , H-6 ), 7.15 (1 H, d, 7 6 , H-5'), 6.57 (1 H, s, H-3), 3.96 
(2 H, s) and 2.55 (3H , s); 6 ^ ( C D 3 S O C D 3 )  176.5 (4^ -y), 171.7 (4^ y^),
158.8 (4 y^), 154.1 (4 ^^ ), 140.8 (4^y), 135.9 (CH), 133.0 (CH), 130.0 (CH),
128.2 (4:y), 125.2 (4^ )^, 125.0 (CH), 123.8 (CH), 123.1 (4 y^), 107.5 (CH),
7835.1 (CHz) and 16.3 (CH3); m/^ 300 (M+, 100%), 255 (18), 227 (8 ), 179
(16), 161 (12), 133 (20), 122 (20), 106 (12) and 77 (13).
d. Preparation of sodium 2-r3-methvl-2-thienyDbenzopvran-4-one-8- 
acetate 209
The method of C2f was followed using 2-(3-methyl-2-thienyl) 
benzopyran-4-one-8 -acetic acid (1.0 g, 3.3 mmol) to afford sodium 2-f3- 
methyl-2-thienvl) benzopyran-4-one-8-acetate (0.05 g, 5%) as a white 
powder, m.p. >350 °C; 1696, 1610, 1580, 1239, 1093, 860 and
754 cm -i; 6 ^ (D2 O) 7.50 (1 H, dd, J  8 , 2, H-5), 7.35 (1 H, dd, J  8 , 2,
H-7), 7.26 (1 H, d, J  6 , H-4'), 7.14 (1 H, t, J  8 , H-6 ), 6.60 (1 H, d, J 6 , 
H-5'), 6.02 (1 H, s, H-3), 3.45 (2 H, s) and 2.08 (3 H, s); 6 ^ (D2O)
182.6 (4ry), 181.1 (4ry), 163.7 (4ry), 156.6 (4ry), 145.3 (4ry), 139.1 (CH),
136.0 (CH), 133.4 (CH), 130.2 (4ry), 129.7 (4ry), 128.3 (CH), 125.6 (CH),
124.5 (4ry), 107.6 (CH), 41.1 (CH2) and 19.4 (CH3); m/k (FAB, glycerol) 
667 ([2M+&a]+, 9%), 345 ([M+&a]+, 56), 323 ([M+H]+, 30), 301 ([M - 
&
'()*
16), 278 (16), 256 (14), 176 (100) and 154 (57).
3, 2 -(3-M ethoxy-2-th ienyI)benzopyran-4-one-8-acetic  Acid
a. Preparation of methvl 3-methoxythiophene-2-carboxvIate 210 
The method of C2a was followed by Dr R. B. Ritchie using 3- 
methoxythiophene-2-carboxylic acid (5.0 g, 32 mmol) to yield methyl 3- 
methoxythiophene-2-carboxylate (4.7 g, 8 6 %) as colourless needles, m.p. 
51-52 "C (lit. , 120 5 4  T ) ;  ôy 7.39 (1  H, d, 7 4, H-5), 6.83 (1  H, d, 7 4,
H-4), 3.94 (3 H, s) and 3.80 (3 H, s).
79b. Preparation of 8-allyl-2-r3-methoxv-2-thienynbenzopvran-4-one 211 
The method of C le was followed by Dr R. B. Ritchie using methyl 3- 
thiophene-2 -carboxylate (4.7 g, 27 mmol) to afford 8 -ally l-2 -(3 - 
methoxy-2-thienvDbenzopvran-4-one (1.4 g, 17%) as colourless needles, 
m.p. 106-108 “C (Found: C, 68.0; H, 5.0. C 17H 14O3S requires C, 68.4; H, 
4.7%); 1600, 1548, 1210, 1121, 1052, 999, 900, 831 and 718 cm-i;
Ôh 8.04 (1 H, dd, /  8 , 2, H-5), 7.43 (2 H, m, H-7,5'), 7.28 (1 H, t, 7 8 ,
H-6 ), 7.09 (1 H, s, H-3), 6.90 (1 H, d, 7 4, H-4'), 6.15-5.93 (1 H, m),
5.20-5.08 (2 H, m), 3.96 (3 H, s) and 3.63 (2 H, d, 7 6 ); 6 ^ 178.4 (4ry),
159.2 (4ry), 158.1 (4ry), 153.6 (4ry), 135.4 (CH), 133.6 (CH), 129.1 (4ry),
128.9 (CH), 124.5 (CH), 123.9 (4ry), 123.7 (CH), 116.8 (CH2), 116.3 
(CH), 111.4 (4 ry), 106.6 (CH), 58.8 (OCH3) and 33.8 (CH2); m/k 298 (M+, 
100%), 267 (21), 255 (11), 199 (9), 161 (30), 138 (63), 123 (41), 103 
(22) and 77 (32).
c. Preparation of 2-13-methoxy-2-thienyHbenzopyran-4-one-8-acetic acid 
212
The method of C lf  was followed using 8-allyl-2-(3-methoxy-2- 
thienyl)benzopyran-4-one (5.64 g, 20 mmol) to afford 2-(3-methoxv-2- 
thienynbenzopvran-4-one-8-acetic acid (2.84 g, 45%) as colourless 
crystals, m.p. 252-254 “C (Found: C, 61.0; H, 3.6. C 16H 12O5S requires C, 
60.8; H, 3.8%); 1700, 1579, 1320, 1118, 981, 839, 799 and 749 cm-
( C D 3 S O C D 3 )  13.0-12.0 (1 H, br s, OH), 7.95 (1 H, dd, 7 8 , 2, H-
5), 7.72 (1 H, dd, 7 8 , 2, H-7), 7.42 (1 H, t, 7 8 , H-6 ), 7.36 (2 H, m, H- 
4',5'), 7.12 (1  H, s, H-3), and 3.92 (5 H, s); 5^ (CD3SOCD3) 177.1 (4 7^ ),
171.8 (4:y), 161.8 (4n )^, 154.0 (4^y), 153.2 (4n )^, 140.7 (4^y), 135.6 (CH),
126.3 (CH), 125.4 (4^y), 124.8 (CH), 123.6 (CH), 123.2 (4 n^ ), 106.5 (CH),
103.9 (CH), 60.1 (OCH3) and 35.8 (CH2); m/z 316 (M+, 41%), 272 (26), 
162 (87), 132 (59), 91 (12) and 77 (100).
80d. P reparation  o f so d iu m  2-r3 -m ethoxv-2 -th ienv l)benzopyran -4 -Q ne-8 - 
acetate 213
The method of C2f was followed using 2-(3-methoxy-2-thienyl) 
benzopyran-4-one-8-acetic acid (1.0 g, 3.2 mmol) to afford sodium 2-(3- 
methoxv-2-thienvD benzopvran-4-one-8-acetate (0.70 g, 65%) as a white 
powder, m.p. >350 T ;  1700, 1569, 1241, 1085, 860 and 751 cm~
1; 5h (D2O) 7.45 (2 H, m, H-5,7), 7.18 (1 H, t, J  8 , H-6 ), 6.71 (2 H, m,
H-3, 4'), 6.52 (1 H, d, 7 2, H-5'), 3.72 (3 H, s) and 3.70 (2 H, s); 
ôc (D2O) 182.4 (4ry), 180.4 (4^y), 164.6 (4ry), 154.5 (4ry), 154.2 (4ry),
141.9 (4ry), 138.5 (CH), 129.5 (CH), 128.4 (CH), 127.9 (CH), 125.1 (4 y^),
124.2 (CH), 107.0 (4ry), 105.1 (CH), 58.4 (OCH3) and 41.4 (CH2); m/z 
(FAB, glycerol), 415 (M+, 21%), 371 (6 ), 348 (5), 329 (16), 176 (100), 
165 (11), 154 (46), 119 (30), 105 (42), 91 (65) and 77 (49).
4. 2 -(2 -F ury l)benzopyran-4 -one-8 -acetic  Acid
a. Preparation of methyl 2-furoate 222
The method of C2a was followed using 2-furoic acid (20.0 g, 179 mmol) 
to yield a yellow liquid which was Kugelrohr distilled to afford methyl 2- 
furoate (14.2 g, 63%) as a colourless liquid, b.p. (oven temp.) 182- 
183 "C (lit.,121 18L3 T ) ;  0^7.59 (1 H, d, 7 2, H-5), 7.18 (1 H, d, 7 2,
H-3), 6.51 (1 H, t, 7 2, H-4) and 3.90 (3 H, s).
b. Preparation of 8-allvl-2-f2-furvDbenzopyran-4-one 220
The method of C le  was followed using methyl 2-furoate (1.39 g,
11 mmol) to afford 8-allyl-2-(2-furvDbenzopyran-4-one (1.54 g, 56%) as 
yellow cubes, m.p. 164-166 “C (Found: C, 76.2; H, 4.8. C 16H 12O 3 
requires C, 76.2; H, 4.8%); 1732, 1632, 1601, 1275, 1174, 1078,
988, 922, 883 and 825 cm-i; 0^ 8.08 (1 H, dd, 7 8 , 2, H-5), 7.62 (1 H, 
d, 7 8 , H-5'), 7.53 (1 H, dd, 7 8 , 2, H-7), 7.32 (1 H, t, 7 8 , H-6 ), 7.09 
(1 H, d, 7 8 , H-3'), 6.72 (1 H, s, H-3), 6.61 (1 H, m, H-4'), 6.12-5.98
(1 H, m), 5.22-5.13 (2 H, m) and 3.69 (2 H, d, 7 8 ); 5^ 178.0 (4''y),
154.8 (4fy), 153.7 (4^), 146.5 (4'^ y), 145.8 (CH), 135.3 (CH), 134.0 (CH),
129.2 (4 0 "), 124.9 (CH), 124.2 (4‘T'), 123.9 (CH), 116.9 (CH^), 112.8 (CH),
112.5 (CH), 105.3 (CH) and 33.9 (CH^); m/i 252 (M+, 100%), 224 (19), 
190 (10), 160 (37), 140 (28), 131 (89), 103 (40), 92 (25), 84 (53) and 77 
(52).
c. Preparation of 2-('2-furvl)benzopvran-4-one-8-acetic acid 224
The method of C lf  was followed using 8-alIyl-2-(2-furyI)benzopyran-4- 
one (5.1 g, 20 mmol) to afford 2-('2-furvl)benzopyran-4-one-8-acetic 
acid (2.3 g, 43%) as colorless needles, m.p. 244—246 °C (lit.,"' 240- 
2 4 2 'O ;  1718, 1642, 1603, 1245, 1082, 873 and 760 cm -';
5h (CD 3SO C D 3) 8.07 (1 H, d, 7 2 , H-5'), 7.93 (1 H, dd, 7 8 , 2 , H-5), 
7.73 (1 H, dd, 7 8 , 2, H-7), 7.43 (1 H, t, 7 8 , H-6 ), 7.33 (1 H, d, 7 2, H- 
3'), 6.84 (1 H, d, 7 2, H-4'), 6.62 (1 H, s, H-3) and 3.95 (2 H, s); 
Sc (CD3SOCD 3) 176.6 (4ry), 172.3 (4^y), 154.4 (4>y), 153.8 (4ry), 147.7
(CH), 145.6 (4:y), 136.0 (CH), 125.7 (CH), 125.3 (4 o'), 123.9 (CH), 123.7 
(4ry), 114.2 (CH), 113.3 (CH), 104.4 (CH) and 35.6 (CH2); m/z 270 (M+, 
99%), 256 (85), 225 (43), 134 (57), 133 (76), 120 (43), 106 (48), 92 
(100) and 77 (48).
d. Preparation of sodium 2-('2-furvlibenzopvran-4-one-8-acetate 226 
The method of C2f was followed using 2-(2-furyl)benzopyran-4-one-8- 
acetic acid (1.0 g, 3.7 mmol) to give sodium 2-('2-furvl)-benzopvran-4- 
one-8 -acetate (0.98 g, 91%) as a white powder, m.p. >350 °C;
1702, 1578, 1290, 1237, 1088, 1014, 850 and 752 cm -'; Sg (D2O) 7.62 
(2 H, m, H-5,4'), 7.45 (1 H, d, 7 8 , H-7), 7.24 (1 H, t, 7 8 , H-6 ), 7.05 
(1 H, d, 7  2 , H-5'), 6.58 (1 H, d, 7 2, H-3'), 6.26 (1 H, s, H-3) and 3.55 
(2H , s); Sc (D2O) 182.8 (4ry), 181.6 (4^y), 158.7 (4ry), 156.4 (4a), 150.0
81
82(CH), 147.7 (4ry), 139.1 (CH), 129.8 (4 ry), 128.3 (CH), 125.7 (CH), 124.9 
(4 ry), 118.0 (CH), 115.9 (CH), 105.7 (CH) and 41.3 (CHi).
5. 2 -(3 -F ury l)benzopyran-4 -one-8 -acetic  Acid
a. Preparation of methyl 3-furoate 223
The method of C2a was followed using 3-furoic acid (20.0 g, 179 mmol) 
to afford methyl 3-furoate (15.6 g, 69%) as a colourless liquid b.p. (oven 
temp.) 159-160 T  (lit. , 122 1 6 O T ) ;  0^ 8.04 (1 H, d, J  1, H-2), 7.45
(1 H, dd, y 2, 1, H-4), 6.73 (1 H, d, 7 2, H-5) and 3.87 (3 H, s).
b. Preparation of 8-allyl-2-G-furvTbenzopyran-4-one 221
The method of C le was followed using methyl 3-furoate (1.39 g, 
11 mmol) to afford 8 -allyl-2-(3-furvDbenzopvran-4-one (2.11 g, 76%) as 
colourless needles, m.p. 131-132 “C (Found: C, 76.5; H, 4.7. C16H 12O3 
requires C, 76.2; H, 4.8%); 1634, 1587, 1213, 1169, 1018 and
875 cm -i; 0^ 8.05 (1 H, dd, 7 8 , 2, H-5), 8.02 (1 H, s, H-2'), 7.51 
(1 H, d, 7 2, H-5'), 7.49 (1 H, dd, 7 8 , 2, H-7), 7.31 (1 H, t, 7 8 , H-6 ),
6.72 (1 H, d, 7 2, H-4'), 6.49 (1 H, s, H-3), 6.11-5.96 (1 H, m), 5.19- 
5.14 (2H , m) and 3.65 (2H , d, 7 7); 0^ 178.2 (4^ :y), 158.2 (4^y), 153.9
(4 ry), 144.7 (CH), 142.8 (CH), 135.3 (CH), 134.0 (CH), 129.1 (4^), 124.8 
(CH), 124.0 (4^), 124.0 (CH), 120.5 (4^), 116.9 (CH^), 107.5 (CH), 107.0 
(CH) and 34.0 (CH2); m/z 252 (M+, 100%), 224 (7), 160 (12), 145 (9), 
131 (44), 115 (9), 103 (15) and 77 (18).
c. Attempted preparation of 2-(3-furyDbenzopyran-4-one-8-acetic acid 
225
The method of C lf  was followed using 8-allyl-2-(3-furyl)benzopyran-4- 
one (2 .1  g, 8 .2  mmol) to afford a white solid only after evaporation to 
dryness. This solid dissolved in the minimum of water and was shown by 
^H +MR not to be the expected product.
83
6. 2-(3-Chloro-2-benzothienyl)benzopyran-4-one-8-acetic acid
a. Preparation of methvl 3-chlorobenzorb1thiophene-2-carboxylate 214 
Following a procedure by Krubsack and Higa (lit.,^^^) a solution of 
cinnamic acid (14.8 g, 100 mmol) in thionyl chloride (25 g, 210 mmol) 
was heated under reflux for 2  h and then pyridine (2 . 0  g, 2 0  mmol) in 
thionyl chloride (5.0 g, 4.2 mmol) was added with continued heating 
under reflux for 12 h and the mixture allowed to cool. The elemental 
sulphur was filtered off and the filtrate evaporated. The resulting solid 
was recrystallised from hexane to give 3 -chlorobenzo[b]thiophene-2 - 
carbonylchloride 216 (3.9 g, 16%) as a yellow powder, m.p. 111-113 °C 
(lit.,123 113.5-114.5 °C)
The acid chloride was added portionwise into boiling methanol (100 ml) 
and the solvent removed to give methvl 3-chlorobenzorb1thiophene-2- 
carboxvlate (3.61 g, 95%) as a light yellow needles, m.p. 80-81 °C 
(Found: C, 53.0; H, 3.2. C 10H7CIO2S requires C, 53.0; H, 3.1%);
1710, 1302, 1222, 1083, 1051, 932, 814 and 743 cm-i; 6^7.93 (1 H, d, 
7 7), 7.77 (1 H, d, 7 7), 7.47 (2 H, m) and 3.94 (3 H, s); (4ry),
138.5 (4ry), 136.9 (4^y), 128.2 (CH), 128.2 (4ry), 127.5 (4ry), 125.4 (CH),
123.8 (CH), 122.7 (CH) and 52.5 (OCH3); m/z 226 (35C1-M+, 55%), 195 
(100), 167 (34), 132 (30), 123 (29) and 8 8  (15).
b. Preparation of 8-allyl-2-(3-chloro-2-benzothienyl)benzopvran-4-one 
217
The method of C le was followed using methyl 3-chlorobenzo[bjthiophene- 
2-carboxylate (2.49 g, 11 mmol) to afford 8 -a lly l-2 -(3 -ch lo ro -2 - 
benzothienyPbenzopyran-4-one (0.85 g, 22%) as cream needles, m.p. 
148-149 °C (Found: C, 68.3; H, 4.0. C20H 13CIO2S requires C, 68.1; H, 
3.7%); 1732, 1635, 1594, 1511, 1222, 1133, 1067, 938, 757 and
614 cm-i; 0^ 8.05 (1 H, dd, 7 8 , 2, H-5), 7.95 (1 H, m), 7.85 (1 H, m).
847.60 (1 H, dd, J  8 , 2, H-7), 7.58-7.50 (2 H, m), 7.38 (1 H, t, J  8 , H-6 ),
7.29 (1 H, s, H-3), 6.16-6.00 (1 H, m), 5.24-5.14 (2 H, m), 3.71 (2 H, 
d, 7 8 ); Ôc 177.9 (4n )^, 156.5 (4^^), 153.8 (4n )^, 137.4 (4::y), 137.3 (4n^),
135.2 (CH), 134.2 (CH), 129.5 (4^y), 127.7 (4^y), 127.5 (CH), 125.6 (CH),
125.1 (CH), 123.83 (4^y), 123.81 (CH), 123.0 (CH), 122.4 (CH), 117.1 
(CH2), 110.3 (CH) and 33.7 (CH2) (one quaternary carbon not apparent); 
m/z 352 (35C1-M+, 6 6 %), 318 (38), 226 (55), 195 (100), 168 (38), 132 
(48) and 77 (17).
c. Preparation of 2-r3-chloro-2-benzothienvDbenzopyran-4-one-8-acetic 
acid 218
The method of C lf  was followed using 8-allyl-2-(3-chloro-2- 
benzothienyl)benzopyran-4-one (7.04 g, 20 mmol) to afford 2-t3-chloro- 
2-benzothienvDbenzopvran-4-one-8-acetic acid (0.89 g, 12%) as a cream 
powder, m.p. 132-134 °C (Found: M+, 371.0157. C 19H 11CIO4S requires 
M, 371.0145); 3400 (br), 1681, 1560, 1251, 1125, 1013, 879, 839
and 748 cm-i; 0^ (CD3SOCD3) 8.10 (1  H, dd, 7 8 , 2 , H-5), 7.97 and 
7.57 (4 H, AB pattern, 7 7), 7.78 (1 H, dd, 7 8 , 2, H-7), 7.47 (1 H, t,
7 8 , H-6 ), 7.12 (1 H, s, H-3) and 3.98 (2 H, s) (acid proton not apparent); 
ôc (CD3SOCD3) 176.6 (4ry), 171.9 (4^y), 156.2 (4^y), 153.9 (4ry), 139.2
(4ry), 136.53 (CH), 136.50 (4 y^), 129.3 (4 y^), 128.4 (CH), 126.62 (CH), 
126.60 (4ry), 125.7 (CH), 124.1 (4^y), 123.9 (CH), 123.7 (4ry), 123.5 (CH),
122.9 (CH), 110.0 (CH) and 35.4 (CH2); m/z (FAB, glycerol) 371 (35C1- 
M++H+, 4%), 326 (9), 305 (28), 289 (10), 262 (10), 199 (18), 176 (22), 
154 (100), 136 (93), 119 (41), 105 (43), 91 (90) and 77 (54).
85d. Preparation o f sodium  2-(3-chlQ ro-2-benzoth ienyD benzopyran-4-one- 
8-acetate 219
The m ethod of C2f was follow ed using 2 -(3-ch loro-2- 
benzothienyl)benzopyran-4-one-8-acetic acid (0.7 g, 1.9 mmol) to afford 
sodium 2-n-chloro-2-benzothienvDbenzopvran-4-one-8-acetate (0.58 g, 
78%) as a white powder, m.p. >350 °C; 1615, 1561, 1211, 1129,
1067, 1010, 874, 840 and 743 cm~i; 0^ (D2 O) 7.43 (3 H, m), 7.15 
(2 H, m), 6.89 (2 H, m), 6.78 (1 H, m) and 3.62 (2 H, s); 0^ (D 2O)
182.1 (4n^), 180.9 (4 y^), 168.3 (4^y), 159.6 (4^7), 156.0 (4n )^, 139.5 (4»7),
139.1 (CH), 138.9 (4^), 130.4 (CH), 129.6 (CH), 128.0 (CH), 125.7 (CH),
125.5 (4^y), 125.2 (CH), 124.72 (CH), 124.70 (4^y), 124.2 (4^y), 109.4 
(CH) and 40.7 (CH2).
7. 2 -(4 -P yridy l)benzopyran-4 -one-8 -acetic  Acid
a. Preparation of methyl isonicotinate 229
The method of C2a was followed using isonicotinic acid (20.0 g, 
148 mmol) to afford methyl isonicotinate (14.2 g, 65%) as a colourless 
liquid, b.p. (oven temp.) 104 “C at 21 mmHg (lit.,^^'’- 207-209 °C);
Ôy 8.79 and 7.82 (4 H, AB pattern, 7 9) and 3.95 (3 H, s).
b. Preparation of 8-allyl-2-(4-pyridyDbenzopyran-4-one 227
The method of C le was followed using methyl isonicotinate (1.51 g,
11 mmol) to afford 8-allyl-2-(4-pyridyllbenzopyran-4-one (2.60 g, 89%) 
as yellow needles, m.p. 146-148 °C (Found: C, 77.7; H, 4.8; ,- 5.4. 
CnHis,Oz requires C, 77.6; H, 5.0; ,, 5.3%); 1664, 1598, 1549,
1209, 1158, 1014 and 992 cm-i; 0^ 8.83 (2 H, dd, 7 6 , 2, H-3’,5'), 8.09 
(1 H, dd, 7 8 , 2, H-5), 7.76 (2 H, d, 7 6 , H-2',6'), 7.57 (1 H, dd, 7 8 , 2, 
H-7), 7.37 (1 H, t, 7 8 , H-6 ), 6.92 (1 H, s, H-3), 6.17-6.04 (1 H, m), 
5.23-5.13 (2H , m) and 3.69 (2H , d, 7 6 ); 0^ 178.1 (4:^ y), 159.9 (4"^ y),
153.9 (4»:y), 150.7 (2 x CH), 139.2 (4^ y^), 134.9 (CH), 134.5 (CH), 129.4
86(4:y), 125.3 (CH), 123.91 (CH), 123.90 (4^y), 119.5 (2 x CH), 117.1 (CH^),
108.9 (CH) and 33.8 (CH2); 263 (M+, 100%), 234 (11), 208 (6 ), 145
(7), 131 (21), 115 (11), 103 (11), 89 (11) and 77 (18).
c. Attempted preparation of 2-(4-pyridyDbenzopvran-4-one-8-acetic acid 
231
The method of C lf  was followed using 8-allyl-2-(4-pyridyl)benzopyran-4- 
one (5 .3  g, 2 0  mmol) to afford a black powder (0 . 6  g) which did not melt 
at the literature temperature m.p. >350 °C (lit.,^  ^ 275-277 °C).
8 . 2 -(2 -Q uinoly l)benzopyran-4-one-8-acetic  Acid
a. Preparation of methvl quinoline-2-carboxylate 230
The method of C2a was followed using quinaldic acid (20.0 g, 116 mmol) 
to afford methyl quinoline-2-carboxylate (18.4 g, 85%) as pink needles, 
m.p. 83 'C (lit.,125 85 T ) .
b. Preparation of 8-allyl-2-(2-quinolyl)benzopyran-4-one 228
The method of C le was followed using methyl quinoline-2-carboxylate 
(2.06 g, 11 mmol) to yield 8-allvl-2-(2-quinolvD benzopvran-4-one 
(2.41 g, 70%) as yellow needles, m.p. 148-150 °C (Found: C, 80.3; H,
4.7 ./ 4.4. C21H 15.O2 requires C, 80.5; H, 4.8; ., 4.5%); 1645, 
1583, 1504, 1209, 1125, 916, 830 and 752cm -i; 0^ 8.30 (1 H, d, 7 8 ), 
8.13-8.05 (3 H, m), 7.83-7.70 (2H , m), 7.65-7.51 (3 H, m), 7.35 (1 H, 
t, 7 8 , H-6 ), 6.21-6.05 (1 H, m), 5.20-5.13 (2 H, m) and 3.80 (2 H, d,
7 6 ); Ôc 178.8 (4^y), 161.3 (4^y), 154.1 (4:"y), 149.3 (4»^ y), 147.9 (4:y),
137.3 (CH), 135.2 (CH), 134.1 (CH), 130.4 (CH), 130.2 (CH), 129.5 (4 n^ ),
128.7 (4«^ y), 128.0 (CH), 127.6 (CH), 125.1 (CH), 124.6 (4‘y), 124.1 (CH),
117.5 (CH2), 117.1 (CH), 109.0 (CH) and 34.1 (CH2 ); m/z 313 (M+, 
100%), 287 (22), 284 (19), 256 (10), 154 (14), 128 (11), 103 (6 ) and 77 
(5).
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c. Preparation of 2-r2-quinolvDbenzopyran-4-one-8-acetic acid 232 
The method of C lf  was followed using 8 -allyl-2-(2-quinolyl)benzopyran- 
4-one (6.27 g, 20 mmol) to afford 2-(2-quinolynbenzopvran-4-one-8- 
acetic acid (0.38 g, 6 %) as a orange needles, m.p. 234-236 ° C  (Found: C ,  
70.0; H, 4.4; 0, 3.7. C 2 0 H 1 31 O 4  + 0.75 H2O requires C ,  69.7; H, 4.2; 02 
4.0%); 1739, 1634, 1581, 1250, 1210, 1117, 1089, 841 and 771 cm-
1; Ôfj ( C D 3 S O C D 3 )  14.0-12.0 (1 H, br s, OH), 8.65 and 8.27 ( 2  H, A B  
pattern, J  9, H-3’,4'), 8.12 (2 H, dd, J  8 , 2), 8.01 (1 H, dd, J  8 , 2, H-5), 
7.87 (1 H, t, 7 7), 7.81 (1 H, dd, 7 8 , 2, H-7), 7.71 (1 H, t, 7 7), 7.49 
(1  H, t, 7 8 , H-6 ), 7.41 (1  H, s, H-3) and 4.10 ( 2  H, s); 5^ ( C D 3 S O C D 3 )
177.0 (4=7), 171.4 (4^), 160.8 (4^^), 154.0 (4^y), 148.6 (4 n^ ), 147.1 (4^7),
137.9 (CH), 135.8 (CH), 130.7 (CH), 129.4 (CH), 128.5 (4n )^, 128.2 (CH),
128.0 (CH), 125.7 (4^y), 125.2 (CH), 123.71 (4ry), 123.7 (CH), 117.6 
(CH), 107.9 (CH) and 35.6 (CH2); m/z 331 (M+, 46%), 287 (100), 273 
(44), 259 (13), 245 (13), 230 (17), 216 (10), 154 (50), 128 (21), 105 (16) 
and 77 (26).
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F. Preparation of Derivatives with Different Groups in the 2- 
Position
1. 2-Benzylbenzopyran-4-one-8-acetic Acid
a. Preparation of methyl phenvlacetate 233
The method of C2b was followed using phenylacetic acid (20.0 g, 
148 mmol) to yield a yellow oil which was Kugelrohr distilled to yield 
methyl phenylacetate (18.3 g, 84%) as a colourless liquid b.p. (oven 
temp.) 81 T  at 0.3 mmHg (lit.,i26 220 'C); 6^7 .18  (5H , m), 3.67
(3 H, s) and 3.59 (2 H, s).
b. Preparation of 8-allyl-2-benzylbenzopyran-4-one 234
The method of C le was followed using methyl phenylacetate (1.65 g, 
11 mmol) to afford 8-allvl-2-benzvlbenzopyran-4-one (1.48 g, 49%) as 
yellow plates, m.p. 59-60 °C (Found: C, 82.6; H, 6.2. C 19H 16O2 requires 
C, 82.6; H, 5.8%); 1643, 1599, 1272, 1167, 1078, 993, 891, 804,
772 and 759 cm-i; 0^ 8.03 (1 H, dd, 7 8 , 2, H-5), 7.47 (1 H, dd, 7 8 , 2,
H-7), 7.38-7.25 (6 H, m, H-6,2',3',4',5',6'), 6.13 (1 H, s, H-3), 5.97-5.83 
(1 H, m), 5.06 (2 H, m), 3.93 (2 H, s) and 3.54 (2 H, d, 7 8 ); 178.6
(4n^), 167.5 (4n )^, 154.4 (4^ )^, 135.3 (CH), 134.9 (4^y), 133.8 (CH), 129.32 
(4ry), 129.30 (2 x CH), 128.9 (2 x CH), 127.4 (CH), 124.7 (CH), 123.7 
(CH), 123.6 (4 n^ ), 116.7 (CH2), 110.3 (CH), 40.8 (CH2) and 33.8 (CH2); 
m/z 276 (M+, 100%), 185 (6 ), 161 (22), 132 (23), 115 (25), 91 (20) and 
77 (16).
c. Preparation of 2-benzylbenzopyran-4-one-8-acetic acid 237
The method of C lf  was followed using 8-allyl-2-benzylbenzopyran-4~one 
(5.52 g, 20 mmol) to afford 2-benzylbenzopyran-4-one-8-acetic acid 
(0.71 g, 12%) as yellow cubes, m.p. 140-142 °C (lit.,^^ 143-145 °C); 
1716, 1650, 1603, 1590, 1228, 1169, 1132, 935, 758 and 702 cm-i;
89ôg 12.5-11.5 (1 H, br s, OH), 7.90 (1 H, dd, J 8 , 2, H-5), 7.67 (1 H, dd,
J  8 , 2, H-7), 7.40-7.33 (5 H, m, H-2',3’,4',5',6'), 7.27 (1 H, t, J  8 , H-6 ),
6.26 (1 H, s, H-3), 3.99 (2 H, s) and 3.83 (2 H, s); 5^ 176.9 (4 a), 171.8
(4 a), 167.8 (4 a), 154.2 (4 a ), 135.6 (4 a), 135.4 (CH), 129.1 (2 x CH), 
128.6 (2 X  CH), 127.0 (CH), 125.1 (4 a), 124.7 (CH), 123.6 (CH), 123.0 
(4 a), 109.5 (CH), 39.5 (CHj) and 34.6 (CH^); m/z 294 (M+, 100%), 277 
(30), 249 (29), 179 (26), 133 (34), 115 (22), 105 (16), 91 (46) and 77 
(15).
d. Preparation of sodium 2-benzvlbenzopvran-4-one-8-acetate 239 
The method of C2f was followed using 2-benzylbenzopyran-4-one-8-acetic 
acid (1.0 g, 3.4 mmol) to afford sodium 2-benzvIbenzopvran-4-one-8- 
acetate (0.95 g, 8 8 %) as a white powder, m.p. >350 °C; 1610, 1560,
1209, 1070, 1031, 980, 874, 820, 748 and 683 cm -'; 5g (DjO) 7.67
(1 H, d, J  8 , H-5), 7.50-7.20 (7 H, m), 7.15 (1 H, s, H-3), 3.55 (2 H, s) 
and 3.53 (2 H, s); 6 ^ (D2O) 183.9 (4 a), 181.5 (4ry), 161.8 (4 a), 157.4
(4 a ), 139.9 (CH), 138.8 (4 a), 134.7 (CH), 132.5 (2 x CH), 131.4 ( 2  x 
CH), 130.8 (4 a), 126.4 (CH), 124.5 (4 a), 120.2 (CH), 111.4 (CH), 47.2 
(CH2) and 41.4 (CH2); m/z (FAB, glycerol) 339 ([M-t-3a]+, 39%), 317 
([M+H]+, 20), 250 (15), 199 (16), 176 (100), 167 (31), 154 (30), 133 (32), 
105 (40), 91 (56) and 77 (35).
2. 2 -D iphenylm ethylbenzopyran-4-one-8-acetic Acid
a. Preparation of methvl diphenvlacetate 236
The method of C2b was followed using diphenylacetic acid (20.0 g,
90 mmol) to yield methyl diphenylacetate (19.4 g, 91%) as cream plates, 
m.p. 58-60 °C (lit.,‘2y 59-62 °C); 8 g 7.31 (10 H, m), 5.05 (1 H, s) and
3.76 (3 H, s).
90b. P reparation  o f  8-ally l-2-d iphenvlm ethylbenzopvran-4“One 235
The method of C le was followed using methyl diphenylacetate (2.49 g,
11 mmol) to afford 8-allvl-2-diphenvlmethvlbenzopyran-4-one (1.63 g, 
42%) as yellow rhomboid crystals, m.p. 135-137 ^C (Found: C, 85.0; H, 
5.7. C25H20O2 requires C, 85.2; H, 5.7%); 1647, 1598, 1164, 1074,
957, 898 and 782 cm~i; 0^ 8.05 (1 H, dd, J  8 , 2, H-5), 7.45 (1 H, dd,
J  8 , 2, H-7), 7.40-7.20 (11 H, m, H-6 , 2 x Ph), 6.17 (1 H, s, H-3), 5.85- 
5.64 (1 H, m), 5.37 (1 H, s), 4.95-4.81 (2 H, m) and 3.42 (2 H, d, J  8 );
Ôc 178.6 (4^y), 169.2 (4:y), 154.4 (4^y), 138.9 (2 C, 4^y), 135.1 (CH),
133.9 (CH), 129.6 (4"7), 129.0 (4 x CH), 128.8 (4 x CH), 127.5 (2 x CH),
124.8 (CH), 123.8 (4^), 123.7 (CH), 116.6 (CH2), 112.1 (CH), 56.1 (CH) 
and 33.9 (CHg); m/z 352 (M+, 100%), 274 (1 2 ), 191 (16), 161 (84), 115 
(19) and 77 (14).
c. Preparation of 2-diphenvlmethylbenzopyran-4-one-8-acetic acid 238 
The m ethod of C l f  was fo llow ed  using  8 -a lly l-2 -  
diphenylmethylbenzopyran-4-one (7.05 g, 20 mmol) to afford 2- 
diphenvlmethvlbenzopyran-4-one-8-acetic acid (0.67 g, 9%) as yellow 
plates, m.p. 171-172 °C (Found: C, 77.8; H, 4.7. C24H 18O4 requires C, 
77.8; H, 4.9%); 3400-2800 (br), 1733, 1635, 1260, 1207, 1134,
1031, 935, 864, 817 and 702 cm-i; 0^ (CD3SOCD3) 8.12 (1  H, dd, J  8 ,
2, H-5), 7.52 (1 H, dd, J  8 , 2, H-7), 7.36-7.19 (11 H, m, H-6 , 2 x Ph),
6.32 (1 H, s, H-3), 5.38 (1 H, s) and 3.59 (2 H, s) (acid proton not 
apparent); 0^ (CD3SOCD 3) 178.7 (4^y), 174.8 (4ry), 169.4 (4»:y), 154.7
(4n^), 138.8 (2 C, 4^ y), 135.3 (CH), 129.0 (4 x CH), 128.8 (4 x CH), 127.5 
(2 X  CH), 125.3 (4 :7 ), 125.0 (CH), 123.62 (CH), 123.60 (4^y), 112.0 (CH),
56.1 (CH) and 34.9 (CH2); m/z 370 (M+, 23%), 325 (20), 283 (18), 213 
(23), 184 (33), 167 (100), 133 (33), 106 (84), 89 (18) and 77 (100).
d. Preparation of sodium 2-diphenvlmethylbenzopyran-4-one-8 -acetate 
240
The method of C2e was followed using 2-diphenylmethylbenzopyran-4- 
one-8 -acetic acid (1.0 g, 2.7 mmol) to afford sodium  2- 
diphenvlmethvlbenzopyran-4-one-8-acetate (0.84 g, 79%) as a white 
powder, m.p. >350 T ;  1610, 1031, 980, 820 and 683 cm-i;
Ôh (DiO) 7.84 (2 H, m, H-4'), 7.58 (1 H, dd, J 8 , 2, H-5), 7.41-7.22
(11 H, m, H-7,2’,3',5’,6'), 7.07 (1 H, t, J 8 , H-6 ), 6.25 (1 H, s, H-3), 6.18 
(1 H, s) and 3.52 (2 H, s); 0^ (D^O) 183.4 (4^), 181.4 (4^ )^, 172.8 (4^y),
157.3 (4«^ y), 138.6 (CH), 137.9 (4^), 136.1 (CH), 132.2 (4 x CH), 131.7 (4 
X CH), 130.2 (CH), 129.6 (4:y), 127.8 (CH), 125.4 (CH), 125.0 (4^y), 124.7 
(CH), 111.5 (CH), 57.1 (CH) and 41.1 (CHi).
3. 2-(4-Chlorostyryl)benzopyran-4"one-8-acetic Acid
a. Preparation of methvl 4-chlorocinnamate 245
The method of C2b was followed using 4-chlorocinnamic acid (20.0 g, 
110 mmol) to yield methyl 4-chlorocinnamate (14.9 g, 69%) as 
colourless needles, m.p. 75-76 °C (lit.,^ ^^  75-76 °C).
b. Preparation of 8-allyl-2-14-chlorostvryPbenzopyran-4-one 243
The method of C le was followed using methyl 4-chlorocinnamate (2.16 g,
11 mmol) to afford 8-allyl-2-r4-chlorostyryPbenzopvran-4-one (0.64 g, 
18%) as yellow needles, m.p. 180-182 “C; 1652, 1593, 1208, 1088,
908, 837, 815 and 763 cm-i; ôy 8.09 (1 H, dd, J  8 , 2, H-5), 7.58-7.22
(7 H, m), 6.79 (1 H, half AB pattern, J  15), 6.31 (1 H, s, H-3), 6.20-
6.00 (1 H, m), 5.21-5.17 (2 H, m) and 3.73 (2 H, d, J  8 ); 0^ 178.6
(4:y), 160.9 (4^y), 153.9 (4^y), 135.7 (4*y), 135.4 (CH), 135.3 (CH), 134.2 
(CH), 133.5 (4:-y), 129.3 (2 x CH), 129.2 (4n )^, 128.8 (2 x CH), 124.8 
(CH), 124.1 (4 y^), 124.0 (CH), 121.1 (CH), 117.0 (CHg), 110.8 (CH) and
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34.1 (CH2); m/z 322 (35C1-M+, 100%), 305 (48), 189 (27), 161 (26), 131 
(58), 103 (28) and 77 (42).
c. Attempted preparation of 2-r4-chlorostyryDbenzopyran-4-one-8-acetic 
acid 241
The m ethod of C l f  was fo llow ed using  8 -a lly l-2 -(4 - 
chlorostyryl)benzopyran-4-one (6.5 g, 20 mmol) to afford a white solid 
only on evaporation of solvent. This solid dissolved readily in water and 
was shown by 4MR not to be the correct product.
4. 2 -(2-(2 -th ieny l)etheny l)benzopyran-4-one-8-acetic  acid
a. Preparation of methvl 3-12-thienvDacrylate 246
The method of C2b was followed using 3-(2-thienyl)acrylic acid (20.0 g, 
130 mmol) to afford methyl 3-(2-thienyl)acrylate (15.6 g, 72%) as a 
colourless liquid, b.p. (oven temp.) 85 °C at 1 mmHg (lit.,^^  ^ 135 °C at 
12 mmHg).
b. Preparation of 8-allvl-2-r2-(2-thienyl)ethenyDbenzopvran-4-one 244 
The method of C le  was followed using methyl 3-(2-thienyl)acrylate 
(1.85 g, 11  mmol) to afford 8 -allyl-2 -(2 -12-thienyl)ethenvl)benzopyran- 
4-one (0.57 g, 18%) as yellow needles, m.p. 136-139 °C; 1603, 
1589, 1294, 1212, 1171, 1070, 955, 859 and 695 cm-i; Ôy 8.06 (1 H,
dd, J  8 , 2, H-5), 7.67 and 6.57 (2 H, AB pattern, J  16), 7.51 (1 H, dd,
/  8 , 2, H-7), 7.41-7.03 (4 H, m, H-6,3',4',5'), 6.29 (1 H, s, H-3), 6.20-
6.00 (1 H, m), 5.27-5.13 (2 H, m) and 3.73 (2 H, d, J  8 ); 6 ^ 178.5
(4^y), 161.1 (4:y), 153.9 (4^y), 140.4 (4^y), 135.4 (CH), 134.0 (CH), 129.5 
(CH), 129.12 (4^y), 129.11 (CH), 128.2 (CH), 128.0 (CH), 124.7 (CH),
124.1 (4^y), 123.9 (CH), 119.5 (CH), 116.9 (CH^), 110.2 (CH) and 34.1 
(CHz); m/z 294 (M+, 100%), 277 (57), 261 (32), 161 (30), 134 (63), 103 
(17) and 77 (23).
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c. Attempted preparation of 2-r2-r2-thienvDethenyDbenzopyran-4-one-8- 
acetic acid 242
The m ethod of C lf  was follow ed using 8 -ally l-2 -(2 -(2 - 
thienyl)ethenyl)benzopyran-4-one (5.9 g, 20 mmol) to afford a white 
solid only on evaporation of the solvent. This solid was shown not to be 
the correct product on analysis by iH 5MR.
5. Attempted preparation of 2-phenylethynylbenzopyran-4-one- 
8-acetic Acid
a. Preparation of phenylpropiolic acid 250
A solution of phenylacetylene 247 (20.0 g, 196 mmol) in dry THF 
( 2 0 0  ml) was stirred vigorously under nitrogen while butyl lithium 
(2.5M, solution in hexanes, 12.8 ml) was added dropwise. The mixture 
was stirred for 2  h and then carbon dioxide was bubbled through the 
mixture for 2 h. The suspension that formed was added to water (200 ml) 
and extracted with ether (2 x 50 ml). The aqueous portion was acidified 
with concentrated hydrochloric acid to pH 4 and then extracted with ether 
(2 X 100 ml) which was dried and evaporated to give phenylpropiolic acid 
(12.4 g, 43%) as a yellow solid, m.p. 134-137 T . (lit.,i3o 135-137 °C); 
Ôh 11.7 (1 H, br s, OH) and 8.09 (5 H, s).
b. Preparation of methyl phenvlpropiolate 251
The method of C2b was followed using phenylpropiolic acid (12.4 g, 
85 mmol) to afford a yellow oil which was Kugelrohr distilled to yield 
methyl phenylpropiolate (10.5 g, 77%) as a colourless liquid, b.p. (oven 
temp.) 107 °C at 0.13 mmHg (lit.,^3i 132-133 “C at 16 mmHg); Ôh 3.80
(3 H, s) and 7.95 (5 H, s).
94c. Preparation of 2-r3-allvl-2-hydroxvphenvlV6-phenvlpvran-4-one 255 
The method of C le was followed using methyl phenylpropiolate (1.58 g,
11 mmol) to yield 2-G -allvl-2-hvdroxvphenvl)-6-phenylpvran-4-one 
(2.48 g, 74%) as yellow needles, m.p. 178-180 “C (Found: C, 79.3; H, 
5.3. C20H 16O 3 requires C, 78.9; H, 5.3%); 2520 (br, OH), 1652,
1585, 1568, 1287, 1217, 948, 877, 738 and 685 cm-i; ôy 9.3 (1 H, br s, 
OH), 7.85 (1 H, d, 7 2), 7.83 (1 H, d, 7 4), 7.71 (1 H, dd, 7 8 , 2), 7.59 
(1 H, d, 7 2), 7.53-7.47 (3 H, m), 7.29 (1 H, dd, 7 8 , 2), 6.98 (1 H, t,
7  8 ), 6.83 (1 H, d, 7 6 ), 6.13-6.02 (1 H, m), 5.27-5.11 (2 H, m) and 
3.70 (2H , d, 7 6 ); 181.8 (4^y), 164.1 (4n )^, 162.7 (4n^), 154.5 (4^y),
136.2 (CH), 133.4 (CH), 131.7 (4n )^, 131.5 (CH), 129.2 (2 x CH), 128.4 
(4n^), 126.7 (CH), 126.1 (2 x CH), 120.1 (CH), 118.9 (4^^), 116.4 (CH2),
115.1 (CH), 110.75 (CH) and 34.7 (CH2); 304 (M+, 100%), 276 (83),
157 (52), 129 (44), 115 (62), 102 (43), 91 (32) and 77 (59).
d. Preparation of 2-G-allvl-2-methoxyphenvl)-6-phenvlpvran-4-one 252 
A suspension of sodium hydride (0.24 g, 9.8 mmol) in THF was prepared 
by firstly washing the hydride in light petroleum (40 ml), decanting the 
liquid and transferring the solid to THF (200 ml). This solution was then 
heated under reflux for 10 min and 2-(3-allyl-2-hydroxyphenyl)-6- 
phenylpyran-4-one was added portionwise over 10 min followed by 
dimethyl sulphate (3.7 g, 39 mmol). The mixture was allowed to cool 
and concentrated ammonia (40 ml) was added after stirring for 1 day, 
water ( 2 0 0  ml) was added and the mixture extracted into methylene 
chloride, dried and evaporated to yield a yellow oil. C o lu m n  
chromatography (ethyl acetate/petrol 2:1) on this crude oil yielded 2-(3- 
allyl-2-methoxvphenvlV6-phenylpyran-4-one as a light yellow oil, b.p. 
194 'C  (Found: M+, 318.1256. C21H 18O3 requires M, 318.1254);
1600, 1259, 1089, 1005, 873, 771 and 693 cm-i; 0^ 7.88-7.81 (2 H, 
m), 7.63 (1 H, dd, 7 8 , 2), 7.52-7.49 (3 H, m), 7.37 (I H, dd, 7 8 , 2),
7.20 (1 H, t, 7 8 ), 7.00 (1 H, d, 7 2), 6.83 (1 H, d, 7 2), 6.10-5.90 (1 H, 
m), 5.20-5.03 (2 H, m), 3.69 (3 H, s) and 3.50 (2 H, d, 7 7); 180.5
(4ry), 163.7 (4n )^, 162.0 (4 0 )^, 156.8 (4<7), 136.6 (CH), 134.8 (4^ )^, 133.5 
(CH), 131.4 (CH), 129.1 (2 x CH) 129.0 (4^y), 127.7 (CH), 125.9 (2 x 
CH), 125.3 (4ry), 124.4 (CH), 116.5 (CHz), 115.6 (CH), 111.1 (CH), 61.3 
(OCH3) and 33.8 (CH2 ); m/z 318 (M+, 100%), 290 (83), 275 (9), 258 
(14), 247 (41), 230 (9), 185 (13), 172 (74), 157 (39), 147 (79), 141 (40), 
128 (60), 115 (67), 105 (77), 91 (42) and 77 (70).
e. Preparation of 2-r3-carboxymethvl-2-methoxvphenvlV6-phenylpyran- 
4-one 253
The method of C lf  was followed using 2-(3-allyl-2-methoxyphenyl)-6- 
phenylpyran-4-one (0.25 g, 0.82 mmol) to yield 2-f3-carboxvmethyl-2- 
methoxvphenvlV6-phenylpyran-4-one (0.10 g, 38%) as a cream powder, 
m.p. 212-214 °C (Found: C, 71.3; H, 4.6. C20H 16O5 requires C, 71.4; H, 
4.8%); 3060-2940 (br), 1720, 1621, 1546, 1196, 1004, 947, 892,
781 and 682 cm-i; ôy (CD 3SOCD 3) 8.06 (2 H, m), 7.79 (1 H, d, 7 8 ), 
7.63 (3 H, m), 7.59 (1 H, d, 7 8 ), 7.36 (1 H, t, 7 8 ), 7.11 (1 H, s), 6.83 
(1 H, s), 3.75 (2 H, s) and 3.69 (3 H, s) (acid proton not apparent); m/z 
336 (M+, 100%), 308 (75), 292 (13), 265 (44), 236 (9), 190 (61), 147 
(96), 135 (36), 115 (41), 105 (81), 91 (24) and 77 (51).
f. Preparation of sodium 2-(3-methylcarboxylato-2-methoxvphenvlV6- 
phenylpyran-4-one 254
The method of C2f was followed using 2-(3-carboxymethyl~2- 
methoxyphenyl)-6-phenylpyran-4-one (0.10 g, 0.3 mmol) to afford 
sodium 2-13-methylcarboxylato-2-methoxvphenvlV6-phenvlpvran-4-one 
as a cream powder (0.094 g, 89%), m.p. 267-268 “C; 1713, 1612,
1555, 1119, 1000, 980, 739 and 680cm -i; ôy (DgO) 7.51-7.20 (5H , 
m), 7.16-7.01 (3 H, m), 6.82 (1 H, s), 6.55 (1 H, s) and 3.57 (5 H, m);
95
96ôc (D2O) 184.7 (4ry), 182.3 (4ry), 166.7 (4ry), 164.6 (4ry), 159.1 (4ry),
138.3 (CH), 135.2 (CH), 134.6 (4ry), 131.9 (4^y), 131.5 (CH), 129.9 (4^y),
128.0 (2 X CH), 127.3 (CH), 125.6 (2 x CH), 116.2 (CH), 111.6 (CH),
63.2 (OCH3) and 41.4 (CH2).
6 . 2 ,2 '-b i(8 -ca rb o x y m eth y lb en zo p y ran -4 -o n e )
a. Preparation of 2.2’-bir8-allylbenzopyran-4-one) 269
The method of C le was followed using dimethyl oxalate 266 (Aldrich,
0.65 g, 5.5 mmol) to yield 2.2'-biC8-allylbenzopyran-4-onel (0.87 g, 
43%) as colourless needles, m.p. 200-203 °C (Found: C, 77.8; H, 4.6. 
C24H 18O4 requires C, 77.8; H, 4.9%); 1620, 1591, 1187, 1119, 913,
845, 796 and 750 cm-i; 0^ 8.10 (2 H, dd, 7 8, 2, H-5), 7.60 (2 H, dd,
7 8, 2, H-7), 7.40 (2 H, t, 7 8, H-6), 7.10 (2 H, s, H-3), 6.20-6.00 (2 H, 
m), 5.25-5.11 (4H , m) and 3.72 (4H , d, 7 6); 0^ 177.8 (2 C, 4^ -y),
154.8 (2 C, 4^y), 153.8 (2 C, 4n )^, 135.1 (2 x CH), 134.7 (2 x CH), 129.7 
(2 C, 4:y), 125.6 (2 X  CH), 124.2 (2 C, 4^y), 124.1 (2 x CH), 117.5 (2 x 
CH2), 110.2 (2 X CH) and 33.8 (2 x C%); 370 (M+, 100%), 330 (61),
301 (8), 255 (6), 211 (12), 185 (10), 161 (15), 140 (31), 131 (32), 115 
(33), 103 (29), 92 (10) and 77 (34).
b. Attempted preparation of 2.2'-biC8-carboxymethvlbenzopvran-4-one) 
The method of C2f was followed using 2,2'-bi(8-allylbenzopyran-4~one) 
(7.40 g, 20 mmol), however, the compound was essentially insoluble in 
the reaction mixture and therefore the powder obtained was confirmed by 
iH 6MR to be the starting material.
7. 2 ,2 ’-(l,4 -p h en y Ien e)d i(8 -ca rb o x y m eth y lb en zo p y ran -4 -o n e)
a. Preparation of dimethvl terephthalate 267
The method of C2b was followed using terephthalic acid (20.0 g, 
120 mmol) to yield dimethyl terephthalate (9.4 g, 40%) as a white
97powder, m.p. 141-143 “C (lit.,i32 140-142 T ) ;  8.09 (4 H, s) and
3.92 ( 6  H, s).
b. Preparation of 2.2'-ri.4-phenvleneldir8-allvlbenzopyran-4-onel 270 
The method of C le was followed using dimethyl terephthalate (1.07 g,
5.5 mmol) to yield 2.2'-( 1.4-phenylene)dir8-allvlbenzopyran-4-onel 
(0.98 g, 40%) as a yellow powder, m.p. 288-290 °C (Found: M+, 
446.1528. C30H22O4 requires M, 446.1518); 1563, 1345, 1195, 1109,
1055, 987, 906, 820, 784 and 740 cm-i; 0^8.15-8.09 ( 6  H, m, H- 
5,2',3%5%6'), 7.60 (2 H, dd, 7 8 , 2, H-7), 7.39 (2 H, t, 7 8 , H-6 ), 6.93 
(2H , s, H-3), 6.18-6.01 (2H , m), 5.24-5.16 (4H , m) and 3.77 (4H , 
m); 8 c 178.5 (2 C, 4^ -y), 161.5 (2 C, 4^ -y), 154.2 (2 C, 4^y), 135.2 (2 x
CH), 134.8 (2 C, 4^ -y), 134.4 (2 x CH), 129.5 (2 C, 4 ^^ ), 126.8 (4 x CH),
125.3 (2 X CH), 124.1 (2 C, 4^), 124.0 (2 x CH), 117.2 (2 x CH2), 108.3 
(2 X CH) and 34.0 (2 x CH2); 446 (M+, 100%), 418 (5), 391 (1), 287
(5), 223 (7), 160 (9), 131 (48), 115 (16), 103 (20) and 77 (23).
c. Attempted preparation of 2.2'-(1.4-phenvleneM F8-carboxymethyl- 
benzopyran-4-one)
The method of C lf  was followed using 2,2'-(l,4-phenylene)di(8- 
allylbenzopyran-4-one) (8.92 g, 20 mmol), however, the compound was 
essentially insoluble in the reaction medium and the powder obtained was 
shown to be the starting material by ^H 7MR.
8. 4 ’,4''-O xydi(8-carboxym ethylflavone)
a. Preparation of dimethyl 4.4'-oxydibenzoate 268 
The method of C2b was followed using 4,4'-oxydibenzoic acid (20.0 g, 
77 mmol) to afford dimethyl 4,4'-oxydibenzoate (13.3 g, 60%) as 
colourless needles, m.p. 154-155 °C (lit.,^33 156-158 °C); 8 ^ 8.05 and
7.05 (8  H, AB pattern, 7 8 ) and 3.90 (3 H, s).
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b. Preparation of 8 -allvl-4'-C4 -methoxvcarbonvlphenoxy)flavone 271 
The method of C le  was followed using dimethyl 4,4'-oxydibenzoate 
(3 .1 5  g, 11 m m o l) to  y ie ld  8 - a 11 y 1 - 4 ' - ( 4 - 
methoxvcarbonvlphenoxvlflavone (0.73 g, 16%) as a yellow powder, 
m.p. 143-145 °C; (KBr) 3151, 1710, 1660, 1600, 1500, 1381, 1281, 
1252, 1173, 1121, 1007, 862 and 782 cm-i; 6 ^ 8.11 (1 H, dd, 7 8 , 2, H-
5), 8.07 and 7.17 (4 H, AB pattern, 7 9), 7.93 and 7.09 (4 H, AB pattern, 
7 9), 7.55 (1 H, dd, 7 8 , 2, H-7), 7.36 (1 H, t, 7 8 , H-6 ), 6.79 (1 H, s, H- 
3), 6.15-6.02 (1 H, m), 5.19-5.12 (2 H, m), 3.92 (3 H, s) and 3.75 (2 H, 
d, 7 6 ); 8 c 178.6 (4n )^, 166.4 (4^y), 162.3 (4 nr), 160.2 (4":y), 159.1 (4^y),
154.2 (4 n^ ), 135.3 (CH), 134.2 (CH), 131.9 (2 x CH), 129.4 (4^ )^, 128.2 (2 
X CH), 127.6 (4n )^, 125.9 (4^7), 125.0 (CH), 124.0 (CH), 124.0 (4n )^, 119.6 
(2 X CH), 118.6 (2 X CH), 117.0 (CHz), 107.0 (CH), 52.1 (OCHg) and 34.0 
(CH2); TM/z 412 (M+, 100%), 381 (10), 286 (8 ), 255 (10), 221 (11), 190 
(13), 165 (11), 150 (12), 104 (10), 91 (15) and 77 (8 ).
c. Attempted preparation of 4'-f4-methoxycarbonvIphenoxy)flavone-8- 
acetic acid
The m ethod of C l f  was fo llow ed using 8 -a lly l-4 '-(4 - 
methoxycarbonylphenoxy)flavone (8.24 g, 20 mmol) but this was 
essentially insoluble in the reaction medium and afforded a yellow powder 
which on analysis by iH 8MR was shown to be the starting material.
d. Preparation of 4'.4"-oxvdiC8 -allvlflavonel 272
The method of C le was followed using dimethyl 4,4'-oxydibenzoate 
(1.57 g, 5.5 mmol) to yield 4 '.4"-oxvdil8-allv lflavonel as a yellow 
powder (1.72 g, 29%), m.p. 189-191 "C (Found: C, 81.0; H, 3.7. 
C36H26O5 requires C, 81.2; H, 3.8%); 1733, 1634, 1582, 1293, 1238,
1173, 1117, 921, 838 and 751 cm-i; 8 ^ 8.12 (2 H, dd, 7 8 , 2, H-5),
7.96 and 7.21 ( 8  H, AB pattern, J  9, H-2',3',5',6'), 7.56 (2 H, dd, J  8 , 2, 
H-7), 7.37 (2 H, t, 7 8 , H-6 ), 6.81 (2 H, s, H-3), 6.16-6.03 (2 H, m), 
5.20-5.13 (4 H, m) and 3.76 (4 H, d, 7 6 ); 8 ^ 178.6 (2 C, 4n )^, 162.3 (2
C, 4n )^, 159.2 (2 C, 4^ )^, 154.2 (2 C, 4<7), 135.3 (2 x CH), 134.2 (2 x CH),
129.4 (2 C, 4n )^, 128.3 (4 x CH), 127.7 (2 C, 4^ )^, 125.0 (2 x CH), 124.04 
(2 X CH), 124.01 (2 C, 4*'^ ), 119.6 (4 x CH), 117.0 (2 x CH^), 107.0 (2 x 
CH) and 34.0 (2 x CHz); m/z 538 (M+, 6 %), 298 (3), 256 (5), 241 (2), 
211 (3), 182 (4), 170 (7), 163 (10), 131 (11), 119 (10), 107 (36), 91 (100) 
and 77 (21).
e. Preparation of 4'.4"-oxydir8-carboxymethylflavone)
The method of C lf  was followed using 4',4"-oxydi(8-allylflavone) 
(10.8 g, 20 mmol) to afford 4 \4"-oxyd i(8 -carboxvm ethv lflavone) 
(1.5 g, 13%) as a white powder, m.p. 267-269 “C (Found: M +-CO 2 , 
530.1355. C34H22O5 requires M, 530.1366); 3400, 1701, 1640, 1595,
1241, 1179, 834 and 785 cm-i; 8 ^ (CD3SOCD3) 8.15 (2H, dd, 7 8, 2, 
H-5), 8.01 and 7.20 (8 H, m), 7.77 (4 H, d, 7 8, H-7), 7.47 (2 H, t, 7 8, 
H-6), 7.14 (2 H, s, H-3) and 4.04 (4 H, s) (acid protons not apparent); 
8c (CD3SOCD3) 177.2 (2 C, 4ry), 172.3 (2 C, 4ry), 161.9 (2 C, 4ry), 159.1
(2 C, 4ry), 154.4 (2 C, 4ry), 136.0 (2 x CH), 132.1 (4 x CH), 126.6 (2 C, 
4ry), 125.4 (2 X CH), 125.2 (2 C, 4ry), 124.0 (2 x CH), 123.5 (2 C, 4^y),
119.0 (4 X CH), 106.8 (2 x CH) and 35.8 (2 x CH2); 574 (M+, 10%),
530 (17), 500 (58), 486 (100), 472 (41), 458 (46), 416 (59), 402 (46), 366 
(36), 338 (25), 238 (56), 218 (46), 189 (34), 165 (40), 147 (46), 120 (50) 
and 106 (56).
e. Preparation of sodium 4'.4"-oxvdh8-carboxyIatomethylflavone)
The m ethod of C2f was follow ed using 4 ',4 "-oxyd i(8 - 
carboxymethylflavone) (1.0 g, 1.7 mmol) to afford sodium 4'.4"- 
oxydir8-carboxylatomethvlflavonel (0.95 g, 94%) as a white powder,
99
100m.p. >350 °C; 1571, 1530, 1223, 1149, 1082, 998, 861, 827 and
772 cm-i; Sg (D2O) 7.87 and 7.11 (8  H, AB pattern, /  9), 7.73 (2 H, d,
J  8 , H-5), 7.52 (2 H, d, /  8 , H-7), 7.01 (2 H, t, J  8 , H-6 ), 6.71 (2 H, s, 
H-3) and 3.70 (4 H, s); 5c (D2 O) 181.9 (2 C, 4-ry), 177.7 (2 C, 4ry),
161.5 (2C , 4ry), 156.7 (2 C, 4'y), 139.1 (2 C, 4ry), 135.0 (2 x CH),
133.8 (4 X CH), 131.1 (2 x CH), 128.3 (2 x CH), 128.2 (2 C,4ry), 121.7 
(2 X CH), 121.3 (2 C,4ry), 121.1 (4 x CH), 109.4 (2 x CH) and 41.7 (2 x 
CH2).
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G. Preparation of Derivatives with Different Groups in the 8- 
Position
1. 8-(3-Hydroxy-2-oxopropyl) Compounds
a. Preparation of 8-f3-hvdroxy-2-oxopropyDflavone 
To a stirred solution of 8 -allylflavone (2.88 g, 11 mmol) in glacial acetic 
acid ( 1 0 0  ml), water ( 1 0 0  ml) and acetone ( 1 0 0  ml) was added potassium 
permanganate (2.6 g, 16.5 mmol) over a period of 1 h. On standing 1 h 
further a precipitate was seen which was decolourised by the addition of a 
saturated solution of sodium metabisulphite (approx. 50 ml). The mixture 
was reduced in volume and extracted with CH2CI2 (400 ml). The extract 
was washed with water (2 x 100 ml), dried and evaporated. The 
resulting yellow solid was triturated with dry ether at 0 “C and filtered to 
yield 8-13-hvdroxv-2-oxopropyüflavone (2.1 g, 6 6 %) as a yellow 
powder, m.p. 200-202 T  (Found: C, 71.6; H, 4.7. CigHi^O^ + 0.5 H2O 
requires C, 71.3; H, 5.0%); 3300 (hr), 1723, 1641, 1591, 1490,
1054, 8 8 8 , 779, 759 and 701 cm-i; 6 ^ 8.16 (1 H, dd, 7 8 , 2, H-5), 7.77 
(2 H, dd, 7  6 , 7 2, H-2',6'), 7.56 (1 H, dd, 7 8 , 2, H-7), 7.52-7.39 (3 H, 
m, H-3',4’,5’), 7.38 (1 H, t, 7 8 , H-6 ), 6.79 (1 H, s, H-3), 4.41 ( 2  H, s),
4.09 (2 H, s) and 3.30-3.00 (1 H, br s, OH,); 6 ^ 205.9 (4n )^, 178.3 (4^ :y),
163.4 (4 0 )^, 154.3 (4^y), 135.5 (CH), 131.8 (CH), 131.7 (4":y), 129.3 (2 x 
CH), 129.1 (4":y), 126.2 (2 x CH), 125.6 (CH), 125.1 (CH), 122.7 (4:y),
107.9 (CH), 68.0 (CH2) and 40.2 (CH2); 294 (M+, 15%), 279 (100),
252 (5), 235 (53), 207 (6 ), 178 (9), 160 (3), 133 (69), 106 (21) and 77 
(30).
h. Preparation of 2'.3'-dimethoxv-8-13-hvdroxv-2-oxopropvDflavone 
The method of G la was followed using 8-allyl-2’,3'-dimethoxyflavone 
(3.5 g, 11 mmol) to yield 2 ' . 3 ' - d i m e t h o x v - 8 - f 3 - h v d r o x v - 2 -  
oxopropyllflavone (2 .6  g, 6 6 %) as a yellow powder, m.p. 155-157 "C
102(Found: C, 68.1; H, 5.1. requires C, 67.8; H, 5.1%); 3306
(br), 1730, 1624, 1599, 1279, 1015, 881, 804 and 764 cm-i; 8 ^ 8.00 
(1 H, dd, J  8 , 2, H-5), 7.70 (1 H, d, J  8 , 2, H-7), 7.47 (1 H, t, J  8 , H-6 ), 
7.31 (3 H, m, H-4',5',6'), 6.84 (1 H, s, H-3), 5.50-5.30 (1 H, br s, OH), 
4.25 (2 H, s), 4.18 (2 H, s), 3.90 (3 H, s) and 3.79 (3 H, s); 207.6
(4'y), 177.1 (4^y), 160.5 (4>-y), 154.2 (4 '?), 152.9 (4='y), 147.2 (4 y^), 135.9 
(CH), 125.4 (4^y), 124.9 (CH), 124.6 (4 'y), 124.5 (CH), 123.4 (CH), 123.0 
(4V), 120.2 (CH), 115.8 (CH), 111.2 (CH), 67.4 (CH^), 60.4 (OCH3), 55.9 
(OCH 3) and 40.5 (CH2 ); m/z 354 (M+, 52%), 324 (61), 310 (31), 295 
(44), 267 (28), 254 (8 ), 239 (6 8 ), 162 (43), 147 (84), 133 (90), 119 (22), 
105 (50) and 77 (64).
c. Preparation of 2'.5'-dimethoxv-8-r3-hvdroxv-2-oxopropvl')flavone 
The method of G la was followed using 8-allyl-2,5-dimethoxyfIavone 
(3.55 g, 11 mmol) to yield 2 ' . 5 ' - d i m e t h o x v - 8 - ( 3 - h v d r o x v - 2 - 
oxopropvDflavone (2.22 g, 57%) as a white powder, m.p. 182-184 °C 
(Found: C, 68.0; H, 5.4. C2oH,gOg requires C, 67.8; H, 5.1%); 3440,
1720, 1630, 1581, 1500, 1243, 1037, 890, 806 and 774 cm-i; 8 ^ 8.19 
(1 H, dd, J  8 , 2, H-5), 7.57 (1 H, dd, J  8 , 2, H-7), 7.39 (1 H, t, J  8 , H-
6 ), 7.27 (1 H, d, 7 2, H-6 '), 7.07 (1 H, s, H-3), 7.03-6.96 (2 H, m, H- 
3',4'), 4.37 (2 H, s), 4.05 (2 H, s), 3.87 (3 H, s), 3.85 (3 H, s) and 3.20 
(1 H, br s); 8 c 206.1 (4''y), 178.6 (4''y), 160.8 (4-'y), 154.4 (4>-y), 153.5
(4:y), 152.2 (4^), 135.3 (CH), 125.5 (CH), 124.9 (CH), 124.1 (4‘'y), 122.6 
(4ry), 121.2 (4'-y), 117.8 (CH), 114.3 (CH), 113.1 (CH), 112.8 (CH), 67.9 
(CH 2 ), 56.1 (OCH3 ), 55.9 (OCH3 ) and 40.2 (CH2 ); m/z 354 (M+, 95%), 
324 (14), 311 (6 ), 295 (63) 281 (16), 267 (31), 235 (7), 187 (10), 161 
(38), 147 (39), 133 (100), 119 (200), 105 (42), 91 (10) and 77 (44).
1032. 8-(5-T etrazolylm ethyI)flavone
a. Preparation of methyl 2-methoxv-3-methylbenzoate 274
A solution of sodium hydroxide (17.2 g, 430 mmol) in water (100 ml) 
was added to a solution of 3-methylsalicylic acid 273 (21.3 g, 140 mmol) 
and dimethyl sulphate (160 ml, 1 .6 8  mol) in dichloromethane ( 1 0 0  ml).
BenzyItributylammonium chloride (4.42 g, 30 mmol) was then added. 
The mixture was then stirred vigorously for 12 h. The organic layer was 
separated and evaporated and the residue was extracted with petroleum 
(b.p. 40-60 °C). The extract was dried and evaporated to yield methyl 3- 
methyl-2-methoxybenzoate (23.4 g, 93%) as a colourless liquid, b.p. 
(oven temp.) 250 °C at atmospheric pressure (lit.,^ "^^  249.5-250.5 °C);
Ôh 7.59 (1 H, dd, J  8 , 2, H-6 ), 7.25 (1 H, dd, J  8 , 2, H-4), 6.98 (1 H, t,
J  8 , H-5), 3.84 (3 H, s), 3.78 (3 H, s) and 2.25 (3 H, s).
b. Preparation of methyl 3-bromomethyl-2-methoxybenzoate 275
A solution of l,3-dibromo-5,5-dimethylhydantoin (2.38 g, 8.3 mmol), 
m ethyl 2-m ethoxy-3-m ethylbenzoate (3.0 g, 16.7 mmol) and 
azobis(isobutyronitrile) (0.13 g, 0.8 mmol) in carbon tetrachloride 
(50 ml) was heated under reflux for 8 h and then left to cool overnight. 
The colourless precipitate of 5,5- dime thy Ihydantoin was filtered off and 
the filtrate evaporated. The residue was extracted with hexane (100 ml), 
and the extract dried and evaporated to afford methyl 3-bromomethyl-2- 
methoxybenzoate (3.31 g, 77%) as a colourless liquid, b.p. 262 °C at 
atmospheric pressure (lit.,^^^ 125 “C at 1.5 mmHg); 0^ 7.81 (1 H, dd,
J  8 , 2, H-6 ), 7.57 (1 H, dd, J  8 , 2, H-4), 7.13 (1 H, t, J  8 , H-5), 4.58 
(2 H, s), 3.95 (3 H, s) and 3.91 (3 H, s).
c. Preparation of methyl 3-methoxvmethyl-2-methoxybenzoate 276
A solution of methyl 3-bromomethyl-2-methoxybenzoate (2.40 g,
9.3 mmol) in methanol (50 ml) was stirred vigorously as sodium (0.4 g.
10417 mmol) was added in small pieces. The solution was then heated under 
reflux for 4 h and evaporated leaving a solid which was dissolved in water 
(20 ml). Extraction with ethyl acetate (50 ml), drying and evaporation 
yielded methyl 3-methoxymethyl-2-methoxybenzoate (2.03 g, 95%) as a 
pale brown liquid, b.p. 97 °C at 1 mmHg (lit.,^^’^ ^^  87-95 °C at 0.06 
mmHg); 6 ^ 7.72 (1 H, dd, 7 7, 2), 7.54 (1 H, dd, 7 7, 2), 7.11 (1 H, t,
7 7), 4.50 (2 H, s), 3.87 (3 H, s), 3.81 (3 H, s) and 3.40 (3 H, s).
d. Attempted preparation of 8 -methoxvmethvlflavone 277
A suspension of sodium hydride (1.00 g, 24 mmol) in THF (200 ml) was 
stirred vigorously and heated under reflux for 1 0  min after which a 
solution of methyl 3-methoxymethyl-2-methoxybenzoate (5.04 g,
24 mmol) and acetophenone (2.88 g, 24 mmol) in THF (50 ml) were 
added dropwise. The mixture was heated under reflux for a further 4 h 
and allowed to cool. A solution of hydrobromic acid (20 ml) in acetic 
acid (40 ml) was added carefully and the mixture heated under reflux for 
3 h, the solvent evaporated and the brown tar analysed by ^H 9MR which 
showed that the correct material was present only in minute quantities with 
the main components being starting materials.
e. Preparation of l-(2-methoxv-3-methvlphenylV3-phenvlpropane-1.3- 
dione 282
A solution of methyl 2-methoxy-3-methylbenzoate (3.80 g, 22 mmol) and 
acetophenone (2.70 g, 22 mmol) in THF (30 ml) was added dropwise 
into a suspension of sodium hydride (0.52 g, 22 mmol) in THF (100 ml) 
being stirred and heated under reflux. After 24 h the mixture was poured 
onto crushed ice ( 2 0 0  g), neutralised with 1 0 % hydrochloric acid and 
extracted into dichloromethane (100 ml). The extract was dried and 
evaporated to give l-r2-methoxy-3-methvlphenylV3-phenvlpropane-1.3- 
dione (4.76 g, 79%) as a colourless oil, b.p. 163 “C; v (9eat) 3040,
1052906, 2837, 1585, 1451, 1211, 1080, 993, 762 and 682 cm-i; 6 ^ 8.01
(2 H, m), 7.70 (1 H, dd, J  8 , 2), 7.59-7.43 (3 H, m), 7.36 (1 H, dd, J  8 ,
2), 7.20-7.10 (2 H, m), 3.81 (3 H, s) and 2.37 (3 H, s); 6 ^ 185.9 (4 ry),
185.2 (4ry), 134.7 (CH), 132.4 (CH), 132.2 (4ry), 129.7 (4ry), 128.7 (2 x 
CH), 127.9 (CH), 127.2 (2 x CH), 127.2 (4 ry), 124.2 (CH), 97.5 (CH), 61.4 
(OCH3) and 16.0 (CH3); 268 (M+, 69%), 164 (77), 120 (27), 91 (100)
and 77 (43).
f. Preparation of 8 -methvlflavone 283
A solution of l-(2-methoxy-3-methylphenyl)-3-phenylpropane-l,3-dione 
(2.5 g, 9.3 mmol) in hydrobromic acid (15 ml) and acetic acid (15 ml) 
was heated at 80 ‘’C for 2 h then water (50 ml) was added and the mixture 
extracted with methylene chloride (2 x 50 ml), which was dried and 
evaporated to give a white solid. This was recrystallised from methanol to 
afford 8 -methylflavone (1.6 g, 73%) as colourless thin plates, m.p. 168- 
169 °C (lit.,137 170 “C); 8 ^ 8.07 (1 H, dd, J  8 , 2, H-5), 7.96 (2 H, m,
H-2',6'), 7.55 (4 H, m, H-7,3’,4’,5'), 7.32 (1 H, t, 7 8 ), 6.85 (1 H, s, H-
3) and 2.62 (3 H, s).
g. Preparation of 8 -bromomethylfIavone 278
A solution of 8 -methylflavone (7.43 g, 31 mmol) was stirred in carbon 
tetrachloride (450 ml) was heated under reflux for 10 min. A catalytic 
amount of azobis(isobutyronitrile) (0.3 g, 1.8 mmol) was added followed 
by l,3-dibromo-5,5-dimethylhydantoin (4.50 g, 16 mmol) and the 
mixture heated under reflux for 8 h after which it was allowed to cool and 
the precipitate that formed during the reaction filtered off and washed 
with carbon tetrachloride (20 ml). The solid was then recrystallised from 
ethanol to afford 8 -bromomethylflavone (6.73 g, 69%) as colourless 
needles, m.p. 180-182 "C (lit.,^^ 182-184 T ) ;  6 ^ 8.24 (1 H, dd, 7 8 , 2,
H-5), 8.05-8.00 (2 H, m, H-3',5'), 7.75 (1 H, dd, 7 8 , 2, H-7), 7.60-7.56
106(3 H, m, H-2',4',6'), 7.40 (1 H, t, J  8 , H-6 ), 6.89 (1 H, s, H-3) and 4.84 
(2 H, s).
h. Preparation of 8 -cyanomethvlflavone 279
A solution of potassium cyanide (0.85 g, 13 mmol) in ethanol (100 ml) 
and water (20 ml) was heated under reflux for 5 min. 8 - 
Bromomethylflavone (3.70g, 13 mmol) was then added portionwise as a 
slurry in boiling ethanol (50 ml) and the mixture heated under reflux for 
4 h after which it was allowed to cool overnight. The precipitate that 
formed was filtered off and washed with copious amounts of water then 
recrystallised from ethanol to afford 8 -cyanomethylflavone (2.82 g, 83%) 
as orange plates, m.p. 178-180 “C (lit.,^^ 180-181 °C); 8 ^ 8.23 (1 H,
dd, 7 8 , 2, H-5), 7.98-7.90 (2 H, m, H-3',5'), 7.78 (1 H, dd, 7 8 , 2, H-7), 
7.59-7.54 (3 H, m, H-2',4',6'), 7.46 (1 H, t, 7 8 , H-6 ), 6.85 (1 H, s, H-3) 
and 4.09 (2 H, s); 8 ^ 177.7 (4ry), 163.2 (4ry), 153.6 (4ry), 133.7 (CH),
132.0 (CH), 131.4 (4ry), 129.3 (2 x CH), 126.3 (2 x CH), 125.3 (CH),
124.2 (4ry), 119.7 (4ry), 116.7 (4^y), 108.0 (CH) and 18.9 (CH2).
i. Preparation of 8-(5-tetrazolylmethvDflavone 281
A solution of 8 -cyanomethylflavone (0.52 g, 2.0 mmol), sodium azide 
(0.14 g, 2.2 mmol) and ammonium chloride (0.12 g, 2.2 mmol) in dry 
DMF (20 ml) was heated under reflux under nitrogen for 8  h. The 
solvent was evaporated and the brown residue purified by chromatography 
with ethyl acetate/CH iC la to remove impurities to yield 8-15- 
tetrazolylmethyPflavone as a beige solid (0.11 g, 16%), m.p. >350 “C. 
This compound was converted directly into the potassium salt.
j. Preparation of potassium 8 -tetrazolatomethylflavone 280
To a hot solution of potassium carbonate (0.02 g, 0.2 mmol) in water
(5 ml) was added 8 -tetrazolylmethylflavone (0.06 g, 0.2 mmol). The
107solution was allowed to cool and the undissolved material was filtered off. 
This solution was then evaporated to dryness to yield potassium 8- 
tetrazolatomethvlflavone as a cream powder (0.05 g, 73%), m.p. >350‘*C;
Ôh 8.13 (1 H, m), 8.01 (1 H, m), 7.83 (1 H, m), 7.63-7.41 (5 H, m),
6.95 (1 H, s) and 4.39 (2 H, s).
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H. In vitro and in vivo Testing
I. Materials and methods
Cell lines and culture conditions
A panel of human and murine tumour cell lines were used including; 
MAC 15A^3  ^ (derived from an ascitic murine adenocarcinoma of the 
colon), MAC 16^^ (slow growing, solid and cachectic murine 
adenocarcinoma of the colon), MAC 26^  ^ (well differentiated solid murine 
adenocarcinoma of the colon) WEHI~3B^39 (murine myelo-monocytic 
leukaemia), K562^^® (human chronic myelogenous leukaemia with 
erythroid characteristics), HT-29,^^^ HCLO, DLD-H^^ ^nd HCT-18 
(human adenocarcinomas of the colon), HRT-18^"^^ (human rectal 
adenocarcinoma) and BM (murine bone marrow). With the exception of 
WEHI-3B and K562, all cell lines were routinely maintained as monolayer 
cultures in RPMI 1640 medium supplemented with 10% foetal calf serum, 
penicillin/streptomycin (50 lU ml V50 jig ml-i), sodium pyruvate (1 mM) 
and buffered with HEPES (25 mM). The exceptions, WEHI-3B and K562 
cell lines, were maintained as suspension cultures in RPMI 1640 as above. 
Primary bone marrow cultures were set up as follows; Bone marrow cells 
were obtained from the femurs of non tumour bearing :MRI mice and 
collected in RPMI 1640 at 4 ‘'C. Immediately prior to chemosensitivity 
testing, cells were cultured in 96 well plates containing RPMI 1640 
supplemented with 20% foetal calf serum and 10% WEHI-3B conditioned 
medium.
2. In vitro chemosensitivity
An MTT assay^^“^ was used to assess chemosensitivity following the 
continuous (96 h) exposure of cell lines to each compound as described 
below. Approximately 0.5 to 1 x 10  ^ viable cells (BM cells were plated
109out at 5 X 105 cells per well) were plated into 96 well culture vessels 
containing 180 |il of RPMI 1640 medium. 20 ml of drug solution was 
added to each well to give a final concentration of 500 jig ml-i (8 wells 
per drug exposure were used). Following a 4 day incubation at 37 °C in 
an atmosphere containing 5% CO2, 150 ml of old medium was replaced 
with 150 ml of fresh RPMI 1640 immediately prior to the addition 
(20 ml) of MTT solution (5 mg ml-i). Following a further 4 hour 
incubation at 37 °C, 180 ml of medium was removed and discarded from 
each well and the formazan crystals dissolved in 150 ml of DMSO. 
Absorbance of the resulting solution was read at 550 nm using an ELISA 
spectrophotometer. All results were expressed in terms of % survival 
taking the control absorbance values to represent 100% survival. From 
the dose response curves constructed, IC50 (the concentration required to 
reduce cell survival by 50%) values were estimated.
3. Solubility of compounds
FAA sodium salt analogues were reconstituted in saline. A range of 
physiologically acceptable solvents ie saline, saline +/- ;aOH/HCl, DMSO 
or ethanol were available if any analogues proved insoluble in saline. The 
final concentration of solvents used was less than 0.01% and solvent 
controls were used throughout.
4. Anti-tumour activity in vivo 
Animals and tumour system
Pure strain ;MRI mice were used from the Bradford Clinical 
Oncology Unit inbred colony. ;MRI mice were housed in cages in an air 
conditioned room where regular alternate 12 h cycles of light and 
darkness were maintained. Animals were supplied with pellet diet (CRM 
Labsure, Croydon, UK) and water ad libitum.
110The development of several adenocarcinoma of the colon in <MRI 
mice from primary tumours induced by the prolonged administration of 
1,2-dimethylhydrazine has been described elsewhere7"^5 The tumour line 
used in this study was MAC 15A grown subcutaneously as a poorly 
differentiated, solid tumour in <MRI mice.
5. Chemotherapy
Chemotherapy began when tumours had reached a size that could be 
accurately measured and had an established vasculature. Anti-tumour 
activity was assessed by tumour weights and all tumours were of 
comparable size. All drugs were administered intraperitoneally (ip) at 
comparable doses to FAA. Drug vehicles differed depending on the 
analogue used with the majority administered using saline. FAA itself was 
administered in 20% cremophor/saline, saline + <aOH and arachis oil as 
positive controls.
6. Statistical analysis
Statistical analysis was performed using one way analysis of variance 
on tumour w e i g h t s . W h e r e  significant differences between mean 
tumour weights were obtained Tukeys test^^  ^ was performed to determine 
whether or not treated tumour weights were significantly different from 
control tumour weights.
DISCUSSION
I l l
A. Development of a General Method for Flavone Production
Various literature methods were available for flavone production as 
described in the Introduction to the thesis. Factors considered in choosing 
the appropriate reaction scheme were cost of starting materials, ease of 
synthesis and overall yield.
1. The Basic Route
In previous work in this laboratory Sharma had found that a base induced 
condensation was a viable method to making flavones.^^ This method was 
chosen due to the wealth of information already available on the reaction. 
However, several problems remained and the synthesis could not be 
directly used to make 6-unsubstituted flavones. In his synthesis the 
penultimate step to flavone acetic acid formation was the acid hydrolysis 
of a cyanomethyl group. The cyanomethyl group originated from cyanide 
attack on a chloromethyl moiety, a group which was difficult to introduce 
into the correct position to give 96.
o o
MeMe
OH OH
105
Separ ate isomers
O
Me
OH
96
In his synthesis he had to block the site para to the hydroxyl with a methyl 
group to force the chloromethyl onto the 3-position since the mixture of
isomers formed, 96 and 105, was impossible to separate efficiently. In 
our case we wanted flavones and not 6-methylflavones and therefore had 
to find another way of introducing the acetic acid group. This masked 
acetic acid had to be inert in the base condensation and subsequent acid 
cyclisation reactions. The patent by Denny et on the production of 
xanthenone-4-acetic acids showed that an allyl group could be oxidised to 
give the target acetic acid 20. Likewise flavone-8-acetic acid 107 could 
be formed by oxidative cleavage of the corresponding 8-allylflavone 106.
112
O
- r  R
O
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KMnO
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The starting materials for the condensation consisted of an aryl ester 
74 and the acetophenone 109. The problem was to place an allyl group at 
the 3-position on the acetophenone. This was readily solved by making 
use of the Claisen rearrangement.
cC oMe
95
o
Me
Base
108
Me
OH
109
113
Using standard procedures the hydroxy acetophenone 95 was reacted with 
allyl bromide to give the allyl ether 108 which could be rearranged under 
Claisen conditions to yield the 3-allyl-2-hydroxyacetophenone 109. This 
material was produced on a large scale as it would always form one of the 
two starting materials in the base condensation.
The other reactants in the condensation were the aromatic esters 74. 
The esters used were commercially available or synthesised using known 
procedures from the corresponding carboxylic acids 110.
M eOH/HHO MeO
110 74
SOCl MeOH
Cl
111
R
Initially acidic methanol was used for the conversion of the carboxylic 
acids 110 into their corresponding esters 74. This method, however, 
gave low yields and was therefore superceded by using thionyl chloride to 
firstly produce the acid chloride 111 in excellent yield, followed by 
reaction with methanol to synthesise the ester in very good overall yield.
The condensation of the dianion of 109 with 74 initially gives a P- 
diketone 112 and in the early stages of the project the p-diketones were 
isolated. Isolation and purification of the yellow l-(3-allyl-2- 
hydroxyphenyl)-3-aryl-1,3-propanediones 112 was followed by acid 
catalysed cyclisation in methanol to give the allylflavone 106. Various 
tautomeric forms of 112 are possible, but it was clear from the =MR 
spectra that the compounds existed exclusively in one form. It is most
likely that this is the form 113 in which hydrogen bonding across two six- 
membered rings is possible and this is clearly preferred to the alternative 
114 in which there is only one such interaction.
114
O O O OH
114 113
-rR
2. Optimisation of the Condensation to Allow a One-pot Synthesis 
After several derivatives were prepared using this route it seemed 
probable that the condensation and cyclisation steps could be combined. 
The reasoning behind this was that, at the end of the condensation reaction, 
the mixture had to be acidified to slightly acidic pH. If the mixture was 
made more acidic and methanol was added then cyclisation could be 
brought about without isolation of the intermediate.
Colour changes during this one-pot synthesis were indicative of 
product formation. A colourless solution of the ester in THF with >aH in 
suspension changed to a bright orange on completion of the condensation 
reaction. Addition of methanol to destroy any unreacted base changed the 
solution to burgundy, which dissipated to an orange hue upon 
acidification. After heating under reflux for several hours to form the 
flavone itself, the colour of the solution was bright green. The many 
colours, although never analysed spectrally, were used in conjunction with 
thin layer chromatography to assess reaction progress.
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Me MeO+
O
Condensation
74One-pot
method Cyclisation
O O
5.5 eq. KMnO,
One-pot method conditions
1. NaH in T H F /A 3-5h
2. Acidic methanol / A 3-5 h
NaHCO
All reactions were followed on silica plates (run predominantly in ether) 
with rf values showing relative polarities of component side groups. 
Workup of the green allylflavone was via evaporation of the methanol and 
THF followed by aqueous extraction with several base washings. These 
washings designed to remove any unreacted hydroxyacetophenones and 13- 
diketone intermediates may, with hindsight, have resulted in a reduced 
yield of desired product due to flavone B-ring opening. Recrystallisation 
from ethanol with addition of charcoal yielded the pure compounds as 
colourless or yellow needles or cubes.
3. Oxidation
Oxidation of the allyl moieties proved more problematic than anticipated. 
Various oxidising agents were used such as oxone, ozone and acidic %
'  116
potassium permanganate. Oxone, an effective agent for conversion of 
sulphides to sulphoxides and sulphones proved completely ineffective for 
double bond cleavage. Ozone, on the other hand, was too powerful an 
oxidising agent as it attacked the internal enone double bond causing 
breakdown of the molecule. Finally permanganate was decided upon and 
after optimisation of the reaction conditions this was used as a standard 
method. A solution of the allylflavone in acetic acid/acetone/water ( 2 : 2 : 1 )  
was stirred at <5 while solid KMn0 4  (5.5 eq.) was added in portions 
over 6 hours. Addition of saturated sodium metabisulphite to the resulting 
brown suspension gave a white solid, and the mixture was then partially 
evaporated under reduced pressure and poured onto water. A white 
precipitate of FAA then precipitated which could be recrystallised from a 
1 :1  mixture of acetic acid / water or ethanol. The yield of this reaction 
was consistently low at 30 to 50 percent.
4. Sodium Salt Formation
The sodium salts of the flavone-8-acetic acids 115 were formed, initially, 
using sodium hydroxide in the minimum of water. The route, although 
successful in preparing the salts, gave brown decomposition products when 
the water was removed. This may be due to the instability of the B-ring 
of the flavone 116 to nucleophilic attack leading to breakdown products.
o
116
A new route to salt formation was sought and the literature yielded a 
method by Denny et In their work they took the minimum volume
of water, normally 3-5 ml and heated it to about 70 “C. They then added
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the desired amount of sodium bicarbonate and the corresponding acid and 
waited until the solid had disappeared. They then filtered any remaining 
solid material, cooled the mixture to room temperature and poured it into 
a large volume of A. R. acetone to yield the sodium salt as a fine white 
precipitate. This precipitate was filtered off and washed with more 
acetone and dried in the air. Although this method gave a slightly reduced 
yield this was more than offset by the improved purity of the product.
B. Mono-substituted Flavone-8-acetic Acid Derivatives
1. Synthesis
As the previous literature on flavone-8-acetic acids contained many 
synthetic derivatives but few in vitro and in vivo results, it was considered 
prudent to firstly synthesise simple derivatives. These target flavones 
were mono-substituted on the C-ring and the pendant groups differed in 
chemical and electronic nature.
Seven aromatic methyl esters were prepared or bought including the 
unsubstituted parent 117, 2-methoxybenzoate 118, 3-methoxybenzoate 
119, 4-m ethoxybenzoate 120 , 4-m ethylbenzoate 121 and 4- 
chlorobenzoate 122. The one-pot method proved robust for these 
examples forming 123, 124, 125, 126, 127 and 128 respectively. It 
was decided that the method would become the standard route for flavone 
synthesis due to the acceptable yields obtained. Oxidation of these 
compounds gave the flavone-8-acetic acids 129, 130, 131, 132, 133 and 
134 in poor to reasonable yields. The sodium salts 135, 136, 137, 138, 
139 and 140 were formed in good to excellent yields.
+118
MeO
GOGH COGNa
Ar
Ar = Phenyl 1 1 7
2'-Methoxyphenyl 1 1 8
3'-Methoxyphenyl 1 1 9
4'-Methoxyphenyl 1 2 0
4’-Methylphenyl 1 2 1
4'-Chlorophenyl 1 2 2
4'-Nitrophenyl 1 4 1
123 129 135
124 130 136
125 131 137
126 132 138
127 133 139
128 134 140
142
Methyl 4-nitrobenzoate 141 was also prepared and the coupling reaction 
attempted to form 142. In this case unfavourable electronic effects 
probably inhibited the formation of the diketone and so the flavone 142 
was never formed.
The following compounds were then ready to test -
G
CGGNa
135
COGNa GMe
CGGNa
136
GMe
O
CGGNa
GMe
CGGNa
137
CGGNa
140
119
2. In vitro results
MAC15A tumour cells were cultured as described in the Experimental 
section. The results for synthesised compounds are shown in tabular form 
below, with the percentage survival of cells shown inside the boxes.
% Survival of Tumour Cells
Dose Rate |ag/ml
Comnound Ar = 0 0.1 1 10 100 500
135 " 0 100 100 100 100 70 5
136 OMe"6 100 88 85 69 19 3.5
137 U 100 100 100 92 57 11
138 100 96 100 86 48 31
140 100 100 100 97 26 31
The table shows that at the low drug dose of 1 p.g/ml all the cells survived 
except those treated with the 2-methoxy derivative. Increasing the dosage 
led to activity for all derivatives with the 2-methoxy derivative 136  
showing greatest activity at each dosage. The 3-methoxy 137 and 4- 
methoxy 138 show reasonable activity at median doses with the former 
being most potent at the highest drug concentration. The 4-chloro 
derivative 140 gave very similar results to the 4-methoxy congener 
showing the importance of not only electronic effects but also steric effects 
to elicit the cytotoxic response.
At the higher doses, the pharmaceutical window conceptualised by 
Zaharko et seems to operate as seen especially in the 4-chloro case.
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3. In vivo results
All of the mono-substituted flavone-8-acetic acid salts were tested in vivo 
against MAC15A as described in the Experimental section. Each 
compound was tested at a certain dosage as dictated by the previous 
activity in vitro. The results are presented in terms of tumour growth 
delay in the table below.
Ar = Dose 1 
mgkg-i
Growth
Delay
(days)
Significance Dose 2 
mgkg-i
Growth
Delay
(days)
Significance
" 0 50 0 100 1 0.05
OMe 300 4.1 <0.01 400 3.9 <0.01
294 1.8 <0.01
300 1.6 <0.05 500 3.6 <0.05
80 0
300 0.8 450 0
Unsubstituted FAA salt was inactive at the lowest dose but showed a 
significant growth delay of 1 day at double the initial dose. Statistical 
analysis was carried out using a Mann-Whitney test on treated cancer sizes.
The most startling result was that for the 2-methoxy derivative 
which elicited the largest growth delay at 300 mgkg-% This significant 
result was mirrored at the 400 mgkg-^ concentration, however, as with the 
in vitro results a pharmaceutical window was apparent and the increased 
drug dose resulted in a lower growth delay. The 4-methoxy and 3- 
methoxy derivatives gave much smaller growth delays at 300 mgkg- ^ than 
their 2-methoxy counterpart, however, at the higher dose, 4-methoxy
121
derivative gave a comparable growth delay of 3.6 days to the 2-methoxy 
derivative.
?o significant growth delays were noted for the 4-methyl and 4- 
chloro analogues.
All of the monosuhstituted sodium salt FAA derivatives had been 
previously synthesised by other w o r k e r s . T h e  only previously 
reported in vivo results for these compounds are shown below.^^’^ ? ^he 
percentage tumour growth inhibition (TGI) is a measure of the 
effectiveness of the drug, and the other column shows the non-invasive 
measurement of anti-cancer drug effectiveness as a increase in lifespan 
(ILS) as compared to control animals. It should be noted that these results 
are for colon 38 (C38) and pancreatic (P) cancers, rather than the 
MAC15A adenocarcinoma used in our studies.
Comnound Ar = TGI ILS
135 " 0 96%(C38) 17% (PS)
137 V 100% (C38) ?ot quoted
138 ' a . . ?ot quoted 41% (PS)
140 " a . 18%(C38) ?ot quoted
Sharma synthesised many 6-methyl FAA derivatives in this l a b o r a t o r y . ^ ^  
These compounds were tested against various tumour cell lines in vitro 
and in vivo including MAC15A^^^ (derived from an ascitic murine 
adenocarcinoma of the colon), MAC 16^  ^ (slow growing, solid and 
cachectic murine adenocarcinoma of the colon), MAC26^^ (well 
differentiated solid murine adenocarcinoma of the colon), WEHI-3B^^^ 
(murine myelo-monocytic leukaemia), K562^^® (human chronic 
myelogenous leukaemia with erythroid characteristics), HT-29 "^^ ,^ HCLO, 
DLD-L"^^, HOT-18 (human adenocarcinoma of the colon), HRT-18^"^^
122
(human rectal carcinoma) and BM (murine bone marrow). However only 
the results for MAC15A will be shown as direct comparison can be drawn 
with our results. The compounds were delivered to the tumour cells using 
saline.
Compound
104
Ar =
In vitro 
IC50 llgml-i
In vivo 
% TGI at
100 mgkg-i 200 mgkg-i 300 mgkg-i'O 210 32 4 16
" 0 " ° " 68 39 27 25
100 14 36 0
350 36 56 94t
X» 60 21 21 36
14/5 deaths
It can be seen that the most effective compound in vitro is the heterocyclic 
3-fury 1 derivative. It will be seen later that these encouraging results 
helped us decide on using certain analogues in our study.
From the activity data it was seen that the methoxy group gave very 
promising results. It was therefore decided to try different polymethoxy 
derivatives and more elaborate heterocyclic examples for testing in an 
attempt to increase drug potency.
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C. Polymethoxylated Flavone-8-acetic Acid Derivatives
I. Synthesis
a. Dimethoxy Analogues
Dimethoxyflavone-8-acetic acid derivatives were made using the same 
robust method as that for the monosubstituted derivatives. Early in vitro 
results showed that the most effective compound possessed a 2-methoxy 
group on the C-ring and on that basis many 2-methoxy containing 
disubstituted analogues were synthesised. The corresponding methyl 
esters, 2,3-dimethoxybenzoate 143, 2,4-dimethoxybenzoate 144, 2,5- 
dimethoxybenzoate 145 and the 2,6-dimethoxybenzoate 146 proved 
straightforward to synthesise. All of these esters condensed and cyclised 
without any problems forming 147, 148 and 149 in good to excellent 
yields with the exception of the 2,6-dimethoxy analogue 146 which failed 
to condense with the anion of the acetophenone probably due to steric 
hindrance. This compound 150, complete with its loss in degrees of 
freedom, would have been interesting to test as the C-ring would have 
been twisted and locked into an almost perpendicular conformation 
relative to A- and B-rings.
The sequence was then continued using the normal method to give 
the 2-methoxy disubstituted FAA derivatives 151, 152 and 153 and their 
corresponding sodium salts 154, 155 and 156. Of these compounds only 
the 2,4-dimethoxy FAA 152 had been reported before.^^-^^
It was decided to make several 3-methoxy containing derivatives due 
to the previous testing results to complement the 2-methoxy derivatives in 
estab lish ing  structu re-activ ity  re la tionsh ips. M ethyl 3,4- 
dimethoxybenzoate 157, methyl 3,5-dimethoxybenzoate 158 and methyl 
3,4-methylenedioxybenzoate 159 were synthesised and coupled with 3- 
allyl-2-hydroxyacetophenone to form 160, 161, and 162 respectively.
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MeO
O
A
Ar =
2',3'-Dimethoxyphenyl 
2',4'-Dimethoxyphenyl 
2',5'-Dimethoxyphenyl 
2',6'-Dimethoxyphenyl 
3',4'-Dimethoxy phenyl
3 ' ,5 '-Dimethoxyphenyl
3',4'-Methylene-
dioxyphenyl
4'-Chloro-
2'-methoxyphenyl5'-Chloro-
2'-methoxyphenyl
COOH COONa
143
144
145
146
157
158
159
169
170
147
148
149
150 
160 
161 
162
171
172
151
152
153
163
164
165
173
174
Ar
154
155
156
166
167
168
175
176
The standard reaction conditions then gave the three carboxylic acids, 
163, 164 and 165 and their salts 166, 167 and 168, of which only two, 
163 and 164, had previously been synthesised in patent work.25-89 1^3 
had a TGI of 70% against colon 38 carcinoma while no activity results 
existed for the latter. The other 3,4-disubstituted FAA derivative, 165, 
and its corresponding salt 168, was designed to check if the ‘locked’ 
alkoxy function helped activity.
Two other di-substituted ester derivatives were synthesised in which 
one group was a chlorine and the other an 2-methoxy group. These 
isomeric structures, 169 and 170, differed in the position of the 
chlorines, one meta to the methoxy and the other para  to the methoxy 
group. The 4-chloro-2-methoxyphenyl allyl derivative 171 and the 5- 
choro-2-m ethoxyphenyl congener 172 were oxidised to their 
corresponding acetic acids 173 and 174. The salts 175 and 176 were 
formed in high yields.
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The following disubstituted derivatives were then ready to test -
OMe OMeOMe
OMe
OMeCOONa
155
COONa
154
COONa
156 OMe
OMeOMe
COONa OCOONa
166
OMe COONa
OMe 168167
o
OMe
COONa
175
Cl
OMe
COONa
b. Trimethoxy Analogues
Trimethoxy allyl analogues 177, 178 and 179, as with the di-substituted 
derivatives, proved straightforward to make from their corresponding 
methyl esters 180, 181, and 182. However the 8-allyl-2’,4’,6’- 
trimethoxyflavone 183 like the 2,6-dimethoxy derivative, could not be 
obtained since the ester 184 failed to undergo condensation presumably 
due to steric hindrance. The corresponding salts 185, 186 and 187 of the 
acid analogues 188, 189 and 190 were obtained readily using the normal 
methods.
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H” OAMeO Ar
Ar =
2',3',4'-Trimethoxyphenyi 180 
2',4',5'-Trimethoxyphenyl 181 
2',4',6'-Trimethoxyphenyl 184  
3',4',5'-Trimethoxyphenyl
COONaCOOH
177
178 
183
179
188
189
190
Ar
185
186
187
The following trisubstituted derivatives were ready to test -
OMeOMe
OMe OMe
COONa OMe COONa OMe COONa OMe
OMe OMe185 186 187
To date there have been no trisubstituted derivatives documented in the 
literature.
c. Tetramethoxy Analogues
The tetra-substituted derivatives were all made from 3,4,5- 
trimethoxybenzoic acid 191 following Mayer and Fikentscher’s 
p r o c e d u r e . I n  their procedure they took the carboxylic acid 191 and 
brominated the 2-position using bromine in chloroform with a catalytic 
quantity of water present. This 2-bromo-3,4,5-trimethoxybenzoic acid 
192 was then made into the 2,3,4,5-tetramethoxybenzoic acid 193 by 
reaction with excess sodium methoxide in methanol in the presence of very 
finely divided copper bronze.
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OMe
OMeOMeOMeHO
CHCl
OMeOMeOMe
OMe191
OMe180
OMe192
OMe194
OMe193
1. SOC12 1. SOCI2 1. SOCI2
2. MeOH 2. MeOH 2. MeOHV 1 r
OMe
OMeOMeOMe MeOMeOMeO
OMeOMeOMe
OMe195
Both of these carboxylic acids were esterified forming 194 and 195 
respectively and used to produce the corresponding allylflavones 196 and 
197. The flavone-8-acetic acids 198 and 199 and their salts 200 and 201 
were then formed with little difficulty.
o o o
+ oAMeO Ar
COOH COONa
Ar =
2'-Bromo-3',4',5'-
trimethoxyphenyl
2 ' ,3 ' ,4 \ 5 '-
T etramethoxypheny 1
194
195
196
197
198
199
Ar
200
201
The following tetrasubstituted derivatives were ready to test
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OMe
OMeOMe
OMeCOONaOMeCOONa
OMeOMe 201200
2. In vitro Testing
The in vitro activity against MAC 15A was determined as described in the 
Experimental section and the results are presented in terms of IC50 values
Cmpd
@A.
Ar = IC50 values 
mgkg-i
Cmpd
@o.
Ar — IC50 values 
mgkg-i
135 'O 6.8+1.5 175 3.5+2.2
154 OMex5r°“ 325+74 185 OMe\A ^O M ev:_ 16+7
155
M e O O M e
17+3.5 186 OMe
MeO OMe
123+10
156 J u 8.8±2.4 187 ^ f ^ O M e
OMe
41+9
166
^ = ^ O M e
>500 200 Br\ J î 5 . 0 M eV -
OMe
19+1.2
167 OMeV
OMe
65+10 201 OMev J ^ O M e
^ f ^ O M e
OMe
30+7.2
168 17+4
It can be seen from these results that the 2- methoxy sub stitute d derivatives, 
in the main, show the best activity. Analysis of these results is indicative 
of an electronic factor which may be influencing anti-tumour activity. If
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the tetramethoxy derivative is compared to any of the methoxy derivatives 
it is plain that there can be no additional steric factors operating in these di 
or trisubstituted analogues which are not present in the tetrasubstituted 
derivative.
If compounds with equivalent steric bulk i.e. the 4-chloro-2- 
methoxy and the 2,4-dimethoxy derivatives are compared then there has to 
be a combination of electronic and steric factors affecting activity.
All of the 2-methoxy containing disubstituted compounds show 
significant activity in vitro. The 2,4-dimethoxy 155 and 2,5-dimethoxy 
156 compounds showed twenty fold or greater activity than the 2,3- 
dimethoxy derivative 154. The 3-methoxy containing disubstituted 
derivatives showed good to reasonable activity except for the 3,4- 
dimethoxy compound 166 which proved effectively inactive. It is 
interesting to note that the close relative of this compound, 3,4- 
methylenedioxy 168, was very active. Once again this activity must be 
due to an electronic effect, however it could be argued that this derivative 
has fewer degrees of freedom with regards to space and hence fits more 
snugly into the active site. However, the trisubstituted derivatives and 
tetrasubstituted derivatives tend to disprove this argument.
The trisubstituted compounds especially the 2,3,4-trimethoxy 185 
and the 3,4,5-trimethoxy 187 derivatives showed significant activity in the 
MAC 15 screen. Both of the tetrasubstituted derivatives gave good results 
in the in vitro screen with the halo derivative slightly more active than its 
congener.
3. In vivo testing
Using the in vitro results as the basis for the dosage regime in vivo, the 
polymethoxylated derivatives were tested against subcutaneous MAC15A 
tumours. The results are presented in terms of tumour growth delay.
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Cmpd
Bo
Ar — Dose 1 
mgkg-i
Growth
Delay
(days)
Significance Dose 2 
mgkg-i
Growth
Delay
(days)
135 " 0 50 0 100 1.0
154 OMe
" à r “ ”
500 1.7
155
MeO OMe
450 2.8 <0.05 550 3.2
156
M e O ^ ^
500 0
166 324 1.9 <0.01 400 1.1
167
V
OMe
400 1.4
168 " a > 37 0 50 0
175 39 0.8 50 0
185 OMe\^L^OMe
^ '^ ^ O M e
450 0.5
186 sy^O M e
M e O O M e
500 0
187
OMe
500 1.7 <0.05
200 Br\ ^ ^ _ O M e
^ f ^ O M e
OMe
500 3.1 <0.01
201 OMe\A ^O M e
^ ^ O M e
OMe
500 1.2
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At equivalent doses the dimethoxy derivatives showed variable 
results. The 2,4-dimethoxy derivative, with the best in vitro result, 
stopped the cancer growing for about 3 days with the 2,3-dimethoxy 
derivative inhibiting growth for about 2 days. It is interesting to note that 
even at such a high dosage the 2,5-dimethoxy derivative is inactive in vivo. 
Whether this effect is due to under/overshooting the pharmaceutical 
window requires further study. The very good in vitro result perhaps 
indicates that the concentration of the drug used here was too high to elicit 
a response.
The 3,4-dimethoxy derivative shows a contrasting result to that 
obtained in vitro. A median dose of this drug caused a respectable growth 
delay of about 2 days whereas at the higher dose of 600 mgkg-i no growth 
delay was observed. Even more startling was the discovery that the close 
congener, 3,4-methylenedioxy 168, which was very active in vitro, 
showed no activity, albeit at low dosage. This effect may be due to 
undershooting the pharmaceutical window.
Of the three trisubstituted derivatives only the 3,4,5-trimethoxy 
derivative 187 showed any statistically significant growth delay. These 
results at least showed correlation between the in vitro and in vivo tests 
with the 2,4,5-trimethoxy derivative 186, which was least active in vitro, 
also proving inactive in vivo at high dose.
The halo-substituted tetrasubstituted derivative 200 gave 
significantly the best growth delay of 3.1 days at high dose whereas its 
tetramethoxy congener 201 gave a growth delay of 1.2 days at the same 
dose.
D. Heterocyclic Flavone-8-acetic Acid Derivatives
Since it appeared that the presence of one or more electron-donating 
methoxy groups on the 2-aryl substituent was generally beneficial for
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activity, it was decided to synthesise compounds with the 2-aryl substituent 
replaced by a range of 7c-excessive heteroaromatic groups and for 
comparison some 7t-deficient heterocyclic groups.
1. Synthesis
a. Sulphur containing heterocyclic derivatives
Sulphur, oxygen, and nitrogen heterocyclic carboxylic acid esters were all 
made. The allyl derivatives including 3-thienyl 202 and 3-methyl-2- 
thienyl 2 03  proved straightforward to synthesise from their 
corresponding esters 204 and 205. These allyl derivatives were oxidised 
under normal conditions to form the corresponding carboxylic acids 206 
and 207 and converted to their sodium salts 208 and 209. The 8-allyl- 
(3-methoxythienyl)flavone 210 was synthesised by Dr. Robert Ritchie in 
this laboratory from the methyl ester 211 of 3-methoxythiophene-2- 
carboxylic acid (gifted by Synthetic Chemicals Ltd.). This derivative was 
then oxidised by the author to the carboxylic acid 212 which was 
converted to its sodium salt 213.
+
Ar =
3-Thienyl 
3 -Methyl-2-thieny 1 
3-Methoxy-2-thienyl
MeO
O
A Ar
COOH COONa
204
205  
211
3-Chloro-2-benzo[b]thienyl 2 1 4
202
203
210
217
206
207
212
218
Ar
208
209
213
219
The most exotic sulphur-containing methyl ester 214 was prepared using 
the procedure of Krubsack and Higa.^^  ^ The action of thionyl chloride on 
cinnamic acid produced firstly the acid chloride 215. Addition of
pyridine and more thionyl chloride to the reaction mixture gave the fused 
chlorobenzothiophene acid chloride 216 and elemental sulphur after 
heating for 12 hours under reflux. After filtration of the solid sulphur 
and evaporation of all volatile components in the mixture a white solid, 
which was the acid chloride 216, was obtained. This compound was 
added slowly into boiling methanol to form the methyl ester 214 and then 
the methanol was removed. This ester itself was a new compound, only 
the ethyl ester being isolated before by Krubsack and Higa.^^^
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SOCl
215
1. SOCl SOC12
Pyridine2. SOCI2 /Pyridine
Cl
MeOH
OMe
214 216
The methyl ester was then coupled to 3-allyl-2-hydroxyacetophenone to 
form the allyl compound 217 in reasonable yield. The low yielding 
oxidation of the allyl compound to the acid 218 proved straightforward 
and the salt 219 was formed without too much difficulty.
The following sulphur-containing derivatives were ready to test
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O O O
COONa
208
Me
COONa
209
OMe
COONa
213
o
COONa
219
b. Oxygen containing heterocyclic derivatives
Two allyl derivatives 220 and 221 were synthesised without problem 
from the corresponding esters 222 and 223. Of the two oxygen 
containing heterocyclic allyl derivatives made only the 2-furyl derivative 
oxidised properly to give the desired product. These acids 224 and 225 
were designed to be complimentary to their sulphur analogues. Isolation 
of the acid 224 was surprising due to the inherent instability of the oxygen 
heterocycle under acidic oxidising conditions.
Ar =
2-Furyl
3-Furyl
OAMeO
COOH COONa
222
223
220
221
224
225
Ar
226
The 3-furyl allyl precursor 221 was apparently too sensitive for the 
oxidising conditions and no solid material was obtained. The sodium salt 
226 of the 2-furyl acid was synthesised easily and in excellent yield.
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Only one oxygen-containing derivative was ready to test
o
COONa
226
c. Citrogen containing heterocyclic derivatives
The nitrogen heterocyclic allyl derivatives, 227 and 228, likewise showed 
no difficulty in preparation from their corresponding methyl esters 229 
and 230 and 3-ally 1-2-hydroxyacetophenone under basic conditions.
Ar =
4-Pyridyl
2-Quinolyl
Me H- OA
COOH COONa
229
230
227
228
231
232
Ar
The oxidation of 227 to 231 gave the same problem as the 3-furyl 
derivative in that no precipitate was found on normal workup. This was 
possibly due not only to the breakup of the benzopyranone fragment but 
also to the oxidation of the nitrogen to the C-oxide. The quinoline 
derivative 232 also gave the same problem in that no solid was obtained at 
the end of the oxidation reaction. This was unfortunate as these nitrogen 
containing derivatives would have been useful in obtaining quantitative 
structure activity relationships.
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Do nitrogen-containing derivatives were ready to test.
2. In vitro Testing
The heterocyclic derivatives were evaluated against MAC 15A in vitro and 
the results are shown below.
Cmpd Do Ar = IC50 value 
mgkg-i
135 6.8+1.5
208 129+40
209 6.4+1.3
213 19+2.6
219 4.8+3.0
226 " 0 26+10
These in vitro results showed that heterocyclic analogues had comparable 
activity to their carbocyclic counterparts. All the heterocyclic analogues 
gave promising activity results with the 3-methyl-2-thienyl 209 and the 3- 
chloro-2-benzo[b]thienyl derivatives 219 giving results among the best of 
all the compounds tested.
Other in vitro results
Only one heterocyclic derivative, synthesised by Dr. Ritchie, had been 
tested. This 2-thienyl derivative had an IC50 value of 30±9.6 which was 
almost four-fold more active than the 3-thienyl derivative. This value
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compares well with the 2-furyl derivative shown above with the 2-furyl 
analogue being slightly more active.
3. In vivo activitv
Only two of the heterocyclic derivatives were tested against MAC 15A in 
vivo. Both of these compounds were significantly active with the 3- 
methyl-2-thienyl derivative 209 giving the best activity recorded for the 
smallest amount of drug. This compound would possibly have been 
inactive at much higher drug dose whereas the 3-thienyl derivative 208 
would probably be less active at lower doses.
Cmpd
E
o
Ar = Dose 1 
mgkg-i
Growth
Delay
(days)
Significance Dose 2 
mgkg-i
Growth
Delay
(days)
Significance
135 " 0 50 0 100 1.0 0.05
208 272 2.3 <0.01 350 2.9 <0.01
209 > 80 4.1 <0.01
The above results are startling as they show probably the most active 
derivative synthesised to date. It is difficult to imagine why this is the case 
except for the fact that it perhaps fits into the active site more snugly than 
the other sulphur derivative. This activity is mirrored by its remarkable 
activity in vitro followed closely by its 3-methoxy congener.
E. Extended Analogues of Flavone-8-acetic Acid
It seemed clear that for activity both the carboxylic acid group of FAA 
and the 2-aryl substituent are essential. In order to further examine the
structure-activity relationships for this class of compounds, it was decided 
to vary the distance between these groups.
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1. Synthesis
a. Alkyl or alkenyl extension
Phenylacetic acid was made into the acid chloride and esterified to produce 
233 which was then condensed with the acetophenone to form 234 in 
reasonable yield. The methylene extension of the phenyl ring disrupted 
the conjugation of the system giving an allyl molecule which has a lower 
melting point than usual.
+ oA,MeO R
R =
Benzyl
Diphenylmethyl
4-Chlorostyryl
2-(2-Thlenyl)-ethenyl
233
236
243
244
234
235
241
242
COOH
237
238
245
246
COONa
239
240
The other extended derivative, 8-allyl-2-diphenylmethylbenzopyran-4-one 
235, was also straightforward to make from methyl diphenylacetate 236. 
Both of the corresponding carboxylic acids, 237 and 238 readily formed 
by the usual method, differed from the normal flavone-8-acetic acids in 
that they were soluble in dichloromethane. This increase in solubility was 
probably due to an increased flexibility and hence decreased planarity of 
the structure. Formation of the sodium salts, 239 and 240, was therefore 
problematic as both the carboxylic acids and the sodium salts were soluble 
in the acetone/water mixture used to isolate the pure sodium salt but the 
compounds were obtained in good yield.
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The double-bond extended allyl compounds, 241 and 242, proved 
straightforward to synthesise from their esters, 243 and 244, albeit with 
very poor yields. Unfortunately these compounds did not give rise to the 
expected acids 245 and 246 since the double-bonds of the 2-substituent 
were oxidatively cleaved under the conditions used.
The following compounds were ready to test-
COONa NaOOC
240239
The most interesting of the extended derivatives was obtained 
serendipitously in an attempt to prepare the analogue of FAA with a 2- 
phenylethynyl group. This would have had an unsaturated spacer group 
which could have withstood the oxidative conditions needed to generate the 
acid from the allyl group. The required acetylenic ester was prepared 
starting from phenylacetylene 247. This alkyne was lithiated to give 248 
and carbonylated using gaseous carbon dioxide to afford 249.
■H
247
u ^
248
/
,0
o
/
jvleOH
251 OMe
249 OU
/ =
Cl \  / <
.0
250 OH
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Acidification of the lithium salt gave 250 and subsequent estérification by 
reaction with thionyl chloride and then methanol gave 251. The normal 
route for flavone formation did not, however, lead to the benzopyranone 
252. Instead the quite different compound 255 was obtained.
It seems from experiments carried out on the system later that the 
p-diketone adduct 253 does form as normal. However, attempted 
cyclisation of this results in an alternative mode of reaction as shown in 
254 to give an extended pyranone system 255 formed by Michael 
addition.
Me MeO+
110 O OH
Proton transfer 
O
254 255
This ‘stretched flavone’ 255 was deemed important enough to continue 
along the reaction pathway to the acid. Firstly the free hydroxyl group 
had to be methylated to stop unfavourable side reactions under the
oxidising conditions. The resulting compound 256 was a liquid at room 
temperature, however after undergoing permanganate oxidation a white 
solid was formed. This carboxylic acid 257 was converted into its sodium 
salt 258 using the standard method.
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O
OH
255
o
OMe
ONa 258
Base
OMe
256
[O]
o
OMe
OH 257
This use for the Michael reaction was discovered by Ruhemann et in 
1899 and is widely applicable.
o o
OEt
259
o o 
260
GOGHEtO
OEt OEt
EtO
EtOH +
261
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They discovered that esters of acetylenic acids 259 reacted with p-keto 
esters 260 or p-diketones to form 2-pyrone 261. From their previous 
work on the acetylenic esters 259 and substituted ketones 262 they 
expected these acetylenic P-diketones 263 to condense forming five 264 
or six membered rings 265.
o o
OEt
259
oU
+  RH 20 R' 
262
264 265
R
R"
It is possible that the identical process happens for the alkene derivatives, 
hence explaining the much reduced yields. However, only the correct 
products were retrieved after recrystallisation.
c. Dimeric Derivatives
The last series of 2-substituted derivatives stemmed from the idea of 
increased activity via two active groups on the same molecule. This was 
based on work carried out by Breslow et wherein they discovered 
that bisacetamides were more active as anti-cancer agents than 
monoacetamides by more than a factor of two. Polar solvents were 
s h o w n t o  cause differentiation in murine erythroleukaemia cell lines 
thereby nullifying the cancer. This innovative form of anti-cancer 
treatment was unfortunately not viable due to the low in vivo 
concentration of the polar compound. Rapid deacetylation of the 
compound and rapid renal clearance led to short in vivo exposures.
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Extensive structure-activity relationships showed that the two 
groups, separated by a six carbon spacer unit, were binding at two 
separate receptor sites on the target cell. Further studies showed that if 
the acetamide groups were replaced by hydroxamic acids then even 
greater activity was observed. The most effective compound that induced 
cell differentiation was suberic bishydroxamic acid 274 which was >100 
times more effective than its acetamide counterpart 273.
273
HO .
274
As the cell receptor for FAA was unknown it was considered prudent to 
try out Breslow’s hypothesis for several representative compounds. This 
was brought about by using a series of diesters with which the 
acetophenone anions would add twice.
o
x  =
Me MeO 4-
^  /
A OMe
OMe
266
267
268
Not Isolated 
Not Isolated 
271
269
270 
272
o
Preparation of the dimethyl esters 2 6 6 , 267  and 268  proved 
straightforward from their corresponding carboxylic acids. The solid 
diesters required sonication at the start of the condensation reaction to help 
the crystals to dissolve in the medium.
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The first diester, dimethyl oxalate, was condensed with the two 
equivalents of acetophenone 110 using four equivalents of base. The 
resulting compound 269 however was not really a flavone dimer but a 
benzopyranone dimer. This compound 269, as with the rest of the allyl 
dimers 270, 271 and 272 dissolved only sparingly in the medium dictated 
by the oxidation. Unfortunately this meant that only the diphenyl ether 
linked compound was isolated in very low yield from the oxidation 
reaction. The sodium salt 275 was formed from the carboxylic acid. 
Interestingly, compound 271 was formed by using only half the amount of 
starting acetophenone.
The following dimeric compound was ready to test-
o
COONa NaOOC
2. In vitro testing
Four extended derivatives were tested on MAC 15A cell cultures. Two of 
these compounds were similar in that they both possessed an alkyl 
extension. As discussed earlier they also dissolved in less polar solvents 
due to greater degrees of freedom.
It is perhaps not surprising that the phenylmethyl derivative was 
extremely active in comparison with the parent FAA whereas the 
diphenylmethyl derivative was quite inactive when the theoretical active 
site is envisaged. The benzyl group of 239 can occupy the site intended 
for the phenyl group of FAA with the whole molecule planar, but with
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240 it is impossible for both phenyl groups to be in the plane and the 
significant out-of-plane bulk completely removes the activity.
Cmpd Fo R = IC50 value 
mgkg-i
135 " 0 6.8±1.5
239 3.7±1.3
240
Ph
>500
258 O
OMe —  
COONa
75+18
275 Ether dimer 37+7
It was hoped that the derivative 258  originating from 
phenylacetylene would prove active in the in vitro test. If this was so, it 
would show that the distance between the C-4 carbonyl and the acetic acid 
grouping could be increased. The results were indeed startling as the 
compound was active and comparable to the majority of derivatives 
synthesised.
Only one dimeric compound 275 was submitted for testing. This 
diphenylether dimer was expected to be at least as active as a 4-methoxy 
derivative. The extra bulk of the molecule would hopefully be able to 
avoid unfavourable interaction with the active site due to the flexibility of 
the oxygen linkage. Unfortunately, there was so little of the drug 
available due to the inherent solubility problems that only the in vitro 
testing could be carried out. It is hoped that the next worker on the 
project will be able to synthesise a greater amount of compound and
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submit it for the in vivo test. It is difficult to deduce, at this early stage, 
whether the effect that Breslow saw is operating on the flavone system. 
Certainly good activity was shown but many more derivatives would be 
required to be tested in order to have a more informed opinion.
3. In vivo activity
Only three extended derivatives were tested on the murine tumours in 
vivo. The outstanding IC50 value for the phenylmethyl derivative 
prompted the testers to try a very low dosage in the first instance. When 
this showed no cytotoxicity they increased the dosage of the drug a further 
two times whereupon it should have caused tumour regression. The 
diphenylmethyl derivative was inactive under the testing conditions. The 
results are as follows.
Cmpd
GH
Structure Dose 1 
mgkg-1
Growth
Delay
(days)
Dose 2 
mgkg-i
Growth
Delay
(days)
135 " 0 50 0 100 1.0
239 __Ph 34 0 60 0
240
Ph
500 0
258 0
ClOMe
COONa
500 1.7
The probable cause for the inactivity of both 239 and 240 is metabolic
removal of the drug before is could reach the tumour site or the failure to
147
reach the pharmaceutical window. The benzylic CH’s are clearly 
vulnerable to biological oxidation.
The significant activity of the extended analogue, derived from 
phenylacetylene, 258 shown in vitro was borne out in vivo where there 
was also significant activity albeit at high drug dosage. This result was 
encouraging and will perhaps lead, in the future, to many other optimised 
similar structures. This results shows that it is indeed possible to increase 
the distance between the C-4 carbonyl and the acetic acid group and retain 
activity. It would also be possible to construct a desmethoxy derivative by 
using an acetophenone instead of a bydroxyacetophenone.
F. Derivatives with Different Groups in the 8-Position
1. Svnthesis
The penultimate change to the flavone moiety involved changing the 8- 
position’s acetic acid group into the isosteric tetrazole. This has been 
successfully applied in a number of pharmaceutical c o m p o u n d s . T h e  
route chosen was developed from previous work^ '^^ »^^ °'^  ^ starting from 3- 
methylsalicylic acid 276.
o
Me^SO^
V ^ o „  — '
Me
276
5,5-dimethyl
V ^ O M e
1,3-dibromo- 
t 
hydrnmm.]
Me
277
NaOMe
OMeBase^  Acetophenone OMeOMe
OMeOMe
280 279
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This was methylated twice to give 277 with some difficulty and the 
methyl group brominated to give 278. This bromo-compound was 
converted into the corresponding methoxy derivative 279. It was this 
ester that was condensed with acetophenone under basic conditions. This 
procedure, although identical in conditions to previous condensations, is 
the exact reverse in terms of the starting materials, in that the A-ring is 
formed from the ester and the C-ring formed from the acetophenone. The 
p-diketone 280 formed after the condensation was cyclised using acidic 
conditions of hydrobromic acid in acetic acid to form the 
brom om ethylflavone 281. Unfortunately, due to the difficulty in 
separating the cyclised product from the starting materials this route was 
abandoned in favour of the synthesis below.
Once again 3-methyIsalicylic acid was used and methylated twice to 
give 277. The condensation with acetophenone gave p-diketone 285 and 
subsequent formation of flavone 286 was brought about by warming the 
diketone to 80 °C in a hydrobromic acid and acetic acid mixture. 8- 
Methylflavone 286 had been synthesised previously in the literature. 
For the conversion to 281 l,3-dibromo-5,5-dimethylhydantoin was used 
as the brominating agent instead of I-bromosuccinimide since it was 
found to be a more active and selective agent for this process. Potassium 
cyanide was used to displace the bromine forming 282. The cyano 
compound was reacted with sodium azide by heating under reflux in dry 
DMF.i^^ The crude product was treated directly with potassium carbonate 
and the potassium salt 283 that was formed was separated from unreacted 
cyanide starting material using column chromatography. The acidic silica 
of the column also converted the potassium salt back to the free tetrazole 
284. Addition of potassium carbonate to the free tetrazole followed by 
complete removal of water then gave the purified potassium tetrazole salt 
283.
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OH Me2SÛ4
O
Base  ^
Acetophenone
O O
Me
OMe 
Me 285
276 277
1,3-dibromo-
5,5-dimethyl-
hydantoin
281
AHBr/AcOH
O
Me
286
KCN
O
NaN.
CN N' KNH
282 284 283
The last group of compounds synthesised had a p-hydroxyketone moiety 
on the 8-position instead of the acetic acid group. These compounds were 
formed, by using fewer equivalents of permanganate in the oxidation 
reaction. Only 3 molar equivalents were used instead of 5.5 equivalents 
which led to the isolation of these 8-(3-hydroxy-2-oxopropyl) compounds 
at the end of the reaction. Three derivatives were synthesised, the 
unsubstituted 2-phenyl- 287, the 2,3-dimethoxypheny1- 288 and the 2,5- 
dimethoxyphenyl derivative 289.
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3 eg KMnÇ
COOH
OH
5.5 eq KMnO
R
The following derivatives were ready to test -
o
N~K
283
o
OH
287
o
OMe OMe
OMe
OMeOHOH
288 289
2. In vitro testing
The tetrazole compound 283 was evaluated against MAC15A in vitro. 
Unfortunately, however, it proved to be completely inactive. It is unclear 
why this compound failed to show activity unless it failed to reach the 
pharmaceutical window.
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Cmpd Jo Structure IC50 value 
mgkg-i
283 0
r  J-K+
>500
Similarly disappointing results were seen for the three (3-hydroxyketone 
flavone compounds which proved insoluble in the testing medium and 
therefore were not tested against the MAC15A cell line. A 8-(3-hydroxy-
2-oxopropyl)-3’,4’,5’“trimethoxyflavone synthesised by Ritchie in this 
laboratory elicited a growth delay of 0.2 days when administered at 100 
mgkg-i to murine hosts. This indeed bodes well for other compounds of 
this type should they be synthesised in the future.
3. In vivo testing
Due to insufficient quantity of drug no in vivo testing was carried out on 
the tetrazole derivative.
4. Other Syntheses Attempted
It seemed clear that spacer groups could indeed be useful for increasing 
activity, as seen in the work of Breslow et However methylene
spacer groups could not be used as the acidic hydrogens that they contain 
would react unfavourably under the basic conditions of the one-pot 
reaction. This reaction was tried once however to confirm this hypothesis 
and the consequent analysis showed failure of condensation.
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Less likely More likely
M eO ' yÇ  OMe 
H H
Base
From the abnormal KMR properties (see later) of the 8-ally 1-2^- 
methoxyflavone and its corresponding acid and salt it was decided to 
synthesise the 3-substituted derivative and observe the effect on the Im­
position. A synthesis was attempted which aimed to functionalise the 3- 
position and comes from the work of Li et This preparation takes
substituted flavones 290, and thioflavones 291 under mild conditions with 
I2 and eerie ammonium nitrate (CAK) in acetonitrile and results in 
iodination at the 3-position with varying degrees of success to give 292 
and 293.
—r R
290
o
l2 -C A N /M eC N  
55 - 60°C j 
24 - 80 %
292
Ig-C A N /M eC N  
55-60°C ,
95 - 98 %
T  R
293
CAK is used to form 1+ in essence and it is this species which brings about 
an electrophilic substitution at the 3-position. A series of canonical forms 
are possible which stabilise the intermediate in this process as shown.
x  = o , s
It has been reported however that various side reactions can occur e.g. a 
double iodination at the 3 and 8 p o s i t i o n s . T h e  yields of this reaction 
vary tremendously with the change of the pyranone oxygen for sulphur. 
It has been proposed that the sulphur lone pair is much more basic and can 
therefore stabilise the intermediate cation.
Unfortunately the synthetic procedure failed to produce the required 
3-iodinated compounds for both parent allyl and acetic acid compounds 
123 and 129.
G. Correlation between Structure and Activity
1. Computational Analysis
It can be seen from the preceeding results that one of the most effective 
anti-cancer agents is the 2 -OMe derivative. Exactly why this is so 
effective is unknown as the protein binding site is unresolved but it has 
been noted in the LMR and molecular modelling that something strange is 
happening.
Computational studies were initiated on various derivatives of the 
flavone-8-acetic acid system to firstly check on the overall optimised
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geometry and secondly to perhaps correlate electron density at various 
positions on the molecule with in vitro and in vivo activity. These 
calculations were carried out on a Sun workstation running SunOS4 using 
the program M0PAC5 developed for computational analysis. All 
derivatives studied were entered into the program in the form of cartesian 
coordinates and were subjected to restricted Hartree Fock calculations 
using the AMI H a m i l t o n i a n . T h e  program was also run under the 
PRECISE qualifier which increased selection criteria for the energy 
gradient by 100 fold. The cartesian coordinates section of the output file 
was entered into Chem3D, a molecular viewing package, and the graphic 
file displayed as can seen below. Electron density at various positions 
were also noted for later analysis. It should be noted, however, that there 
are many energy minima on the potential surface varying only by a few 
kcal and because of this the calculations were checked by having different 
starting conformations.
A general feature of the results for FAA, confirmed later by X-ray 
structure determination, was that the flavone moiety, as expected, was 
almost planar. However the acetic acid group was invariably orientated 
almost perpendicular to the flavone. Calculations on the sodium salt of 
FAA however showed a different effect.
The model of the sodium salt analogue below shows that the 
carboxymethyl group has swung around until it is close to the hydrogen on 
C-6". A similar interaction can be seen occurring between the oxygen of 
the 2 '-methoxy and the hydrogen on the 3-position. This would infer 
some kind of interaction if not intramolecular hydrogen bonding.
This type of bonding is rare but has also been postulated by 
Baguley, Ching, Denny et alP^ in the xanthenone-4-acetic acid system. 
Although these results are only high level calculations, the experimental 
facts seem to hold with the theory of some interactions at C-3 hydrogen 
and the C-6" hydrogen and hence their respective carbons. A good
r e v i e w o f  these C -H ...O  hydrogen bonds explains that although the 
effect may be small in energy terms such contacts do exist and help such 
molecules to pack more effectively in the crystal lattice.
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Computational Results for 2 -OMe Flavoneacetic Acid and its Salt
2^-OMeFAA 2^-OMe FAA salt
Interatomic Distance / A  Dihedral Angle / °
A nalogue 1 2 3 4 C7-C8-CH2-CO C3-C2-CF-C6"
2"-OMeFAA 3 .8 4 3 .4 0 5 .0 3 2 .2 7  -157.2 -145.3
2^-OMe FAA salt 2 .8 9 2 .0 6 2 .8 6 2 .2 0  -110.0 -162.7
2. Low Temperature MMR Study
A low temperature and MMR study was carried out on the sodium 
salt of flavoneacetic acid 135 to ascertain the barrier to rotation of the 2- 
phenyl ring. The salt 135 was dissolved in d4-methanol and then, starting 
at 30°C, cooled to -100°C in a series of five steps. Small changes in shift 
positions occurred as the probe cooled which were more dramatic at low 
temperatures. Results from this study are inconclusive as the sample froze 
before the coalescence temperature was reached. A stacked plot of the 
MMR spectra at each temperature follows.
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The top spectrum was recorded at 303 K and shows the region from 100 
to 200 ppm. The overall trend of the spectra shows the quaternaries 
increasing in intensity with the majority of the CH's decreasing. The 
reason for this is unclear. Another facet of the study is the movement of 
the peaks. Although the difference between each spectrum is slight, the 
general trend to lower temperatures shows the hidden quaternaries 
becoming visible. At the lowest temperature the C-3 almost merges with 
the background noise as do some other CH's.
Unfortunately although there is some indication of a slowing down 
of the rotations at 213 K, the coalescence temperature is clearly even 
lower and so not accessible.
3. Comparison between activity and trends in IH and chemical shifts 
Analysis of IH and chemical shifts of the 2, 3 and 4 positions provides 
a good method for quickly identifying flavones. When experimental data 
is tabulated it becomes clear that, within experimental error of O.OSppm, 
certain trends emerge. Such tables for all compounds, both allylflavones 
and flavoneacetic acids, synthesised during the project follow.
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The preceding tables show a summary of proton shifts for both 8-allyl and 
8-acetic acid substitution and adequately show comparison between the 
many C-ring derivatives synthesised. As would be expected, substitution 
on the C-ring by various groups, most notably methoxy, gives distinctive 
results for the C-ring protons. However other positions are affected by 
these substitution patterns. Taking into account experimental error, 
brought about by sample dilution, temperature, machine variability and 
errors in precise referencing, the results for the different positions are 
remarkably consistent.
Certain trends can be seen from the analysis of the H-3 shift. 
Firstly, and most importantly, the shift is increased if a methoxy group is 
present on the 2’-position. This effect must not only be due to an 
electronic component but also a through-space interaction between the 
steric bulk of the methoxy group and the hydrogen on the 3-position. 
Moreover it must be the electronegative oxygen hydrogen-bonding to this 
hydrogen to produce such a dramatic shift effect in comparison with the 
parent allyl derivative.
Increasing the number of methoxy’s on the C-ring changes the H-3 
shift markedly with 2 ’-methoxy containing compounds again having 
higher shifts than the parent allyl compound. The 2 ’,5’-dimethoxy 
derivative has a higher 3-position shift compared to the 2’,4’-dimethoxy 
which is in turn higher than the 3-position shift for the 2’,3’-dimethoxy 
derivative.
Heterocyclic derivatives all have lower 3-position shifts than the 
parent allylflavone with the exception of the 3-methoxy-2-thienyl 
compound which has comparable H-3 shift with the 2’-methoxy derivative. 
The highest shift for the 3-position came from the 3-chlorobenzo-2- 
thiophene derivative attributable to interaction of the chlorine atom and 
the hydrogen. The extended derivatives show a quite marked decrease in
3-position shift due to an interruption of conjugation.
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Analysis of the 3-position shifts for the flavone acetic acids shows 
that the above trend for methoxy substitution is not as marked and is 
generally reversed. Perhaps the less marked results are possibly due to 
changing the solvent to dimethyl sulphoxide, a more polar solvent than 
deuterochloroform. This would reduce the capacity for hydrogen bonding 
and hence would lessen the effect seen on the 3-position. The majority of 
shifts for the 3-position centre around 7 parts per million with only the 
heterocyclic and extended derivatives giving lower shift values. Only four 
results are notable. Both of the tetrasubstituted derivatives give 
remarkably low shifts for the 3-position in comparison with the parent 
flavone acetic acid. Higher than normal H-3 values come from the 3- 
methoxy-2-thienyl and the 3-chloro-2-benzothienyl. Precisely why these 
final examples have high shifts is unknown.
The following tables show the VMR results for all 8-allyl and 8-acetic 
acid derivatives successfully synthesised.
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At first glance the entries in both tables seem similar for each derivative. 
On closer inspection certain facts are prominent. Positions 2 and 3 are the 
only positions to show significant variability on the A- and B-rings. The 
rest of the positions show remarkable similarity with each other varying 
on average by only 0.2 parts per million. This means that it is possible to 
identify the flavone produced by examination of the C-2 and C-3 positions.
Similar effects are seen in the C-2 and C-3 position shifts as with 
those seen in the proton [MR. However both acids and allyl compounds 
show the same trends. Substitution of a 2-methoxy group on the phenyl 
ring gives a characteristic increase in the C-3 to over 110 parts per 
million. Coupled with this effect is the lowering of the C-2 shift 
compared to the parent compound.
Other groups have also looked into the [MR of substituted 
f l a v o n e s . T h e i r  findings coincide with ours in that 2’-methoxy or 
2 ’-halogen substitution on the C-ring leads to anomalous shifts for the 3- 
position.
Correlation was sought between activity and [MR shift for H-3 of 
substituted FAA’s (table 2). A graph of this correlation follows.
Scatter Graph of Proton Shift vs IC<n
1000 1
oto
Ü
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It can be seen that the most active compounds occur at a lower chemical 
shift. The two lowest shifts are attributable to the benzylic derivatives and 
therefore should really be treated separately. However there is no definite 
relationship that can be seen.
Correlation was sought between activity and i^C \MR shift for C-3. 
A graph of this correlation follows.
Scatter Graph of Carbon Shift vs ICsn
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The scatter graph was used to hopefully find areas where active 
compounds clustered. However there seems to be no obvious correlation 
between proton or carbon shift as active compounds occur over the range 
of shifts. There is a slight tendency for the more active compounds to 
have higher carbon chemical shifts for C-3.
4. X-ray Structure Determination
Crystals of the parent acid were grown from glacial acetic acid and water 
(2:1) and sent for structure determination at the SERC X-ray 
Crystallography Unit, Cardiff. This is the first reported structure 
determination for any flavone-8-acetic acid.
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The crystal system was monoclinic and the space group was 
determined as P2(l), Cell volume was determined as 144.0 Â with a 
calculated density of 1.321 Mgm-3. Unit cell dimensions of a=5.214 Â 
alpha=90 deg. b=4.242 Â beta=93.84 deg. and c= 19.490 Â gamma=90 
deg. The picture below is a representation of the system as sent from 
Cardiff. Selected bond lengths and bond angles for only one of the two 
independent flavone molecules are also shown in the following tables.
C 5 C 4 O 4
C 1 7
C I 0
C 1 3 C 1 5
O 1 W
0 2  W
0 4
C 1 6
C I 6
C 1 5
cs •
0 3  ’ C 3  ■
C 6  ’
O  1 ’
C 1 7 ’
CI O’
€14'
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Atoms Length Â Atoms Length A Atoms Length A
0 (1) -CCI) 1.36(2) 0(2) -  0(3) 1.49(2) C (ll) -0 (1 2 ) 1.47(2)
0(1)-C (11) 1.37(2) 0 (3 )-0 (4 ) 1.49(2) 0(12)-0 (13) 1.39
0(2) -  C(9) 1.26(2) 0(5) -  0(6) 1.38(2) C(12)-0(17) 1.39
0(3) -  C(4) 1.21(2) 0(6) -  0(7) 1.40(2) C(13)-0(14) 1.39
0(4) -  C(4) 1.30(2) 0(7) -  0(8) 1.39(2) C(14)-0(15) 1.39
0 (1 )-C (8) 1.39(2) 0(8) -  0(9) 1.50(3) C(15)-0(16) 1.39
0(1) -  0(2) 1.41(2) 0 (9 )-0 (1 0 ) 1.42(3) 0 (16)-0(17) 1.39
C (2)-0 (5 ) 1.34(2) C (1 0 )-C (ll) 1.32(2)
Atoms Angle ° Atoms Angle°
C ( D - 0 (1 )-0 (1 1 ) 118.4(13) 0 (1 )-0 (8 ) -0 (9 ) 116(2)
0 (1 ) -0 (1 ) -0 (8 ) 124(2) 0 (2 )- C ( 9 ) - 0(10) 125(2)
0(1) -  0(1) -  0(2) 114(2) 0 (2 ) -0 (9 ) -0 (8 ) 118(2)
C (8 )-0 ( l) -C (2 ) 122(2) 0(10)- C ( 9 ) - 0(80 117(2)
0 (5 )-C (2 )-C (l) 114.8(14) 0 (1 1 )-0 (1 0 )-0 (9 ) 121(2)
C (5 )-0 (2 )-C (3 ) 123(2) 0 (1 0 )-0 (1 1 )-0 (1 ) 123.3(14)
C (l) -0 (2 )-C (3 ) 122(2) 0 (1 0 )-0 (1 1 )-0 (1 2 ) 125(2)
C (2 )-C (3 )-0 (4 ) 114.7(13) 0 (1 )-0 (1 1 )-0 (1 2 ) 111.3(12)
0 (3 ) -0 (4 ) -0 (4 ) 120(2) 0 (1 3 )-0 (1 2 )-0 (1 7 ) 120.0
0 (3 )-C (4 )-C (3 ) 123(2) 0 (1 3 )-0 (1 2 )-0 (1 1 ) 119.6(9)
0 (4 )-0 (4 )-C (3 ) 116.6(13) 0 (1 7 )-0 (1 2 )-0 (1 1 ) 120.4(9)
C (2 )-C (5)-C (6) 127(2) 0 (1 2 )-0 (1 3 )-0 (1 4 ) 120.0
C (5 )-C (6 )-0 (7 ) 117(2) 0 (1 5 )-0 (1 4 )-0 (1 3 ) 120.0
0 (8 )-0 (7 )-C (6 ) 120(2) 0 (1 4 )-0 (1 5 )-0 (1 6 ) 120.0
C (7 )-C (8 )-0 ( l) 120(2) 0 (1 5 )-0 (1 6 )-0 (1 7 ) 120.0
C (7 )-0 (8 )-C (9 ) 124.8(14) 0 (1 6 )-0 (1 7 )-0 (1 2 ) 120.0
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The results were interesting as not only were there two molecules of FAA 
in the unit cell but also two accompanying molecules of water were 
present. The full numerical data can be seen in Appendix 1 and the 
graphical representations can be seen below.
Several important observations can be made from the crystal structure. 
Firstly the two molecules of FAA are almost flat. This is, of course, 
expected for the pyranone fragment but the C-ring is, from previous 
calculations, shown to be slightly deviant from the benzopyranone plane. 
The molecules are stacked through the C-rings, implying 71-stacking. 
However the rest of the molecule is too bulky to continue this stacking and 
hence it is formed into a helical structure. The C-4 carbonyls of the 
separate molecules of FAA point in approximately opposite directions, 
accounting for the spiral arrangement. The most interesting point about 
the structure is the manner in which the acetic acid groups are arranged. 
]ot only do they lie, as calculated, with the carboxylic acids pointing in 
towards the body of each molecule but they also adopt the same angle of 
deviation from the plane. Also very interesting is that the carbonyl 
oxygen of the carboxylic acid points towards the ether oxygen of the 
pyranone. This, along with the corresponding distances, shows the
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possibility of interaction. The two waters of recrystallisation do not seem 
to interact with the FAA molecules in the unit cell, however, at least one 
of them is close enough to hydrogen bond to the carbonyl oxygen of the 
pyranone. These water molecules hydrogen bond to FAA molecules in 
adjacent unit cells.
Accurate bond lengths and angles can now be used in the 
calculations where before the only accurate model was pyranone. 
Although inferences cannot be drawn between solid state structure and 
computational conformation, it is interesting to note that the calculations 
carried out so far have coincided directly with the X-ray structure.
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Appendix 1
Table 5. Crystal data and structure refinement
Empirical formula 
Formula weight 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions
Volume
Z
Density (calculated) 
Absorption coefficient 
F (000)
0 range for data collection 
Index ranges 
Reflections collected 
Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [I>2sigma(I)] 
R indices (all data)
Absolute structure parameter 
Largest diff. peak and hole
Cl7 Hi4 O5
287.26 
293(2) K 
0.71069 A 
Monoclinic 
P2(l)
a=5.214 Â alpha=90 deg. 
b=4.242 Â beta=93.84 deg. 
c=19.490 A gamma=90 deg. 
144.0 Â3 
4
1.321 Mgm-3 
0.097 mm-i 
596
1.77 to 24.99 deg.
-5<b^, - 8 ^ 1 5 ,  -2 2 ^ 2 1  
5016
2042 / 1 / 374 
1.091
Ri =0.1530, wR2 = 0.3760 
Ri = 0.1800, wR2 = 0.4290 
-2(6)
0.823 and -0.354 e.A-3
Table 6. A tom ic coordinates (x 10^) and equivalent isotropic
displacement parameters (A^ x 10#) for flavone-8-acetic acid.
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U(eq) is defined as one third of the trace of the orthogonalised Uij tensor.
X Y Z U(€
0(1) 1783(21) 8082(8) 5400(5) 43(3)
0(2) 1796(24) 7227(10) 3407(6) 64(4)
0(3) 2090(24) 10349(10) 5743(6) 62(4)
0(4) 1141(25) 10106(11) 6800(6) 74(4)
0(1) 60(33) 8441(12) 4917(9) 44(4)
0(2) -1653(31) 9100(12) 5180(7) 38(4)
0(3) -1521(32) 9372(14) 5918(8) 51(5)
0(4) 720(30) 9974(13) 6141(8) 41(4)
0(5) -3464(32) 9425(13) 4718(8) 50(5)
0(6) -3747(34) 9210(13) 4029(9) 51(5)
0(7) -1999(32) 8569(13) 3782(8) 43(4)
0(8) -86(32) 8187(12) 4227(8) 43(5)
0(9) 1838(34) 7469(14) 4028(10) 52(5)
0(10) 3485(30) 7089(13) 4566(8) 43(4)
0(11) 3482(29) 7414(11) 5200(8) 39(4)
0(12) 5111(20) 7062(8) 5792(5) 40(4)
0(13) 7192(22) 6485(8) 5680(5) 44(4)
0(14) 8756(21) 6158(9) 6235(7) 64(6)
0(15) 8239(26) 6409(11) 6901(6) 77(7)
0(16) 6157(28) 6986(12) 7013(4) 83(7)
0(17) 4594(22) 7313(9) 6458(6) 56(5)
0(D 1485(22) 5662(9) 9702(5) 50(3)
0(Z) 3207(29) 4762(11) 11651(7) 79(5)
182
0(33 1486(26) 7906(12) 9378(7) 73(4)
0(43 -140(34) 7504(13) 8346(8) 97(6)
q i3 160(34) 6024(13) 10238(10) 50(5)
0(23 -1806(30) 6659(12) 10018(9) 41(4)
0(33 -2226(33) 6943(14) 9291(10) 58(5)
0(43 -93(33) 7507(13) 9031(10) 50(5)
0(53 -3245(39) 7033(14) 10518(11) 65(6)
0(63 -2839(42) 6755(16) 11221(12) 72(6)
0(7) -883(41) 6100(16) 11391(9) 66(6)
0(83 608(31) 5728(12) 10909(8) 44(4)
0(93 2633(33) 5017(14) 11060(9) 50(5)
C(103 3930(36) 4682(12) 10484(8) 51(5)
0(113 3423(30) 5002(11) 9830(8) 38(4)
G(123 44539(21) 4689(8) 9211(5) 42(4)
C(133 6678(20) 4104(9) 9241(5) 45(4)
C(143 7706(22) 3806(9) 8638(7) 72(6)
0(153 6595(30) 4093(11) 8005(5) 83(7)
0(163 4456(29) 4678(11) 7974(4) 84(8)
0(173 3428(22) 4976(9) 8577(6) 74(6)
0(1W) 4816(29) 6004(13) 2772(7) 89(5)
0(2W) 7126(34) 3670(12) 2186(8) 93(5)
Table 7. Bond lengths [Â] for flavone-8-acetic acid
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0(1)-C(1) 1.36(2) 0(11-0(13 1.39(2)
0(1)-C(11) 1.37(2) 0 (r)-0 (ir) 1.39(2)
0(2)-C(9) 1.26(2) 0(2')-0(9') 1.23(2)
0(3)-C(4) 1.21(2) 0(3')-0(41 1.18(2)
0(4>-C(4) 1.30(2) 0(4')-0(41 1.33(2)
C(l)-C(8) 1.39(2) 0(rK]@ i 1.38(2)
C(l)-C(2) 1.41(2) 0(r)-0(2i 1.41(2)
C(2)-C(5) 1.34(2) 0g')-0(51 1.38(2)
C(2)-C(3) 1.49(2) 0(2')-0(31 1.48(2)
C(3)-C(4) 1.49(2) 0(3'X](41 1.49(2)
C(5)-C(6) 1.38(2) w x x e i 1.43(2)
C(6)-C(7) 1.40(2) 0(6')-0(7) 1.41(2)
C(7)-C(8) 1.39(2) 0(7)-0gl 1.37(2)
C(8)-C(9) 1.50(3) 0@')-0(91 1.48(3)
C(9)-C(10) 1.42(3) 0(9')-0(101 1.43(3)
C(10)-C(ll) 1.32(2) o(io')-o(ir) 1.36(2)
C(ll)-C(12) 1.47(2) 0(1T)-0(121 1.45(2)
C(12)-C(13) 1.39 O(12')-O(131 139
C(12)-C(17) 1.39 0(12')-0(1T) 1.39
C(13)-C(14) 1.39 0(13')-0(141 1.39
C(14)-C(15) 1.39 0(14'KX151 1.39
C(15)-C(16) 1.39 0(15'K%16') 1.39
C(16)-C(17) 1.39 0(16')-0(17') 1.39
Table 8. Bond angles [deg] for flavone-8-acetic acid
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C (l)-0(1)-C (ll) 118.4(13) c ( r )< x r )C ( i i l 120.6(13)
0(1)-C(1)-C(8) 124(2) o ( rx x rx :(8 1 123(2)
0(1)-C(1)-C(2) 114(2) 0 ( rx :( rx X 2 i 113(2)
C(8)-C(l)-C(2) 122(2) c(8'}C(rKX2l 124(2)
C(5)-C(2)-C(l) 114.8(14) C(5'XXZ>C(11 117(2)
C(5)-C(2)-C(3) 123(2) G(5'X:(Z>-C(31 121(2)
C(l)-C(2)-C(3) 122(2) c(r> c(z> c(3 i 122(2)
C(2)-C(3)-C(4) 114.7(13) C(Z)C(3'X:(41 114.1(14)
0(3)-C(4)-0(4) 120(2) 0(3')-C(4'X)(41 123(2)
0(3)-C(4)-C(3) 123(2) 0(3'>C(4')-C(31 125(2)
0(4)-C(4)-C(3) 116X%13) 0(4')<X4')-0(31 112(2)
C(2)-C(5)-C(6) 127(2) C(2')C(5'XX61 121(2)
C(5)-C(6)-C(7) 117(2) C(5'XX6')C(71 118(2)
C(8)-C(7)-C(6) 120(2) C(8')CCTXX61 122(2)
C(7)-C(8)-C(l) 120(2) C(7'>C(8'>C(r) 118(2)
C(7)-C(8)-C(9) 124.8(14) C(7'KX8'>G(9') 124(2)
C(l)-C(8)-C(9) 116(2) C(T>0(8'XX9') 118(2)
O(2)-C(9)-C(10) 125(2) (]K2')4[:cy).(](i(y) 123(2)
0(2)-C(9)-C(8) 118(2) 0(2'X:(9'X%8') 121(2)
C(10)-C(9)-C(8) 117(2) c(io'x:(9'X:(8') 116(2)
C(ll)-C(10)-C(9) 121(2) C%ll').C(10lHC(91 123(2)
C(10)-C(ll)-O(l) 123.3(14) c(io 'K X ir)-o (r) 119T(14)
C(10)-C(ll)-C(12) 125(2) c ( io ') -c ( irx :( i2 i 128(2)
0(1)-C(11)-C(12) 111.3(12) 0 (r> c ( ir )-c ( i2 i 112.8K13)
C(13)-C(12)-C(17) 120.0 C(13')C(12')-C(1T) 120.0
C(13)-C(12)-C(ll) 119.6(9) c(i3 ')-c (iz )-c(ir) 121T(10)
C(17)-C(12)-C(ll) 120.4(9) C(1T)-C(12’)-C(ir) 118^K10)
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C(12)-C(13)-C(14) 120.0 C(1Z>C(13')-C(141 120.0
C(15)-C(14)-C(13) 120.0 C(15'X:(14'X:(131 120.0
C(14)-C(15)-C(16) 120.0 C (i4 'x :(i5 'x :(i6 i 120.0
C(15)-C(16)-C(17) 120.0 C(15'>C(16')-C(171 120.0
C(16)-C(17)-C(12) 120.0 c (i6 'K :(i7 'x :(i2 i 120.0
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Table 9. Anisotropic displacement parameters (A^ x 10#) for flavone-8- 
acetic acid.
The anisotropic displacement factor exponent takes the form:- 
-2 7i2 [h2 a*2 U ll  + ... + 2 h k a* b* U12]
U ll U22 U33 U23 U13 U12
0(1) 47(7) 35(7) 47(7) 6(5) 5(6) 12(6)
0(2) 81(9) 65(9) 44(8) -10(7) 4(6) 22(8)
0(3) 66(9) 72(10) 48(7) -9(7) 6(7) -16(8)
0(4) 75(9) 94(11) 54(9) 19(8) 2(6) -34(8)
0(1) 36(9) 31(10) 65(12) 9(9) -1(9) -8(8)
0(2) 48(10) 37(10) 30(9) 10(8) 0(8) -9(9)
0(3) 44(10) 59(12) 50(10) 2(9) 9(8) -12(10)
0(4) 35(9) 55(11) 36(10) 12(9) 15(8) 11(9)
0(5) 55(11) 51(12) 47(11) 4(10) 37(9) 24(10)
0(6) 49(11) 51(12) 53(12) 2(9) -4(8) -11(10)
0(7) 49(11) 45(11) 34(9) 1(8) 0(8) 16(9)
0(8) 48(11) 45(11) 35(10) -12(9) -3(8) -3(9)
0(9) 51(11) 52(12) 53(12) -20(10) -8(9) 3(9)
0(10) 45(10) 42(11) 44(11) -2(9) 9(8) 5(8)
0(11) 34(9) 33(10) 51(11) -4(9) 1(8) -11(8)
0(12) 40(9) 24(9) 54(11) 5(8) -14(8) -8(8)
0(13) 42(10) 36(10) 54(11) -12(9) 4(8) -1(9)
0(14) 51(11) 53(13) 85(16) 15(11) -17(11) 15(10)
0(15) 76(15) 89(18) 59(14) 31(13) -38(13) -16(14)
0(16) 70(15) 124(22) 52(13) 13(13) -16(11) 0(15)
0(17) 49(11) 72(14) 49(11) -2(10) 7(8) 28(11)
0(1’) 54(7) 46(7) 49(7) 6(6) 1(5) -5(6)
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W ) 102(10) 89(11) 47(9) 1203 5(7) 21(9)
0(33 52(9) 90(11) 76(9) -7(9) -7(7) -14(9)
0(43 117(12) 104(13) 69(10) -3(9) -6(8) -61(11)
0(13 51(11) 34(10) 66(13) 2(10) 23(9) 9(9)
0(23 36(10) 35(10) 51(11) 0(9) 1(8) -18(9)
0(33 46(11) 43(12) 83(15) 4(11) -13(10) 6(9)
0(43 31(10) 47(11) 68(14) 0(10) -23(9) -1(9)
0(53 65(13) 46(12) 80(15) 9(12) -19(11) -6(11)
0(63 73(15) 54(14) 95(18) -16(12) 41(13) -11(12)
0(7) 83(14) 70(15) 49(11) -9(11) 47(11) -15(14)
0(83 46(10) 40(10) 45(11) 11(9) -2(8) -6(9)
0(93 51(11) 63(12) 36(10) 1(10) 12(8) -4(10)
0(103 71(12) 28(10) 53(12) 12(9) -13(9) 1(9)
0(113 42(10) 21(8) 51(10) 5(8) 10(8) -4(8)
0(123 28(9) 40(10) 60(12) -9(9) 9(8) -6(8)
0(133 35(9) 55(12) 46(10) 0(9) 11(8) -9(9)
0(143 56(13) 80(16) 82(15) 10(13) 36(11) -3(11)
0(153 96(18) 80(18) 75(17) -5(13) 28(14) -25(15)
0(163 108(18) 103(20) 42(12) -14(12) 0(12) -47(16)
0(17) 95(16) 75(15) 50(12) -10(11) -3(12) -8(14)
0(1W) 80(9) 117(14) 68(9) -31(9) 0(7) 31(10)
0(2W) 123(13) 80(10) 76(10) 3(9) 5(9) 33(10)
